CareView Communications Inc Form 10-K March 30, 2016

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-K

(Mark One)

ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended: **December 31, 2015**

TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from_____ to _____

Commission File No.: 000-54090

CAREVIEW COMMUNICATIONS, INC.

(Exact name of registrant as specified in its charter)

Nevada95-4659068(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)

Edgar Filing: CareView Communications Inc - Form 10-K			
<u>405 State Highway 121, Suite B-240, Lewisville, TX 75067</u>			
(Address of principal executive offices)			
Registrant's telephone number, including area code: (972) 943-6050			
Securities registered pursuant to Section 12(b) of the Exchange Act: None			
Securities registered pursuant to Section 12(g) of the Exchange Act: <u>Common Stock, Par Value \$0.001</u> (Title of class)			
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes No			

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. Yes No

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§229.405 of this chapter) is not contained herein, and will not be contained, to the best of the registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer Accelerated filer

Non-accelerated filer Smaller reporting company

(Do not check if smaller reporting company.)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes No

The aggregate market value of the voting common stock held by non-affiliates of the registrant (90,112,618 shares) based on the closing price of the registrant's common stock as reported on OTCQB on June 30, 2015, which was the last business day of the registrant's most recently completed second fiscal quarter, was \$32,440,542. For purposes of this computation, all officers, directors, and 10% beneficial owners of the registrant are deemed to be affiliates.

The number of shares outstanding of the registrant's common stock as of March 30, 2016 was 139,380,748.

DOCUMENTS INCORPORATED BY REFERENCE:

None.

Table of Contents

<u>ITEM 1</u>	<u>.BUSINESS.</u>	3
<u>ITEM</u> <u>1A.</u>	RISK FACTORS.	14
<u>ITEM</u> <u>1B.</u>	UNRESOLVED STAFF COMMENTS.	14
<u>ITEM 2</u>	. <u>PROPERTIES.</u>	14
ITEM 3	LEGAL PROCEEDINGS.	14
<u>ITEM 4</u>	.MINE SAFETY DISCLOSURES.	14
<u>ITEM 5</u>	<u>MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS</u>	15
<u>ITEM 6</u>	SELECTED FINANCIAL DATA.	16
<u>ITEM 7</u>	, <u>MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND</u> * <u>RESULTS OF OPERATIONS.</u>	17
<u>ITEM</u> <u>7A.</u>	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.	23
<u>ITEM 8</u>	S.FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.	23
<u>ITEM 9</u>	<u>CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE.</u>	23
<u>ITEM</u> 9 <u>A.</u>	CONTROLS AND PROCEDURES.	23
<u>ITEM</u> 9 <u>B.</u>	OTHER INFORMATION.	25
<u>ITEM</u> <u>10.</u>	DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE.	26
<u>ITEM</u> <u>11.</u>	EXECUTIVE COMPENSATION.	36
<u>ITEM</u> <u>12.</u>	SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.	38

<u>ITEM</u> <u>13.</u>	CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE.	41
<u>ITEM</u> <u>14.</u>	PRINCIPAL ACCOUNTANT FEES AND SERVICES.	41
<u>ITEM</u> <u>15.</u>	EXHIBITS AND FINANCIAL STATEMENT SCHEDULES.	42

Statement Regarding Forward-Looking Information

This Annual Report on Form 10-K contains forward-looking statements. For example, statements regarding our financial position, business strategy, product development, and other plans and objectives for future operations, and assumptions and predictions about future product demand, research and development, marketing, expenses and revenue are all forward-looking statements. These statements may be found in the items of this Annual Report entitled "Business" and "Management's Discussion and Analysis of Financial Condition and Results of Operations," as well as in this Annual Report generally. These statements are generally accompanied by words such as "intend," "anticipate," "believe," "estimate," "potential(ly)," "plan," "may," "will," "continue," "forecast," "predict," "could," "would," "should," "ex negative of such terms or other comparable terminology.

INTRODUCTORY COMMENT

Throughout this Annual Report on Form 10-K (the "Report"), the terms "we," "us," "our," "CareView," or "our Company" ref to CareView Communications, Inc., a Nevada corporation, and unless otherwise specified, includes our wholly owned subsidiaries, CareView Communications, Inc., a Texas corporation ("CareView-TX") and CareView Operations, LLC, a Nevada limited liability company ("CareView Operations") (collectively known as the "Company's Subsidiaries") and its LLCs, CareView-Hillcrest and CareView-Saline, determined to be variable interest entities ("VIEs") in which the Company exercises control and is deemed the Primary Beneficiary (collectively known as the "Company's LLCs").

PART I

ITEM 1. BUSINESS.

Our Business

Our mission is to be the leading provider of products and on-demand application services for the healthcare industry, specializing in bedside video monitoring, software tools to improve hospital communications and operations, and patient education and entertainment packages. Our proprietary, high-speed data network system is the next generation of patient care monitoring that allows real-time bedside and point-of-care video monitoring designed to improve patient safety and overall hospital costs. The entertainment packages and patient education enhance the patient's quality of stay. Reported results from CareView-driven hospitals prove that our products reduce falls, reduce the cost of sitter fees, increase patient satisfaction and reduce bed turnaround time to increase patient flow. For patients, we have a convenient in-room, entertainment package that includes high-speed Internet, access to first-run on-demand movies and visual connectivity to family and friends from anywhere in the world. For the hospital, we offer tools to

provide superior patient care, peace of mind and customer service satisfaction.

Our CareView System[®] suite of video monitoring, guest services and related applications connect patients, families and healthcare providers. Through the use of telecommunications technology and the Internet, our evolving products and on-demand services greatly increase the access to quality medical care and education for patients/consumers and healthcare professionals. We understand the importance of providing high quality patient care in a safe environment and believe in partnering with hospitals to improve the quality of patient care and safety by providing a system that monitors and records continuously. We are committed to providing an affordable video monitoring tool to improve the practice of nursing, create a better work environment and make the patient's hospital stay more informative and satisfying. Our suite of products and services can simplify and streamline the task of preventing and managing patients' falls, enhance patient safety, improve quality of care and reduce costs associated with bringing information technology directly to patients, families and healthcare providers. Our products and services can be used in all types of hospitals, nursing homes, adult living centers and selected outpatient care facilities domestically and internationally.

The CareView System secure video monitoring system connects the patient room to a touch-screen monitor at the nursing station, allowing nursing staff to maintain a level of visual contact with each patient. This configuration enhances the use of the nurse call system, reduces unnecessary steps to and from patient rooms, and the recording capability allows for a video record of all in-room activity during the length of the patient's hospital stay. The CareView System suite can be easily configured to meet the individual privacy and security requirements of any hospital or nursing facility. The Health Insurance Portability and Accountability Act of 1996 ("HIPAA') compliant, patient approved video record can be included as part of the patient's medical record and serves as additional documentation of bedside care, procedures performed, patient and hospital ancillary activities, safety or care incidents, support to necessitate additional clinical services, and, if necessary, as evidence. Additional HIPAA-compliance features allow privacy options to be enabled at any time by the patient, nurse or physician.

In addition to patient safety and security, we also provides a suite of services to increase patient satisfaction scores and enhance the overall image of the hospital including first-run on-demand movies, Internet access via the patient's television, and video visits with family and friends from most places throughout the world. Through continued investment in patient care technology, our products and services help hospitals and assisted living facilities build a safe, high quality healthcare delivery system that best serves the patient, while striving for the highest level of satisfaction and comfort.

Our Products and Services

We offer a variety of products and services designed to meet individual hospital needs to enhance quality patient care and safety. Our services are offered with no capital expenditure by the hospital and do not require extensive integration with the facility's management information system. For healthcare facilities looking for an effective, affordable and innovative way to improve performance throughout the facility, our products are the answer. CareView-driven facilities have shown documented success in reducing patient falls and sitter costs, improving overall patient satisfaction, streamlining and documenting patient education at the bedside, and improving patient flow and overcrowding. These successes protect the facilities' reimbursement from loss due to never events and poor patient satisfaction.

The CareView System offers the following service packages:

PRIMARY PACKAGE

1. NurseView[®]. The NurseView module allows authorized users to view monitored rooms from the nurse's station. All privacy and access options are determined and configured by the hospital.

2. PhysicianView[®]. The PhysicianView module enables the admitting physicians and non-physician staff members to view their patients from any personal computer. All privacy and access options are determined by the hospital.

Virtual Bed Rails[®]. The Virtual Bed Rails fall prevention module allows the hospital to activate a safety feature **3.** that will notify the nursing station or the caregiver's mobile device when a patient breaches a defined area in the patient room.

Virtual Chair Rails[®]. The Virtual Chair Rails fall prevention module allows the hospital to activate a safety feature **4.** that will notify the nursing station or the caregiver's mobile device when a patient breaches a defined area in the patient room.

Fall Management Program[™]**.** The Fall Management Program allows the hospital to separately file, identify and **5.** research the activity of patients for whom the Virtual Bed Rails or Virtual Chair Rails fall prevention modules were engaged.

6. **Rounding.** We offer a timed rounding module to help nursing staff monitor patients.

7. SecureView[®]. The SecureView module monitors and records bedside activity in the patient's room. All privacy and access options are determined and configured by the hospital.

ADDITIONAL CAREVIEW PRODUCTS

1. **Sitter Management Program.** The CareView Sitter Management Program allows authorized users to monitor an unlimited number of patient rooms from one nursing station or mobile device.

2. **BedView**[®]. The BedView module allows authorized users to monitor the status and availability of facility beds remotely.

- 3. **Patient Education.** We provide a delivery mechanism for patient education materials.
- 4. **FacilityView**[®]. The FacilityView module monitors and records activity in any area that the hospital would desire security cameras to be placed. All privacy and access options are determined and configured by the hospital.
- 5. **Nurse Alerts and Reminders.** The CareView System monitoring system can be configured to provide nursing alerts and reminders.
- 6. **Ulcer Management.** The CareView System can be configured to ensure that patients who are at risk for developing pressure ulcers are turned from position to position.
- **CareView ConnectTM.** This communications device and mobile monitoring system allows all CareView modules to 7. be utilized with handheld mobile devices. CareView ConnectTM can be used to deliver voice communication between mobile devices, patient rooms, and the hospital's phone infrastructure.
- **NICUView®**. The NICUView module provides a live, continual feed from the Neo-Natal Intensive Care Unit 8. ("NICU") to allow parents who have been discharged from the hospital, or friends and family, to view the newborn and obtain clinical information from home.

The CareView Broadcast System. We provide the hospitals with the capability to broadcast to each room a variety 9. of educational, informational and service communications to patients and guests alike. We do not provide educational content. The hospitals are allowed to access the system for:

- a. <u>Welcome message</u> a pre-recorded message welcoming the patient to the facility.
- b. <u>Pre-procedure Education</u> to inform and educate the patient regarding a procedure to be performed (i.e. angioplasty, hip replacement, spine surgery, etc.).

Patient Condition Education – to inform and educate the patient regarding a condition they have and suggested ^c lifestyle improvements to live with those conditions (i.e. high blood pressure, diabetes, etc.).

d. <u>SerenityView</u> - to select scenes and sounds to create a relaxing atmosphere for patients during their stay.

GUEST SERVICES PACKAGE

PatientView[®]. The PatientView module enables patients to allow family members and friends to monitor and 1.videoconference with them in their private rooms. All privacy and access options are determined and configured by the hospital.

2. **NetView**[®]. The NetView module allows the patient access to the internet using the wireless keyboard and the television in the room or personal laptop computers.

MovieView®. The MovieView module provides the connectivity to allow the patient, family and/or friends access 3. to a wide selection of movies for their viewing pleasure while they are in their hospital room. We do not provide the movies or other content.

4. **BabyView**[®]. The BabyView module allows mothers to view their newborn child from their hospital bed in the nursery or NICU.

Pricing Structure and Revenue Streams

The CareView System suite is provided and installed in healthcare facilities at no charge to the facility after which we generate revenue from subscriptions to its services. We work with each hospital on pricing to offer an affordable package based on the demographics of the hospital's patients. The pricing structure with each hospital is negotiated separately and may vary depending on the hospital's desire to include premium services at no charge to the patient. Typically, we offer the Primary Package at a price per bed with varying price structures based on number of beds in each facility. The Guest Services Package is generally offered to the patient as a complimentary service of the hospital; however, hospitals have the option to charge their patients for these services. The hospital may elect to charge a package price for all services for any combination of days, including a package for the patient's entire stay. Each facility may decide to bundle products for specialty pricing to the patients or may offer any or all services at no charge to the patient. All revenue generated by us during the years ended December 31, 2015 and 2014 was derived from the sale of the Primary Package, Additional CareView Products, Guest Services Package and related services to hospitals.

Products in Development

Alternative Sensors. We are in the research and development stages of using alternative sensors, such as thermal 1.cameras, to improve automated monitoring of patient safety as well as other services. We expect the alternative sensors to be deliverable in fourth quarter of 2016.

Improved Asset Management and Tracking Module. We are in the research and development stages of overhauling 2. the improved Asset Management and Tracking Module, based on new technology that provides improved precision, better performance, and is more accessible. We expect the improved Asset Management and Tracking Module to be deliverable in third quarter of 2016.

Improved Detection Algorithms. We are continuing to develop and hone new techniques and algorithms geared 3. towards improving system functionality in the Virtual Bed Rails product. Advances include techniques based on machine learning and statistical probability.

Pressure Ulcer Monitor and Alarm Module. We are in the research and development stages of the Pressure Ulcer 4. Monitor and Alarm module. This module will monitor the patient and identify if the patient is at risk for pressure ulcers through automated computer vision algorithms and techniques. We expect the Pressure Ulcer Monitor and Alarm module to be deliverable in the third quarter of 2016.

Business Intelligence Module. We are in the development stages of a Business Intelligence module. This module 5. will collect and analyze data trends geared towards understanding improved patient safety, staff performance, and industry trends. We expect the Business Intelligence module to be available on or before September 30, 2016.

Products and Services Agreement with Healthcare Facilities

We offer our products and services through a subscription-based model with healthcare facilities through a Products and Services Agreement (the "P&S Agreement(s)"). During the term of the P&S Agreement, we provide continuous monitoring of the CareView System's products and services deployed to the healthcare facility and maintain and service all equipment installed by us. Terms of each P&S Agreement require the hospital to pay us a monthly subscription fee based on the number of selected, installed and activated services. None of the services provided through the Primary Package or GuestView are paid or reimbursed by any third party provider including insurance companies, Medicare or Medicaid. We also enter into corporate-wide agreements with health systems (the "Master Agreement(s)"), wherein the hospitals that are a part of a health system enter into individual facility level agreements that are substantially similar to our P&S Agreements.

Master Agreements and P&S Agreements are currently negotiated for a period of five years with a minimum of two or three years; however, older P&S Agreements were negotiated for a five year period with a provision for automatic renewal. P&S Agreements specific to pilot programs ("P&S Pilot Agreements") contain pricing terms substantially similar to P&S Agreements, are generally three or six-month in length and can be extended on a month to month basis as required. We own all rights, title, and interest in and to the equipment we install at each location and agree to maintain and repair it, although we may charge for repairs or replacements due to damage or misuse. We are not responsible for maintaining data arising from use of the CareView System or for transmission errors, corruption or compromise of data carried over local or interchange telecommunication carriers. We grant each medical facility a limited, revocable, non-transferable and non-exclusive license to use the software, network facilities, content and documentation on and in the CareView System suite to the extent, and only to the extent, necessary to access, explore and otherwise use the CareView System suite in real time. Such non-exclusive license expires upon termination of the P&S Agreement.

We use specific terminology in an effort to better define and track the staging and billing of the individual components of the CareView System suite. The CareView System suite includes three components which are separately billed; the Room Control Platform (the "RCP"), the Nurse Station and mobile devices (each component referred to as a "unit"). The term "bed" refers to each hospital bed as part of the overall potential volume that a hospital represents. For example, if a hospital has 200 beds, the aggregate of those beds is the overall potential volume of that hospital. The term "bed" is often used interchangeably with "RCP" or "Room Control Platform" as this component of the system consistently resides within each hospital room where the "bed" is located. On average, there are six Nurse Stations for each 100 beds. The term "deployed" means that the units have been delivered to the hospital, but have not yet been installed at their respective locations within the hospital. The term "installed" means that the units have been been trained in their use. Units are only deployed upon the execution of a P&S Agreement or P&S Pilot Agreement.

Community Health Systems, Inc.

In January 2014, Community Health Systems, Inc. ("CHS") acquired Hospital Management Associates, Inc. ("HMA"). Post-acquisition, CHS assumed our Master Agreement with HMA. Although that agreement expired on December 31, 2014, we continued to bill CHS on a month to month basis. On April 1, 2015, we closed a Master Agreement with CHS. Under the terms of the Master Agreement we have approximately 1,800 billable units. In early 2016, Mat-Su Regional Medical Center, a legacy CHS facility completed policy revision for patient video monitoring for CHS. With the policy revision complete, we have approval to contact all CHS facilities. We have had meeting with CHS market leaders and their Chief Nursing Officer and have their support, which could result in a potential roll-out of approximately 15,000 additional beds out of their estimated 27,000 staffed beds.

Tenet Healthsystem Medical, Inc.

In February 2014, we entered into a Master Agreement with Tenet Healthsystem Medical, Inc. ("Tenet"). The terms of the Master Agreement provide for the execution of a facilities level agreement with each hospital. Currently we have approximately 1,300 billable units and anticipate adding approximately 1,000 units on or before June 30, 2016. Thereafter, we anticipate a continued roll-out with the potential for an approximate 6,500 additional beds out of their estimated 18,000 staffed beds.

Kaiser Permanente

We currently have approximately 400 billable units in seven Kaiser Permanente ("Kaiser") facilities. In April and May 2014, we executed P&S Pilot Agreements with Kaiser's Baldwin Park and Panorama City facilities, respectively. This

is in addition to our P&S Pilot Agreement with Kaiser Orange County covering its facilities in Anaheim and Irvine, California which was executed in October 2013. The P&S Pilot Agreements for these four facilities provide for a monthly renewal until termination or replacement by a Master Agreement or individual P&S Agreements. We are now in the process of finalizing a conversion from a P&S Pilot Agreement to a P&S Agreement with Kaiser Orange County for approximately 225 beds installed in the Anaheim and Irvine hospitals. In 2015 we executed P&S Pilot Agreements with Kaiser's Northern California division for installation of the CareView System in San Francisco Medical Center, Santa Clara Medical Center and South Sacramento Medical Center. We are awaiting instructions before installation can be completed, however we expect to have all three facilities installed and billable on or before September 30, 2016. We are also in the process of finalizing negotiations for installation of the CareView System in Kaiser's facility in San Jose, California. We anticipate that the timing of the San Jose installation will coincide with the other facility in the Northern California Region.

In early 2016 we commenced discussions with Kaiser Northwest Region for deployment of the CareView System in Kaiser Hospital in Oregon. We are currently in the process of finalizing negotiations with the Northwest Region for installation of the CareView System in two other facilities, the Westside Medical Center and the Sunnyside Medical Center, for an anticipated total of 159 units. We anticipate having finalized P&S Pilot Agreements on or before June 30, 2016. After a successful pilot, in February 2016 we executed a P&S Agreement with Kaiser's Los Angeles Medical Center for a total of 136 units. We are also in pilot discussions with the Kaiser facilities in the San Diego area for installation in San Diego Medical Center/Kaiser Foundation Hospital and future installation in the currently under construction Medical Center in Central San Diego.

While we are continuing our sales efforts at the hospital and regional level, there are still discussions regarding a possible Master Agreement. Notwithstanding those discussions we will continue to sell into other Kaiser Regions and look to convert our P&S Pilot Agreements into P&S Agreements that can be replaced by a Master Agreement if and when one is finalized.

Parkland

In June 2015 we signed a P&S Agreement with Dallas County Hospital District d/b/a Parkland Health & Hospital System ("Parkland") to install 408 units.

Hospital Corporation of America

In February 2015, we executed a P&S Pilot Agreement for 280 beds with Hospital Corporation of America ("HCA") to install the CareView System in their Research Medical Center facility located in Kansas City, Missouri. HCA intends to use all CareView products including NurseView, Virtual Bed Rails, BedView, Patient Services, CareView Connect mobile product and have expressed interest in our Asset Management and Tracking product.

In October 2015, we signed a P&S Pilot Agreement for 40 beds with Blake Medical Center, a hospital in HCA's West Florida Division. The pilot will run from December 2015 through March 2016. We expect to execute two additional P&S Pilot Agreement with hospitals in HCA's West Florida Division, Medical Center of Trinity and Northside Medical Center for approximately 50 beds each during the quarter ended June 30, 2016. Initial feedback is positive and we expect that the CareView System will be further rolled out to the other 14 hospitals in the West Florida Division. The West Florida Division has approximately 3,600 staffed beds.

Banner Health

In June 2015 we entered into a P&S Pilot Agreement with Banner Desert Medical Center for 73 beds which became billable in November 2015. At the request of Banner, we executed an amendment to that agreement to extend the pilot term to one year. The preliminary results have been good and we anticipate rolling out to the rest of the Banner Health System following the successful conclusion of this pilot. Banner Health has approximately 4,400 staffed bed in 24 facilities.

Summary of Product and Service Usage

The following table shows the number of healthcare facilities using our products and services including the number of deployed units, installed units and billable units as of February 29, 2016. The table also shows the number of pilot programs in place and hospital proposals pending approval, estimated bed count if the pilot programs and pending proposals result in executed P&S Agreement, and the estimated total number of licensed beds available under the pilot programs and hospital proposals. There are no assurances that the pilot programs will be extended or the pending proposals will be approved to ultimately result in the number of estimated beds. Further, there are no assurances that we will have access to the total number of licensed beds in each healthcare facility.

Installed Hospitals	Installed Units	Billable Units	Total Staffed Beds in Contracted/ Pilot Hospitals	Potential Units Available Under Current Contract/ Pilot Contracts ^(*)	Units in Negotiation Prior to Contract/ Pilot
107	9,211	8,136	121,956	84,668	49,972

(*) This number represents management's best estimate of the number of units available to us in hospitals that are currently under Master, P&S or Pilot P&S Agreements. We assume that in any given acute care facility, our products and services are appropriate for deployment in approximately 70% of the total staffed beds. If we have specific information from a current contracted or pilot hospital that the number of potential units in that hospital is either higher or lower than 70%, specific number has been used in the aggregate estimate.

Availability of Suppliers

We are not dependent on, nor do we expect to become dependent on, any one or a limited number of suppliers. We purchase parts and components to assemble our equipment and products. We do not manufacture or fabricate our own products or systems, but rely on sub-suppliers and third party vendors to procure and/or fabricate components based on our designs, engineering and specifications. We enter into subcontracts for field installation of our products which we supervise. We manage all technical, physical and commercial aspects of the performance of our contracts with sub-suppliers and third party vendors. To date, we have experienced no difficulties in obtaining fabricated components, materials and parts or in identifying qualified subcontractors for installation work.

Sales, Marketing and Customer Service

We do not consider our business to be seasonal, however the availability of hospital staff is typically less available in December which impacts our ability to sale/install our CareView System. We generate sales leads through a variety of means including direct one-to-one marketing, email and web campaigns, customer and industry referrals, strategic partnerships, and trade shows and events. Our sales team consists of highly trained professionals with many years of experience in the healthcare market.

Our initial focus has been to pursue large for-profit hospital management companies that own multiple facilities and large not-for-profit integrated delivery networks in major metropolitan areas. Our sales staff approaches decision makers for hospitals, integrated delivery networks, and major owners and operators of hospitals to demonstrate the CareView product line. In 2013, we expanded our sales process to include an inside sales team and have expanded our capabilities of providing web-based demonstrations and presentations. In addition, we have begun to rely more heavily on arranging reference calls and site visits between our current customers and our prospects. These efforts have provided a higher volume of qualified sales leads and have resulted in more substantive conversations with a larger number of prospects.

We entered into an exclusive National Business Development Services Agreement ("NBDS Agreement") with Relamatrix Group, Inc. ("RMG") through which RMG facilitated business opportunities for CareView. The NBDS Agreement terminated on January 31, 2014. We may still be liable to pay fees to RMG if we actually contract with hospitals initiated through them. Through the date of this filing, we have not entered into any contracts related with hospitals introduced by RMG.

We ensure high levels of customer service through our account representatives and through our technical support processes. We attempt to position our account representatives geographically close to our customer hospitals to allow them to make regular visits to proactively train staff and address any issues. We offer 24/7 monitoring and phone support through our technical support team which allows us to quickly identify and resolve any technical issues. From time to time we are called upon to service the installed hardware at customer facilities. To facilitate expedient service, our account representatives typically maintain a small supply of RCPs should they need repair or replacement. Historically, our RCPs and Nursing Station units have required little, if any, servicing. We believe that we handle requests quickly and efficiently, and that overall, our customers are satisfied with our level of service.

Intellectual Property

Our success depends, in part, on our ability to obtain patents, maintain trade secret protection and operate without infringing the proprietary rights of others. Our intellectual property portfolio is one of the means by which we attempt to protect our competitive position. We rely primarily on a combination of know-how, trade secrets, patents, trademarks and contractual restrictions to protect our products and to maintain our competitive position. We are constantly seeking ways to protect our intellectual property through registrations in relevant jurisdictions.

We have received patents from the U.S. Patent and Trademark Office and have numerous patents pending. We intend to file additional patent applications when appropriate; however, we may not file any such applications or, if filed, the patents may not be issued. We also have numerous registered trademarks.

We intend to aggressively prosecute, enforce and defend our patents, trademarks and proprietary technology. The loss, by expiration or otherwise, of any one patents may have a material effect on our business. Defense and enforcement of our intellectual property rights can be expensive and time consuming, even if the outcome is favorable to us. It is possible that the patents issued to or licensed to us will be successfully challenged, that a court may find that we are infringing validly issued patents of third parties, or that we may have to alter or discontinue the development of our products or pay licensing fees to take into account patent rights of third parties.

On November 16, 2009, we entered into a joint venture relationship with Rockwell Holdings I, LLC, a Wisconsin limited liability company ("Rockwell"), wherein two Wisconsin limited liability companies were formed, CareView-Hillcrest, LLC ("CareView-Hillcrest") and CareView-Saline, LLC ("CareView-Saline") (together known as the "Project LLCs"). Under the terms of a Master Investment Agreement, CareView and Rockwell each own 50% of the Project LLCs with Rockwell providing the financing and CareView providing the technology and expertise to fully implement the CareView System in Hillcrest Medical Center in Tulsa, Oklahoma and Saline Memorial Hospital in Benton, Arkansas. Pursuant to the terms of the Operating Agreements of each of the Project LLCs, we are the managing member. We consolidate the Project LLCs as we have the power to direct the activities and an obligation to absorb losses.

On March 18, 2014, the Project Notes and Rockwell's Preferential Returns, previously due on June 30, 2014 (the "June 2014 extensions"), were extended to June 30, 2015. On February 19, 2015, the Project Notes and Rockwell's Preferential Returns were extended to June 30, 2016.

In conjunction with an August 2013 extension of the due dates of the Project Notes and Rockwell's Preferential Returns to December 31, 2013, the expiration date of the Project Warrant was also extended from November 16, 2014 to November 16, 2015. In October 2015, the expiration date of the Project Warrant was further extended from November 16, 2015 to November 16, 2017. In both cases, all other provisions of the Project Warrant remained unchanged. The Project Warrant were revalued in August 2013 resulting in a \$25,327 increase in fair value, which has been recorded as non-cash costs included in general and administration expense in the accompanying consolidated financial statements. The Project Warrant were also revalued in October 2015 resulting in a \$102,457 increase in fair value, which has been recorded as non-cash costs included in general and administration expense in the accompanying consolidated financial statements. CareView, as 50% owner of the LLCs, is currently negotiating with Rockwell to settle the debt of the LLCs. Although CareView anticipates that this settlement will be forthcoming in the near future, CareView and the LLCs can give no assurances that a settlement will be negotiated, or if negotiated and settled, that it will be through the issuance of CareView's Common Stock.

Installation and Technical Support

We provide installation and technical support for our customers through third-party providers located across the United States that we contract on a per-job basis.

Competition

We offer products in four distinct categories: clinical video monitoring and fall prevention, patient education and entertainment, patient flow, and mobile communications. We have competitors in each of these product areas; however, we believe that we offer the only integrated suite of products that combines all of these areas into one cost-effective platform. Some of our competitors may be larger, may have greater financial resources, and may have a longer history than us. We compete with them based on price, engineering and technological expertise, knowledge, and the quality of our products, systems and services. Additionally, we believe that the successful performance of our installed products and systems is a key factor in retaining current business and gaining new business as customers typically prefer to make significant purchases from a company with a solid performance history.

<u>Clinical Video Monitoring and Fall Prevention:</u> Cisco Systems, Inc., Avasure (a division of AvaSure Holdings, Inc.), and Royal Philips Electronics all provide clinical video monitoring tools. Cisco offers Virtual Patient Observation, a video monitoring tool aimed at reducing sitter costs and preventing patient falls. AvaSure offers a similar application using cameras mounted on a rolling camera stand, aimed at preventing patient falls. Philips offers the eICU product, which primarily targets a high-definition monitoring of patients in intensive-care applications and also provides telephonic consults.

Alternative fall prevention mechanisms include physical sensors manufactured by Stanley and Posey, and beds which include fall alarms manufactured by Stryker and Hill-Rom. Customers may consider these physical fall prevention mechanisms to be alternatives to a video-based fall prevention system such as the one we offer.

<u>Patient Education and Entertainment:</u> There are many vendors who offer patient entertainment products, and most of them also provide a portal for accessing patient educational content either authored by themselves or by third parties. Our major competitors include The GetWellNetwork (privately held by Welsh, Carson, Anderson and Stowe), Skylight Healthcare Systems, and Sonifi Solutions, Inc., all of which offer interactive patient communications systems.

<u>Patient Flow:</u> These systems may be called patient flow, census, bed tracking, patient tracking, or "bed board" applications. Our major competitors include companies that offer focused solutions such as TeleTracking Technologies, Inc., Aionex, Inc., and BedWatch, Inc. Additionally some Electronic Medical Record vendors offer similar products which may compete with our patient flow product.

<u>Mobile Communications:</u> Some competitors offer mobile communications on smart phones or voice-activated pendants which operate over the hospitals Wi-Fi system, including Vocera, Inc., and Voalte, Inc. Other competitors offer special-purpose phones that operate on the cellular network or other wireless technology, and provide notifications to caregivers within the hospital.

The clinical systems offered by our competitors do not appear to offer a video monitoring and observation option as provided by our system. It appears that we are the only company that offers solutions in more than one of the categories listed above.

In addition to favorable economics and enhanced patient care, safety and satisfaction, we also compete on the basis of quality of services provided. Our management believes that our GuestView patient services suite will provide revenue protection for our contracted hospitals under the Value Based Purchasing initiative which is part of the Patient Protection and Affordable Care Act, prompting hospitals to focus on Patient Satisfaction and Hospital Consumer Assessment of Healthcare Providers and Systems to (i) prompt each healthcare facility to promote patients' use of NetView, MovieView, and PatientView, and (ii) encourage the hospital to expand its use of pre-procedure and condition videos, welcome videos, and other ancillary services.

We believe we also compete based on the success of our products and services which provide our customers with:

·significant and tangible cost savings,

- ·reductions in patient falls and pressure ulcers,
- ·improved documentation, quality and timeliness of patient care,
- ·enhanced safety and security for patients and facilities,
- ·support for new technologies,
- ·business growth,
- ·return on investment, and
- \cdot enhanced patient satisfaction.

We are currently unable to predict what competitive impact any regulatory development and advances in technology will have on our future business and results of operations. We believe our success depends upon our ability to maintain and enhance the performance, content and reliability of our products in response to the evolving demands of the industry and any competitive products that may emerge. We cannot give assurances that we will be able to do so

successfully or that any enhancements or new products that we introduce will gain acceptance in the marketplace. If we are not successful or if our products are not accepted, we could lose potential customers to our competitors.

Domain Names

The Company's maintains a website at www.care-view.com.

Major Customers

We derive all of our revenues from hospitals. For the year ended December 31, 2015 96 hospitals accounted for all of our revenue. During 2015, IASIS Healthcare Corporation ("IASIS"), CHS and Tenet, accounted for 30%, 20% and 15% of our net revenues, respectively. For the year ended December 31, 2014, 91 hospitals accounted for the all of our net revenue. During that period, IASIS, CHS and Tenet accounted for 49%, 21% and 12% of our net revenues, respectively.

Backlog

Our estimated backlog is driven by signed Master and P&S Agreements. Each Master and P&S Agreement establishes the rates that we will charge for the use of our products and services as well as an approximate number of billable units that will be installed. Our RCPs, Nursing Stations and mobile devices are billed on a per unit basis. Most Master and P&S Agreements are for five years but include options to cancel after a minimum of two or three years. Backlog, which covers the non-cancellable period, as of December 31, 2015 is approximately \$8,700,000, of which approximately \$5,400,000 is expected to be billed during 2016. Most of the current backlog will have future value as the Master and P&S Agreements continue beyond the minimum two or three years and the Master and P&S Agreements move toward expiration and potential renewal. The amount of the non-cancellable backlog to be billed beyond December 31, 2016 is approximately \$3,300,000.

Research and Development Activities

The cost of our research and development activities for the years ended December 31, 2015 and 2014 totaled approximately \$1,086,000 and \$843,000, respectively. None of the cost of such activities was borne directly by our customers. To date, we have not performed any customer-sponsored research and development activities relating to any new products or services.

Governmental Approval

Neither our Company nor our products are subject to government approval beyond required Federal Communication Commission ("FCC") certifications. Certain medical devices and applications may be subject to Section 510(k) of the Food, Drug, and Cosmetics Act, which regulates the ability of medical device manufacturers to market their devices. CareView has reviewed the requirements for registration, and at the current time, we do not believe that our suite of applications is subject to 510(k) regulation. Although the parameters of our CareView System products and services complies with HIPAA as far as use by health care providers, CareView itself, as the manufacturer and installer of the units, is not subject to HIPAA regulations. We do not know of any other privacy laws that affect our business as we are not in control of nor do we keep patient medical records in our possession. We are unaware of any probable government regulations that may affect our business in the future. We have received Underwriters Laboratories ("UL") and FCC approval on our products. Additionally, the Center for Medicare and Medicaid Services does not pay or reimburse any party for use of our products and services.

Environmental Laws

Our Company and our products are not affected by any federal, state, or local environmental laws; therefore, we have reserved no funds for compliance purposes.

Employees

As of March 1, 2016, we employed 71 persons on a full-time basis, two of whom are executive officers. None of our employees are covered by collective bargaining agreements and we have never experienced a major work stoppage, strike or dispute. We consider our relationship with our employees to be outstanding.

Financial Information about Segments and Geographic Areas

Our business consists of a single segment of products and services all of which are sold and provided within the United States.

Reports to Security Holders

We are subject to the requirements of Section 13(a) under the Exchange Act which requires us to file annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K, and we are required to comply with all other obligations of the Exchange Act applicable to issuers filing registration statements pursuant to Section 12(g) of the Exchange Act. You may read and copy any materials we file with the Securities and Exchange Commission (the "SEC") at the SEC's Public Reference Room at 100 F Street NE, Washington, DC 20549. You may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC also maintains an Internet site that contains reports, proxy and information statements, and other information filed electronically with the SEC at http://www/sec.gov.

You may obtain a copy, free of charge, of our annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after we electronically file such material with the SEC. You may obtain these reports by making a request in writing addressed to: Steven G. Johnson, Chief Executive Officer, CareView Communications, Inc., 405 State Highway 121, Suite B-240, Lewisville, TX 75067 or by downloading these reports and further information about our company on our website at http://www.care-view.com.

We have adopted a Code of Business Conduct and Ethics for all of our officers and directors and a Code of Ethics for Financial Executives. These codes are available for download on our website or may be obtained free of charge by making a request in writing to Steven G. Johnson, as indicated hereinabove.

ITEM 1A. RISK FACTORS.

We are a smaller reporting company, and as such, are not required to provide information pursuant to this item.

ITEM 1B. UNRESOLVED STAFF COMMENTS.

N/A.

ITEM 2. PROPERTIES.

We lease approximately 16,610 square feet of office and warehouse space at 405 State Highway 121, Suite B-240, Lewisville, TX 75067. On December 8, 2014, we entered into a Lease Extension Agreement (the "Lease Extension"), wherein we extended the Lease through June 30, 2020. The Lease Extension contains a renewal provision under which we may renew the Lease for an additional five-year period under the same terms and conditions. The current base lease rate through June 30, 2016 is \$14,188 monthly. The average base lease rate for the Lease Extension is \$15,465. We believe that these premises are adequate and sufficient for our current needs.

ITEM 3. LEGAL PROCEEDINGS.

None.

ITEM 4. MINE SAFETY DISCLOSURE.

N/A.

PART II

ITEMMARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS5.AND ISSUER PURCHASES OF EQUITY SECURITIES.

Market Information

Our Common Stock is traded on the OTCQB as provide by OTC Market Group, Inc. ("OTCQB") under the symbol "CRVW." The following table shows the high and low sales prices of our Common Stock for each full quarterly period within the two most recent fiscal years. The below market quotations reflect inter-dealer prices, without retail mark-up, mark-down or commission, and may not necessarily represent actual transactions.

Quarter Ended	High	Low
Fiscal Year 2015		
Fourth Quarter	\$0.35	\$0.24
Third Quarter	\$0.40	\$0.31
Second Quarter	\$0.46	\$0.34
First Quarter	\$0.53	\$0.33
Fiscal Year 2014		
Fiscal Year 2014 Fourth Quarter	\$0.49	\$0.30
	\$0.49 \$0.72	\$0.30 \$0.42
Fourth Quarter		

Holders

Records of our stock transfer agent indicate that as of March 18, 2016, we had approximately 100 registered shareholders of record. We estimate that there are approximately 1,075 beneficial shareholders who hold their shares in street name. As of the date of this Report, we had 139,380,748 shares of Common Stock issued and outstanding.

Dividends

Historically, we have not paid dividends on our Common Stock and we currently do not intend to pay any dividends on our Common Stock in the foreseeable future. We currently plan to retain any earnings to finance the growth of our business rather than to pay cash dividends.

Securities Authorized for Issuance under Equity Compensation Plans

As of December 31, 2015, the following table shows the number of securities to be issued upon exercise of outstanding stock options under equity compensation plans approved by our shareholders, which plans do not provide for the issuance of warrants or other rights.

Plan Category	Number of Securities to be issued upon exercise of outstanding options (a)	exe out	eighted-average ercise price of estanding tions	Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a) (c)
Equity compensation plans not approved by security holders	_			
Equity compensation plan approved by security holders: 2007 Plan	318,684	\$	0.52	
Equity compensation plan approved by security holders: 2009 Plan	6,774,927	\$	0.62	
Equity compensation plan approved by security holders: 2015 Plan	2,257,056	\$	0.46	2,662,944
Total	9,350,667	\$	0.58	2,662,944

Recent Sales of Unregistered Securities

None.

Cancellation and Expiration of Options

During the year ended December 31, 2015, options to purchase an aggregate of 521,172 shares of our Common Stock were cancelled due to resignation and termination of employees. In addition, during the same time period, options to purchase an aggregate of 6,795,471 shares of our Common Stock expired.

Purchases of Equity Securities by the Issuer and Affiliated Purchasers

None.

ITEM 6. SELECTED FINANCIAL DATA.

We are a smaller reporting company as defined by <u>Rule 229.10(f)(1)</u> and are not required to provide information under this item.

ITEMMANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS7.OF OPERATIONS.

You should read the following discussion and analysis in conjunction with the information set forth under our consolidated financial statements and the notes to those financial statements included elsewhere in this Annual Report. This discussion contains forward-looking statements based upon current expectations that involve risks and uncertainties. Our actual results may differ materially from those contained in or implied by any forward-looking statements.

Company Overview

Our mission is to be the leading provider of products and on-demand application services for the healthcare industry, specializing in bedside video monitoring, software tools to improve hospital communications and operations, and patient education and entertainment packages. Our CareView System suite of video monitoring, guest services and related applications connect patients, families and healthcare providers. Through the use of telecommunications technology and the Internet, our evolving products and on-demand services greatly increase the access to quality medical care and education for patients/consumers and healthcare professionals. We understand the importance of providing high quality patient care in a safe environment and believe in partnering with hospitals to improve the quality of patient care and safety by providing a system that monitors and records continuously. We are committed to providing an affordable video monitoring tool to improve the practice of nursing, create a better work environment and make the patient's hospital stay more informative and satisfying. Our suite of products and services can simplify and streamline the task of preventing and managing patients' falls, enhance patient safety, improve quality of care and reduce costs associated with bringing information technology directly to patients, families and healthcare providers. Our products and services can be used in all types of hospitals, nursing homes, adult living centers and selected outpatient care facilities domestically and internationally.

Liquidity and Capital Resources

Our cash position at December 31, 2015 was approximately \$17,697,000. We also have \$3,250,000 recorded as restricted cash related to a debt covenant in our credit agreement with PDL BioPharma, Inc. as discussed below.

Pursuant to the terms of a Note and Warrant Purchase Agreement dated April 21, 2011 (as subsequently amended) with HealthCor Partners Fund, LP and HealthCor Hybrid Offshore Master Fund, LP ("HealthCor") we are required to maintain a minimum cash balance \$2,000,000 (see *NOTE 11* in the accompanying consolidated financial statements for further details), and we are in compliance with the minimum cash balance as of the date of this filing.

Our continued successful operation is dependent upon us achieving positive cash flow through operations while maintaining adequate liquidity. We expect that the cash on hand, as well as our existing and projected cash flow from billable contracts, will enable us to continue to operate for the next twelve month period. We believe that our sales and marketing plan to attract new business and our ongoing deployment and installation of units under existing hospital agreements, will meet our near-term cash needs and will help us achieve future operating profitability.

At present, we have sufficient inventory to install and service a select number of large customers, but eventually we will need to address additional capital requirements. To that end, on June 26, 2015, we entered into a Credit Agreement with PDL Biopharma, Inc., as administrative agent and lender ("the Lender"), (the "PDL Credit Agreement") pursuant to which the Lender made available to us up to \$40 million in two tranches of \$20 million each, with each tranche contingent upon us meeting certain milestones. On October 7, 2015, pursuant to the First Amendment to the PDL Credit Agreement (the "First Amendment") the Lender made the first tranche of \$20 million available and funded us \$19,533,992, net of fees. Pursuant to the terms of the PDL Credit Agreement, we are required to maintain a minimum cash balance \$3,250,000, and we are in compliance with the minimum cash balance as of the date of this filing (see *NOTE 13* in the accompanying consolidated financial statements for further details). No funds under the second tranche of the PDL Credit Agreement were available to us as of December 31, 2015.

As of December 31, 2015, our working capital was approximately \$17,370,000, our accumulated deficit was approximately \$107,796,000, and our stockholders' deficit was approximately \$25,724,000. Operating loss was approximately \$6,861,000 and \$6,779,000 for the years ended December 31, 2015 and 2014, respectively. Our net loss attributable to CareView was approximately \$16,285,000 and approximately \$14,452,000 for the years ended December 31, 2015 and 2014, respectively.

The following is a summary of cash flow activity for the years ended December 31, 2015 and 2014.

	2015 (000's)	2014
Net cash flows used in operating activities	\$(5,341)	\$(4,541)
Net cash flows used in investing activities	(4,613)	(1,014)
Net cash provided by financing activities	25,087	3,976
Increase (decrease) in cash	15,133	(1,579)
Cash at beginning of period	2,546	4,125
Cash at end of period	\$17,679	\$2,546

The increase in cash flows used in operating activities of approximately \$800,000 is primarily a result of an increase in revenue of approximately \$2,078,000 partially offset by an increase in operating expenses. The increase in cash flows used in investing activities of approximately \$3,600,000 is primarily a result of the addition of \$3,250,000 of restricted cash as stipulated in our credit agreement with PDL BioPharma, Inc. This amount is partially offset by the purchases and installation of CareView Systems and costs associated with patents and trademarks. The increase in cash provided by financing activities of approximately \$21,111,000 primarily reflects the 2015 \$20,000,000 loan from PDL BioPharma, Inc. (regarding PDL BioPharma, Inc. see *NOTE 13* in the accompanying consolidated financial statements for further details).

Results of Operations

Year ended December 31, 2015 compared to year ended December 31, 2014

Year Ended December 31, 2015 2014 Change (000's)

Revenue, net	\$5,139	\$3,062	\$2,077
Operating expenses:			
Network operations	4,598	3,387	1,211
General and administration	3,744	3,283	461
Sales and marketing	845	676	169
Research and development	1,086	844	242
Depreciation and amortization	1,727	1651	76
Operating expenses	12,000	9,841	2,159
Operating loss	\$(6,861)	\$(6,779)	\$82

Revenue, net

Revenue increased approximately \$2,077,000 for the year ended December 31, 2015 as compared to the year ended December 31, 2014. Hospitals with billable units increased to 96 for the year ended December 31, 2015 as compared to 91 for the comparable period for the prior year. Of the 96 hospitals with billable units on December 31, 2015, 2 hospitals groups accounted for 16 and 45 of the total, respectively. Billable units (RCPs and Nurse Stations) for all hospitals totaled 8,136 (7,573 and 563, respectively) on December 31, 2015 as compared to 5,145 (4,876 and 269, respectively) on December 31, 2014.

Operating Expenses

Our principal operating costs include the following items as a percentage of total expense.

	Year Dece 31, 2015	er			
Human resource costs including herefits	40 %		34 9	7_	
Human resource costs, including benefits	40 %		17 9		
Depreciation and amortization expense Travel and entertainment			10 9		
	119				
Other product deployment costs, excluding human resources and travel and entertainment expense	10 %			<i>Т</i> о т	
Non-cash expense related to option grants	8 9			% 7	
Other expenses		6		% 7	
Professional fees and consulting expenses		%		70	
Research and development costs	2 %	6 2	2 9	%	
Other sales and marketing costs, excluding human resources costs, travel and entertainment expense,	2 9	6	1 9	10	
and consulting expenses					
Operating expenses increased by approximately \$2,159,000 (22%) as a result of the following items:					
		(0	00's	5)	
Increase:					
Human resource costs, including benefits					
Travel and entertainment					
Other expenses					
Other sales and marketing costs, excluding human resources costs, travel and entertainment expense, and consulting expenses					
Depreciation and amortization		76	5		
Research and development costs		61	L		
Non-cash expense related to option grants		60)		
Other product deployment costs, excluding human resources and travel and entertainment expense		1()		

Human resource related costs (including salaries and benefits) increased primarily as a result of a higher average head count in 2015 compared to 2014. While we had 75 employees at December 31, 2015 as compared to 48 for the comparable date for the prior year, on average we employed 65 employees over the course of 2015 as compared to 45 for the comparable prior year period.

Decrease in professional and consulting expenses

(289) \$2,159

Travel and entertainment expense increased as a result of increases in (i) meetings with hospital administrators, (ii) attendance at trade shows and seminar, (iii) training efforts related to supporting our existing installed base and (iv) product deployment and installation efforts.

Other expenses increased primarily as a result of (i) increases in property taxes in 2015 over 2014 and decreases in the recovery of sales taxes in 2015 compared to the recovery in 2014, (ii) costs associated with the modification of the Rockwell's Project Warrants and (iii) increases in miscellaneous general and administration expense, including telephone, business insurances, and bad debt expense.

Other sales and marketing expense increased primarily as a result of added attendance at trade shows and seminar over 2014

The decrease in professional and consulting fees was primarily a result of reduced third party sales and marketing efforts to aid us with our sales and contract negotiations and a reduction in legal fees.

Critical Accounting Estimates and New Accounting Pronouncements

Critical Accounting Estimates

The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America ("GAAP") requires management to make estimates and assumptions that affect reported amounts and related disclosures in the financial statements. Management considers an accounting estimate to be critical if:

·if requires assumptions to be made that were uncertain at the time the estimate was made, and changes in the estimate or different estimates that could have been selected could have a material impact on our results of operations or financial condition.

We base our estimates and judgments on our experience, our current knowledge, our beliefs of what could occur in the future, our observation of trends in the industry, information provided by our customers and information available from other sources. Actual results may differ from these estimates under different assumptions or conditions. We have identified the following accounting policies and estimates as those that we believe are most critical to our financial condition and results of operations and that require management's most subjective and complex judgments in estimating the effect of inherent uncertainties: share-based compensation expense, income taxes, complex derivative financial instruments and impairment of long-lived assets.

<u>Share-Based Compensation Expense.</u> We calculate share-based compensation expense for option awards and certain warrant issuances ("Share-based Award(s)") based on the estimated grant/issue date fair value using the Black-Scholes-Merton option pricing model ("Black-Sholes Model"), and recognize the expense on a straight-line basis over the vesting period, net of estimated forfeitures. We have not included an estimate for forfeitures due to our limited history and we revise based on actual forfeitures each period. The Black-Scholes Model requires the use of a number of assumptions including volatility of the stock price, the weighted average risk-free interest rate, and the vesting period of the Share-based Award in determining the fair value of Share-based Awards. Although we believe our assumptions used to calculate share-based compensation expense are reasonable, these assumptions can involve

complex judgments about future events, which are open to interpretation and inherent uncertainty. In addition, significant changes to our assumptions could significantly impact the amount of expense recorded in a given period.

Income Taxes. As part of the process of preparing our consolidated financial statements, we are required to estimate income taxes in each of the jurisdictions in which we operate. Our provision for income taxes is determined using the asset and liability approach to account for income taxes. A current liability is recorded for the estimated taxes payable for the current year. Deferred tax assets and liabilities are recorded for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using the enacted tax rates in effect for the year in which the timing differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of changes in tax rates or tax laws are recognized in the provision for income taxes in the period that includes the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount more-likely-than-not to be realized. Changes in valuation allowances will flow through the statement of operations unless related to deferred tax assets that expire unutilized or are modified through translation, in which case both the deferred tax asset and related valuation allowance are similarly adjusted. Where a valuation allowance was established through purchase accounting for acquired deferred tax assets, any future change will be credited or charged to income tax expense.

The determination of our provision for income taxes requires significant judgment, the use of estimates, and the interpretation and application of complex tax laws. In the ordinary course of our business, there are transactions and calculations for which the ultimate tax determination is uncertain. In spite of our belief that we have appropriate support for all the positions taken on our tax returns, we acknowledge that certain positions may be successfully challenged by the taxing authorities. We determine the tax benefits more likely than not to be recognized with respect to uncertain tax positions. Although we believe our recorded tax assets and liabilities are reasonable, tax laws and regulations are subject to interpretation and inherent uncertainty; therefore, our assessments can involve both a series of complex judgments about future events and rely on estimates and assumptions. Although we believe these estimates and assumptions are reasonable, the final determination could be materially different than that which is reflected in our provision for income taxes and recorded tax assets and liabilities.

<u>Complex Derivative Financial Instruments.</u> From time to time we sell common stock and we issue convertible debt, both with common stock purchase warrants, which may include terms requiring conversion price or exercise price adjustments based on subsequent issuance of securities at prices lower than those in the agreements of such securities. In these situations, the instruments may be accounted for as liabilities and recorded at fair value each reporting period. Due to the complexity of the agreement, we used an outside expert to assist in providing the mark to market fair valuation of the liabilities over the reporting periods in which the original agreement was in effect. It was determined that a Binomial Lattice option pricing model using a Monte Carlo simulation would provide the most accuracy given all the potential variables encompassing a future dilutive event. This model incorporated transaction assumptions such as our stock price, contractual terms, maturity, risk free rates, as well as estimates about future financings, volatility, and holder behavior. Although we believe our estimates and assumptions used to calculate the fair valuation liabilities and related expense were reasonable, these assumptions involved complex judgments about future events, which are open to interpretation and inherent uncertainty. In addition, significant changes to our assumptions could significantly impact the amount of expense recorded in a given period.

Impairment of Long-Lived Assets. Carrying values of property and equipment and finite-lived intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that their carrying values may not be recoverable. If impairment indicators are present, we determine whether an impairment loss should be recognized by testing the applicable asset or asset group's carrying value for recoverability. This assessment requires the exercise of judgment in assessing the future use of and projected value to be derived from the eventual disposal of the assets to be held and used. Assessments also consider changes in asset utilization, including the temporary idling of capacity and the expected timing for placing this capacity back into production. If the carrying value of the assets is not recoverable, then a loss is recorded for the difference between the assets' fair value and respective carrying value. The fair value of the assets is determined using an "income approach" based upon a forecast of all the expected discounted future net cash flows associated with the subject assets. Some of the more significant estimates and assumptions include: market size and growth, market share, projected selling prices, manufacturing cost and discount rate. Our estimates are based upon historical experience, commercial relationships, market conditions and available external information about future trends.

New Accounting Pronouncements

In February 2016, the FASB issued ASU 2016-02, *Leases* ("ASU 2016-02"). The new standard establishes a right-of-use ("ROU") model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. We are evaluating the impact that ASU 2016-03 will have on our consolidated financial statements and related disclosures.

In April 2015, the Financial Accounting Standards Board ("FASB"), issued Accounting Standards Update ("ASU") No. 2015-03, Interest-Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs. ASU 2015-03 requires that debt issuance costs be reported in the balance sheet as a direct deduction from the face amount of the related liability, consistent with the presentation of debt discounts and further requires the amortization of debt issuance cost to be reported as interest expense. Similarly, debt issuance costs and any discount or premium are considered in the aggregate when determining the effective interest rate of the debt. ASU 2015-03 is effective for fiscal years beginning after December 15, 2015 and interim periods within those fiscal years. Early adoption is permitted for annual or interim reporting periods for which the financial statements have not previously been issued. Management has opted for early adoption of ASU 2015-03 and there was no material effect on the 2015 consolidated financial statements upon adoption.

In February 2015, the FASB issued ASU 2015-02, *Amendments to the Consolidation Analysis* ("ASU 2015-02"). The ASU amends the consolidation guidance for VIEs and general partners' investments in limited partnerships and modifies the evaluation of whether limited partnerships and similar legal entities are VIEs or voting interest entities. The ASU is effective for interim and annual reporting periods beginning after December 15, 2015, with early adoption permitted. We are evaluating the effect that ASU 2015-02 will have on our consolidated financial statements and related disclosures.

In August 2014, the FASB issued ASU 2014-15, *Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern* ("ASU 2014-15"), to provide guidance on management's responsibility to perform interim and annual assessments of an entity's ability to continue as a going concern. ASU 2014-15 also requires certain disclosures if conditions or events raise substantial doubt about the entity's ability to continue as a going concern. ASU 2014-15 also requires certain disclosures if applies to all entities and is effective for annual periods ending after December 15, 2016, and interim periods thereafter, with early adoption permitted. We do not expect the adoption of this standard will have an impact on our financial position, results of operations or cash flows.

In May 2014, the FASB issued ASU 2014-09, *Revenue from Contracts with Customers* ("ASU 2014-09"). ASU 2014-09 is a comprehensive new revenue recognition model, which requires a company to recognize revenue to depict the transfer of promised goods or services to a customer in an amount that reflects the consideration the company expects to receive in exchange for those goods or services. The update will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. In August 2015, the FASB issued ASU 2015-14, *Revenue From Contracts With Customers (Topic 606): Deferral of the Effective Date*, which defers the effective date to fiscal periods beginning after December 15, 2017. Early adoption is permitted for fiscal periods beginning after December 15, 2016. The standard permits the use of either the retrospective or cumulative effect transition method. We are evaluating the effect that ASU 2014-09 will have on our consolidated financial statements and related disclosures. We have not yet selected a transition method.

Recent Events Since December 31, 2015

None.

Off-Balance Sheet Arrangements

As of December 31, 2015, we had no material off-balance sheet arrangements.

Contractual Arrangements

Provided in the table below are our known contractual obligations as of December 31, 2015 for the future periods as indicated.

Contractual Obligations

(in thousands)

			2017	2019	Beyond 2020	
	Total	2016	and	and		
			2018	2020	2020	
Long-Term Debt	\$77,653	\$883	\$6,667	\$13,333	\$56,770	
Operating Lease	843	185	373	285		
Total	\$78,496	\$1,068	\$7,040	\$13,618	\$56,770	

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

We are a smaller reporting company as defined by Rule 229.10(f)(1) and are not required to provide information under this item.

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.

Financial statements begin on page F-1 following this Report.

ITEMCHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND9.FINANCIAL DISCLOSURE.

Not Applicable.

ITEM 9A. CONTROLS AND PROCEDURES.

Evaluation of Disclosure Controls and Procedures

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is accumulated and communicated to management, including our chief executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

As of December 31, 2015, management carried out an evaluation, under the supervision and with the participation of our chief executive officer and principal financial officer, of the effectiveness of our disclosure controls and procedures. Based upon the evaluation, our chief executive officer and principal financial officer concluded that, as of December 31, 2015, our disclosure controls and procedures were effective at the reasonable assurance level.

There are inherent limitations to the effectiveness of any system of disclosure controls and procedures. Accordingly, even effective disclosure controls and procedures can only provide reasonable assurances of achieving their control objectives.

Management's Report on Internal Control Over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting, as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act, is a process designed by, or under the supervision of, the chief executive officer and chief financial officer, or persons performing similar functions, and effected by the board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP and includes those policies and procedures that: (i) pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the Company, (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company, and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company's assets that could have a material effect on the financial statements.

Because of inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions or that the degree of compliance with the policies or procedures may deteriorate.

Our management, under the supervision and with the participation of our chief executive officer and principal financial officer, conducted an evaluation of the effectiveness of our internal control over financial reporting using the criteria set forth in 2013 by the Committee of Sponsoring Organizations of the Treadway Commission in *Internal Control—Integrated Framework*. Based on this evaluation our management concluded that our internal control over financial reporting was effective as of December 31, 2015.

Changes in Internal Control Over Financial Reporting

There were no material changes in our internal control over financial reporting that occurred during the fourth quarter of 2015 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

ITEM 9B. OTHER INFORMATION.

Amendments to the 2011 Note and Warrant Purchase Agreement

As previously reported in our Current Report on Form 8-K filed with the SEC on April 27, 2011, we entered into a Purchase Agreement dated April 21, 2011 (as subsequently amended) with HealthCor. As previously reported in our Current Report on Form 8-K filed with the SEC on December 19, 2014, we entered into the Fifth Amendment with HealthCor and the New Investors.

Sixth Amendment

On March 31, 2015, we entered into the Sixth Amendment pursuant to which, among other things, (i) the requirement to maintain a minimum cash balance of \$5,000,000 was reduced to a minimum cash balance of \$2,000,000 and (ii) the amendment provision was revised to permit the Purchase Agreement to be amended by the Company and the holders of the majority of the Common Stock underlying the outstanding notes and warrants to purchase shares of our Common Stock sold pursuant to the Purchase Agreement (on an as-converted basis). The foregoing description of the Sixth Amendment is qualified, in its entirety, by reference to the Sixth Amendment, a copy of which is attached as an exhibit hereto. On March 31, 2015, we also issued a warrant to HealthCor to purchase up to an aggregate of 1,000,000 shares of our Common Stock in consideration for certain prior waivers of the minimum cash balance requirement in the Purchase Agreement (the "Warrant"). The Warrant has an exercise price per share equal to \$0.53 (subject to adjustment as described therein) and an expiration date of March 31, 2025. We relied upon the exemption from registration provided by Regulation D under the Securities Act of 1933, as amended, for the issuance of this Warrant. The foregoing description of the Warrant is qualified, in its entirety, by reference to the form of Warrant, a copy of which is attached as an exhibit hereto.

Seventh Amendment

On June 26, 2015, we (i) entered into a Seventh Amendment to the HealthCor Purchase Agreement (the "Seventh Amendment") pursuant to which the HealthCor Purchase Agreement was amended to permit the Company to enter into and perform its obligations under the Credit Agreement entered into with PDL BioPharma, Inc., as administrative agent and lender (the "Lender") (the "PDL Credit Agreement"); (ii) executed an Amendment to the Registration Rights Agreement between the Company and HealthCor dated April 21, 2011 (the "RR Agreement") pursuant to which the RR Agreement was amended to make its priority of registration consistent with the Registration Rights Agreement executed by the Company and Lender; (iii) amended the 2011 HealthCor Notes to extend the maturity date, in the event that Tranche Two of the PDL Credit Agreement is funded, for such notes to 90 days after the earlier of the Tranche Two maturity date or repayment date, but not later than December 31, 2022, (iv) amended the 2012 HealthCor Notes, to set the maturity date at January 30, 2022 and, in the event that Tranche Two of the PDL Credit

Agreement is funded, to extend such maturity date to 90 days after the earlier of the Tranche Two maturity date or repayment date, but later than December 31, 2022; and (v) amended each of the Senior Secured Convertible Notes issued under the HealthCor Purchase Agreement (the "HealthCor Notes") to, among other things, subordinate the HealthCor Notes to the loans under the PDL Credit Agreement and to increase certain event of default acceleration and payment thresholds. The foregoing description of the Seventh Amendment is qualified, in its entirety, by reference to the Seventh Amendment, a copy of which is attached as an exhibit hereto.

PART III

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE.

Directors, Executive Officers, Promoter and Control Persons

The following table sets forth information on our executive officers and directors as of the filing of this Report. All executive officers serve at the discretion of the Board of Directors. The term of office of each of our directors expire at our next Annual Meeting of Shareholders or until their successors are duly elected and qualified. We do not have any promoters or control persons.

Name	Ag	ePosition	Date Elected Director	Date Appointed Officer
L. Allen Wheeler	83	Chairman of the Board, Principal Financial Officer, Chief Accounting Officer	January 26, 2006	September 6, 2013
Steven G. Johnsor	n 56	Chief Executive Officer, President, Secretary, Treasurer, Director	April 11, 2006	April 11, 2006
Sandra K. McRee	60	Chief Operating Officer	N/A	November 1, 2013
Jeffrey C. Lightca	p57	Director	April 21, 2011	N/A
David R. White	68	Director	January 1, 2014	N/A
Jason T. Thompson	41	Director	January 1, 2014	N/A
Steven B Epstein	72	Director	April 1, 2014	N/A
Dr. James R. Higgins	66	Director	April 1, 2014	N/A

Mr. Lightcap was elected to serve on our Board of Directors pursuant to the terms of the HealthCor Note Purchase Agreement executed on April 21, 2011. Other than Mr. Lightcap, there are no arrangements or understandings between our directors and executive officers and any other person pursuant to which any director or officer was or is to be selected as a director or officer, and there are no arrangements, plans or understandings as to whether non-management shareholders will exercise their voting rights to continue to elect the current board of directors. There are also no arrangements, agreements or understandings to our knowledge between non-management shareholders that may directly or indirectly participate in or influence the management of our affairs.

In September 2013, our Chief Financial Officer, Treasurer and Secretary resigned. Until such time as those positions are filled, Steven Johnson, our Chief Executive Officer and President, will also serve as our Secretary and

Treasurer. In addition, L. Allan Wheeler, our Chairman of the Board and former chairman of the Audit Committee, will serve as our Principal Financial Officer and Chief Accounting Officer as those positions relate to our annual and quarterly filings with the SEC.

Identification of Certain Significant Employees

Kyle Johnson, our Director of Engineering, and Matthew E. Jackson, General Counsel, are considered significant employees. An overview of their business experience follows in *Business Experience* found within this Item 10.

Family Relationships

There are no family relationships between our officers and members of our Board of Directors.

Business Experience of Directors, Executive Officers and Significant Employees

The business experience of each of our directors, executive officers and significant employee follows:

Steve G. Johnson - Chief Executive Officer, President, Secretary, Treasurer, Director

Steven G. Johnson currently serves as Chief Executive Officer (effective January 1, 2014), President, Secretary, Treasurer and Director. Mr. Johnson also served as Chief Operating Officer until November 1, 2013. In December 2003, he filed for patent protection as the inventor of a Non-Intrusive Data Transmission Network for Use in an Enterprise Facility and Method for Implementing in the United States, which invention was subsequently assigned to CareView and was issued a patent number by the USPTO. The technology underlying this patent is the basis of the CareView System suite. Mr. Johnson is also one of the inventors on three issued patents for a Non-intrusive data transmission network for use in an enterprise facility and method for Using a Video Monitoring System to Prevent and Manage Decubitus Ulcers in Patients in the U.S., and five additional pending patent applications for a System and Method for Implementing in the U.S., a Continuation patent for System and Method for Predicting Falls in the U.S., a Noise Correcting Patient Fall Risk State System and Method for Predicting Patient Falls in the U.S., and a System and Method for Predicting Patient Falls in the U.S., all technology currently being deployed or in further development by CareView. Mr. Johnson has over 20 years of experience in the cable and wireless industry.

Before joining CareView in 2006, he served as Chief Executive Officer of Cadco Systems, a manufacturer of CATV and telecommunications equipment from 1997. From February 1991 to February 1996, he served as CEO, President and Director of American Wireless Systems, which he restructured and sold to Heartland Wireless Communications. Mr. Johnson also served as founder and President of Hanover Systems, a manufacturer of telecommunications equipment. Mr. Johnson has been actively involved with the wireless cable industry since 1984 and has served on the board of directors of the Wireless Cable Association and its FCC regulatory committee. Mr. Johnson developed various electronic telecommunications equipment for the wireless cable industry including microwave downconverters, wireless cable set top converters, antennas, and transmitters. Mr. Johnson's accumulated knowledge in the field of technology, coupled with his development of patentable technology, makes him an invaluable member of our management team. Mr. Johnson earned his BA in Economics and Business Administration from Simpson College and currently serves as a Trustee on the Simpson College Board of Trustees. Mr. Johnson is the father of Kyle Johnson, our Director of Engineering.

Sandra K. McRee - Chief Operating Officer

Sandra K. McRee joined CareView as Chief Operating Officer effective November 1, 2013. Ms. McRee also currently serves as President of McRee Consulting. Ms. McRee most recently served as the Vice Chair of the Board of Directors of IASIS Healthcare Corporation ("IASIS") from April 2010 until October 2011. Previously, she served as Chief Operating Officer of IASIS from May 2001 until October 2010, and President from May 2004 to April 2010. At IASIS, she was responsible for overseeing all aspects of IASIS's hospital operations and was responsible for overseeing clinical systems; developing an appropriate mix of quality services, physician relationships, effective staffing and supply utilization; and managing capital investments related to operations. From April 1999 through May 2001, Ms. McRee was Regional Vice President for Province Healthcare Corporation where she oversaw five facilities in Florida, Louisiana and Mississippi. Ms. McRee has more than 35 years of healthcare management experience. Ms. McRee has spent her entire professional career in the healthcare industry. She currently serves on the Board of Directors of Denver School of Nursing. Ms. McRee previously served on the Boards of EDCare, a national emergency room management company owned by Gemini Investors from August 2005 to July 2008, Mid-Western University from July 2000 to August 2004 and All About Women. Ms. McRee is a member of Women Business Leaders of the U.S. HealthCare Industry Foundation, a nonprofit organization that was established in 2001 to address the unique needs of women serving in a senior executive capacity in the U.S. healthcare industry and was a member of the Executive Leadership Team of Go Red for Women.

L. Allen Wheeler - Chairman of the Board, Principal Financial Officer, Chief Accounting Officer

Mr. Wheeler has served as a Director of CareView since January 2006 and on January 1, 2014 became our Chairman of the Board. In addition, he currently serves as our Principal Financial Officer and Chief Accounting Officer while we seek a qualified candidate to fill those positions. Mr. Wheeler has been a private investor for over 40 years with interests in nursing homes, banks, cable television, radio stations, real estate and ranching. Currently, Mr. Wheeler owns and operates three Abstract and Title companies in Bryan County, Oklahoma. Mr. Wheeler served on the Board of Directors of Texoma Medical Center from 1994 to 2005 and acted as Chairman of the Board from 2002 to 2005. Mr. Wheeler served as President of the Durant Industrial Authority for numerous years. Mr. Wheeler's knowledge of the healthcare industry (as it relates to nursing homes), his technical knowledge of the broadcast television industry, and his expertise relative to investments and equity placements, qualifies him as a significant member of our board of directors. Mr. Wheeler earned his B.A. from Southeastern Oklahoma State University. Mr. Wheeler was elected Alumni of the Year of Southeastern Oklahoma State University in 2001.

Jeffrey D. Lightcap - Director

Mr. Lightcap was elected as a Director of CareView on April 21, 2011. Since October 2006, Mr. Lightcap has served as a Senior Managing Director at HealthCor Partners Management, LP, a growth equity investor in early and near commercial stage healthcare companies in the diagnostic, therapeutic, medtech, and HCIT sectors. From 1997 to mid-2006, Mr. Lightcap served as a Senior Managing Director at JLL Partners, a leading middle-market private equity firm. Prior to JLL Partners, Mr. Lightcap served as a Managing Director at Merrill Lynch & Co., Inc. in charge of leverage buyout coverage for Merrill Lynch's mergers and acquisitions group. Prior to joining Merrill Lynch, Mr. Lightcap was a Senior Vice President in the mergers and acquisitions group at Kidder, Peabody & Co. and briefly at Salomon Brothers. Mr. Lightcap received a B.E. in Mechanical Engineering from the State University of New York at Stony Brook in 1981 and in 1985 received an MBA from the University of Chicago. Mr. Lightcap currently also serves as Chairman of the Board of Directors at Corindus Vascular Robotics, Inc. (NYSE: CVRS), a robotic medical device company and serves as a director of the following companies: IASIS Healthcare Corporation, a private hospital group; Practice Partners in HealthCare, a private ambulatory surgical center company; Paradigm Spine, LLC, a leader in the field of non-fusion, spinal implant technology; Heartflow Inc., a company focused on the non-invasive diagnosis of coronary artery disease; KellBenx, Inc., a prenatal diagnostic technology company; and Claret Medical, Inc., a private embolic protection device company. Mr. Lightcap's experience with fundraising in the private equity market and his leadership skills exhibited throughout his career make him well-qualified to serve as one of the Company's directors.

David R. White - Director

David R. White was elected as a director on January 1, 2014. From December 1, 2000 to November 1, 2010, Mr. White served as the Chief Executive Officer of IASIS Healthcare Corporation and he served as the Chief Executive

Officer of IASIS Healthcare LLC from December 1, 2000 to October 2010. Mr. White served as the President of IASIS Healthcare Corporation from May 22, 2001 to May 2004 and also served as the President of IASIS Healthcare LLC from May 22, 2001 to May 2004. He served as the President and Chief Executive Officer of LifeTrust, from November 1998 to November 2000. From June 1994 to September 1998, Mr. White served as President of the Atlantic Group at Columbia/HCA, where he was responsible for 45 hospitals located in nine states. He has also served as Regional Vice President of Republic Health Corporation. Previously, Mr. White served as an Executive Vice President and Chief Operating Officer at Community Health Systems, Inc. He has been Executive Chairman of Anthelio Healthcare Solutions Inc. since June 2012 and has been its Independent Director since July 28, 2011. He has been Chairman of the Board at IASIS Healthcare Corporation since October 1999. He has been Member of Strategic Advisory Board of Satori World Medical, Inc. since 2011. He has been a Director of REACH Health, Inc. since August 30, 2011. He also serves as a director to CareView Communications, Inc. (OTCQB: CRVW), a healthcare technology company. He served as Non-Executive Director at Parkway Holdings Limited from July 15, 2005 to March 8, 2007. Mr. White earned a B.S. in Business Administration from the University of Tennessee in Knoxville, TN in 1970, and an MS in Healthcare Administration from Trinity University in San Antonio, TX in 1973. Mr. White's lifetime career and knowledge in the healthcare industry makes him well-gualified to serve as a director of the Company.

Jason T. Thompson - Director

Jason T. Thompson was elected as a Director of CareView effective as of January 1, 2014. Mr. Thompson is a partner and a member of the transactional group of Michael Best & Friedrich LLP where he focuses on mergers and acquisitions and general corporate matters, having joined Michael Best in September 2006. Mr. Thompson assists his clients with negotiating and structuring many types of transactions and agreements, including those related to corporate reorganizations, buyout transactions and venture capital investment transactions. In addition, he is President of Thompson Family Holdings, LLC, which invests in, and consults for, a number of healthcare companies, having joined Thompson Holdings in 2010. From 1999 to 2004, Mr. Thompson served as Vice President of Development and Planning for Bulk Petroleum Corporation, where he oversaw sales, operations, client maintenance, scheduling accounting and workforce management for its construction projects. Mr. Thompson currently also serves as a director of the following companies: ClearAudit Audit, LLC, a consulting and technology company specializing in supply chain best practices and cost reduction strategies and O'Sheridan Insurance Alliance, Inc., an insurance and employee benefits company. Prior to joining Bulk Petroleum, Mr. Thompson was a senior auditor with Arthur Andersen. He is a certified public accountant. Mr. Thompson received a BBA in Accounting from the University of Wisconsin - Madison in 1996 and in 2006, received his JD from the University of Wisconsin, where he was a member of the Wisconsin Law Review. His business, accounting and legal experience makes him well-qualified to serve as one of the Company's directors.

Steven B Epstein - Director

Steven B. Epstein was elected as a Director of CareView effective as of April 1, 2014. Mr. Epstein is the founder of Epstein Becker & Green, P.C., a leading law firm in health care law with over 250 lawyers in 10 cities, where he serves as a senior health adviser. Mr. Epstein is a pioneer in the legal specialty known as health care law and provides a wide range of health care organizations and providers with strategic legal guidance responding to the legal challenges and opportunities of the rapidly changing American health care system. Mr. Epstein was instrumental in the acceptance of managed care as the prominent form of health care delivery and has been referred to as the "father of the healthcare [legal] industry", as stated in Chambers USA. Mr. Epstein received his Bachelors of Arts from Tufts University in 1965, where he was awarded the Tufts University Distinguished Alumni Award and served as a member of the Board of Trustees from 1999-2009. He received his Juris Doctor from Columbia Law School in 1968. He is the recipient of Columbia University's Distinguished Alumni Award and Columbia Law School's Medal for Excellence, Columbia Law School's most prestigious award and served as chairman of the Columbia Law School Board of Visitors from 2002-2015. Mr. Epstein currently also serves as a director of the following companies: Discovery Ltd. (JSE: DSY), a South African insurance and wellness company, Accumen, Inc., a private lab services company; Advance Health, a private nurse assessments service company; Haights Cross Communications, Inc. a private education provider company; National Compliance Solutions, Inc.; a private drug and background search company; OrthoSensor, Inc.; a private orthopedic medical device company; ResCare, Inc. a private disability care company; Restorix Health, a private wound care company; and Solis Women's Health, a private mammography company. Mr. Epstein's lifetime legal career and knowledge in the healthcare industry makes him well-qualified to serve as a director of the Company.

Dr. James R. Higgins - Director

Dr. James R. Higgins was elected as a director of CareView effective as of April 1, 2014. Dr. Higgins is a cardiologist practicing in Tulsa, Oklahoma. In addition to being boarded in cardiology he has sub specialty boards in nuclear cardiology, electrophysiology, invasive cardiology, cardiac CT angiography, echocardiography, carotid and peripheral sonography, pacemakers and defibrillators. He graduated summa cum laude with a BS degree in electrical engineering from South Dakota State University and sum cum laude with a MD degree from the University of Rochester School of Medicine and Dentistry. He was an extern at the Massachusetts General Hospital in Boston, and intern, resident, and chief resident at Barnes Hospital, Washington University, in St. Louis Missouri. His cardiology fellowship was obtained at the University of California, San Francisco, Moffitt and Long Hospital. He was then the Director of research and invasive cardiology at Wilford Hall Medical Center, United States Air Force, San Antonio, Texas. In addition to his busy cardiology practice, Dr. Higgins has started and owns a real estate company, an electronic medical billing company, an oil pipeline supply company, and has a large cattle ranch operation in Oklahoma. He has published more than 300 peer review articles and has multiple patents on medical devices, mainly related to pacemakers and internal defibrillators. Dr. Higgin's vast experience in the healthcare industry makes him well-qualified to serve as a director of the Company.

Kyle Johnson - Director of Engineering

Kyle Johnson has served as our Director of Engineering since August 2006 and is responsible for the design and development of our Room Control Platform and deployment of systems to hospitals. From June 2004 to August 2006, he served as Senior Product Manager of Cadco Systems, a company that specializes in broadband electronic design and manufacturing. As Senior Project Manager, Mr. Johnson managed the design and development of several products including the development of the technology used in the CareView System suite. Mr. Johnson is also one of the inventors on one issued patent for a System and Method for Using a Video Monitoring System to Prevent and Manage Decubitus Ulcers in Patients in the U.S. and an additional pending patent application for a System and Method for Predicting Falls in the U.S. (the technology underlying CareView's Virtual Bed Rails). From February 2000 to June 2004, Mr. Johnson served as General Manager and Chief Engineer for 391 Communications, a company that is a service provider to cable and wireless cable companies. Mr. Johnson has been involved in several large scale deployments of CATV, MMDS, and DBS satellite systems, as well as designing and building numerous CATV/MMDS head-ends for major domestic and foreign CATV/MMDS providers. Mr. Johnson is the son of Steven Johnson, our Chief Executive Officer and President.

Matthew E. Jackson - General Counsel

Mr. Jackson joined CareView in 2012. Mr. Jackson is responsible for all company legal matters including drafting and negotiating contracts, litigation, risk management, labor and employment, corporate securities and corporate

governance. Prior to joining the Company, Mr. Jackson practiced as a civil trial lawyer specializing in business litigation and transactional law. Mr. Jackson graduated from the University of Santa Barbara with a Bachelor of Science in Geology and earned his Juris Doctor from Whittier Law School. Mr. Jackson is admitted to practice law in both Texas and California.

Other Directorships

Other than as indicated within this section at *Business Experience*, none of our directors hold or have been nominated to hold a directorship in any company with a class of securities registered pursuant to Section 12 of the Exchange Act (the "Act") or subject to the requirements of Section 15(d) of the Securities Act of 1933, or any company registered as an investment company under the Investment Company Act of 1940.

Committees of the Board

Audit Committee

The Audit Committee reviews and discusses the audited consolidated financial statements with management, discusses with our independent registered public accounting firm matters required to be discussed by Public Company Accounting Oversight Board Auditing Standard No. 16 (Communications with Audit Committees) and Rule 3520 (Auditor Independence), and makes recommendations to the Board of Directors regarding the inclusion of our audited financial statements in this Annual Report on Form 10-K.

Our Audit Committee's primary function is to provide advice with respect to our financial matters and to assist our Board of Directors in fulfilling its oversight responsibilities regarding finance, accounting, and legal compliance. The Audit Committee's primary duties and responsibilities are to: (i) serve as an independent and objective party to monitor our financial reporting process and internal control system, (ii) review and appraise the audit efforts of our independent registered accounting firm, (iii) evaluate our quarterly financial performance as well as its compliance with laws and regulations, (iv) oversee management's establishment and enforcement of financial policies and business practices, and (v) provide an open avenue of communication among the independent accountants, management and our Board of Directors.

For the year ended December 31, 2015, and as of the filing date of this Report, our Audit Committee consisted of three members of our Board of Directors, namely Jason Thompson as Chair, Allen Wheeler and Jeffrey Lightcap. Messrs. Thompson and Lightcap are deemed to be financial experts. Although our Board of Directors believes the members of our Audit Committee will exercise their judgment independently, no member is totally free of relationships that, in the opinion of the Board of Directors, might interfere with their exercise of independent judgment as a committee member. The Audit Committee's Chair and members are to be designated annually by a majority vote of the Board of Directors. Any member may be removed at any time, with or without cause, and vacancies may be filled by a majority vote of the Board of Directors.

Compensation Committee

Our Compensation Committee's function is to provide assistance to our Board of Directors in fulfilling their responsibility to our shareholders, potential shareholders, and the investment community relating to developing policies and making specific recommendations to the Board of Directors with respect to the direct and indirect compensation of our executive officers. The goal of such policies is to ensure that an appropriate relationship exists between executive pay and the creation of shareholder value, while at the same time motivating and retaining key employees. Our Compensation Committee's primary duties and responsibilities are to: (i) review and approve our

Company's goals relevant to the compensation of our Chief Executive Officer, evaluate the Chief Executive Officer's performance with respect to those goals, and set the Chief Executive Officer's compensation based on that evaluation; (ii) assess the contributions of individual executives and recommend to our Board of Directors levels of salary and incentive compensation payable to them; (iii) compare compensation levels with those of other leading companies in the industry; (iv) grant stock incentives to key employees and administer our stock incentive plans; (v) monitor compliance with legal prohibition on loans to directors and executive officers; and (vi) recommend to our Board of Directors as requested.

For the year ended December 31, 2015, and as of the filing date of this Report, our Compensation Committee consisted of three members of ours Board of Directors, namely Allen Wheeler as Chair, Jeffrey Lightcap and David White. Although our Board of Directors believes the members of our Compensation Committee will exercise their judgment independently, no member is totally free of relationships that, in the opinion of our Board of Directors, might interfere with their exercise of independent judgment as a committee member. Our Compensation Committee's Chair and members are to be designated annually by a majority vote of our Board. Any member may be removed at any time, with or without cause, and vacancies may be filled by a majority vote of our Board.

Nominating Committee

We do not currently have a Nominating Committee; therefore, our Board, as a whole, identifies director nominees by reviewing the desired experience, mix of skills and other qualities to assure appropriate Board composition, taking into consideration our current Board members and the specific needs of our Company and our Board. Among the qualifications to be considered in the selection of candidates, our Board considers the following attributes and criteria of candidates: experience, knowledge, skills, expertise, diversity, personal and professional integrity, character, business judgment and independence. Our Board recognizes that nominees for the Board should reflect a reasonable diversity of backgrounds and perspectives, including those backgrounds and perspectives with respect to business experience, professional expertise, age, gender and ethnic background. Nominations for the election of directors may be made by any member of the Board.

Our Board will also evaluate whether the nominee's skills are complementary to the existing Board members' skills; our Board's needs for operational, management, financial, technological or other expertise; and whether the individual has sufficient time to devote to the interests of our Company. The prospective Board member cannot be a board member or officer at a competing company nor have relationships with a competing company and must be clear of any investigation or violations that would be perceived as affecting the duties and performance of a director.

Our Board identifies nominees by first evaluating the current members of our Board willing to continue in service. Current members of our Board with skills and experience that are relevant to the business and who are willing to continue in service are considered for re-nomination, balancing the value of continuity of service by existing members of the Board with that of obtaining a new perspective. If any member of our Board does not wish to continue in service, or if our Board decides not to nominate a member for re-election, our Board identifies the desired skills and experience of a new nominee and discusses with our Board suggestions as to individuals that meet the criteria.

Our Board is comprised of accomplished professionals who represent diverse and key areas of expertise including national business, operations, manufacturing, government, finance and investing, management, entrepreneurship, higher education and science, research and technology. We believe our directors' wide range of professional experiences and backgrounds, education and skills has proven invaluable to our Company and we intend to continue leveraging this strength.

Board Involvement in Risk Oversight

Our Board of Directors is responsible for oversight of our risk assessment and management process. We believe risk can arise in every decision and action taken by us, whether strategic or operational. Our comprehensive approach is reflected in the reporting processes by which our management provides timely information to our Board of Directors

to support its role in oversight, approval and decision-making.

Our Board of Directors closely monitors the information it receives from management and provides oversight and guidance to our management team concerning the assessment and management of risk. Our Board of Directors approves our high level goals, strategies and policies to set the tone and direction for appropriate risk taking within the business.

Our Board of Directors serving on the Compensation Committee have basic responsibility for oversight of management's compensation risk assessment, and that committee reports to the Board on its review. Our Board of Directors also delegated tasks related to risk process oversight to our Audit Committee, which reports the results of its review process to our Board of Directors. The Audit Committee's process includes a review, at least annually, of our internal audit process, including the organizational structure, as well as the scope and methodology of the internal audit process. The Board, as a whole, functions as the nominating committee to oversee risks related to our corporate governance, including director performance, director succession, director education and governance documents.

Code of Business Conduct and Ethics

Our Board of Directors adopted a Code of Business Conduct and Ethics applicable to all of our directors and executive officers. This code is intended to focus the members of our Board of Directors and each executive officer on areas of ethical risk, provide guidance to directors and executive officers to help them recognize and deal with ethical issues, provide mechanisms to report unethical conduct, and help foster a culture of honesty and accountability. All members of our Board of Directors and all executive officers are required to sign this code on an annual basis.

Code of Ethics for Financial Executives

Our Board of Directors adopted a Code of Ethics applicable to all financial executives and any other senior officer with financial oversight responsibilities. This code governs the professional and ethical conduct of our financial executives, and directs that they: (i) act with honesty and integrity; (ii) provide information that is accurate, complete, objective, relevant, and timely; (iii) comply with federal, state, and local rules and regulations; (iv) act in good faith with due care, competence and diligence; and (v) respect the confidentiality of information acquired in the course of their work and not use the information acquired for personal gain. All of our financial executives are required to sign this code on an annual basis.

Insider Trading Policy

Our Board of Directors adopted an Insider Trading Policy applicable to all directors and officers. Insider trading generally refers to the buying or selling of a security in breach of a fiduciary duty or other relationship of trust and confidence while in possession of material, non-public information about the security. Insider trading violations may also include 'tipping' such information, securities trading by the person 'tipped,' and securities trading by those who misappropriate such information. The scope of insider trading violations can be wide reaching. As such, our Insider Trading Policy outlines the definitions of insider trading, the penalties and sanctions determined, and what constitutes material, non-public information. Illegal insider trading is against our policy as such trading can cause significant harm to our reputation for integrity and ethical conduct. Individuals who fail to comply with the requirements of the policy are subject to disciplinary action including dismissal for cause. All members of our Board of Directors and all executive officers are required to ratify the terms of this policy on an annual basis.

Whistleblower Policy

Our Board of Directors adopted a Whistleblower Policy to establish and maintain a complaint program to facilitate (i) the receipt, retention and treatment of complaints received by us regarding our accounting, internal accounting controls, auditing matters or violations of the Code of Conduct and (ii) the confidential, anonymous submission by our employees of concerns regarding questionable accounting or auditing matters. Any person with a concern relating to the Accounting Policies or compliance with our Code of Conduct should submit their concern in writing to the Chair of our Audit Committee. Complaints may be made without fear of dismissal, disciplinary action or retaliation of any kind. We will not discharge, discipline, demote, suspend, threaten or in any manner discriminate against any officer or employee in the terms and conditions of employment based on any lawful actions with respect to (i) good faith reporting of concerns or complaints regarding Accounting Policies, or otherwise specified in Section 806 of the U.S. Sarbanes-Oxley Act of 2002, (ii) compliance with our Code of Conduct or (iii) providing assistance to the Audit Committee, management or any other person or group, including any governmental, regulatory or law enforcement body, investigating a concern.

Related Party Transactions Policy

Our Board of Directors adopted a Related Party Transactions Policy as we recognize that transactions involving related parties present a heightened risk of conflicts of interest and/or improper valuation (or the perception thereof). Therefore, our Board determined that our Audit Committee shall review, approve and, if necessary, recommend to the Board for its approval all related party transactions and any material amendments to such related party transactions. Our Board may determine that a particular related party transaction or a material amendment thereto shall instead be reviewed and approved by a majority of directors disinterested in the related party transaction. No director shall participate in any approval of a related party transaction for which the director is a related party, except that the director shall provide all material information concerning the related party transaction to the committee. Our President is responsible for providing to the Audit Committee, on a quarterly basis, a summary of all payments made by or to us in connection with duly approved related party transactions during the preceding fiscal quarter. The President is responsible for reviewing and approving all payments made by or to us in connection with such related party transactions have been made in accordance with the policy. All related party transactions shall be disclosed in our applicable filings as required by the Securities Act of 1933 and the Securities Exchange Act of 1934 and related rules and regulations.

Committee Charters, Corporate Governance Guidelines, and Codes of Ethics

Our Board of Directors adopted charters for the Audit and Compensation Committees describing the authority and responsibilities delegated to each committee. We post on our website the charters of our Audit and Compensation Committees, our Code of Conduct and Ethics, our Code of Ethics for Financial Executive, and any amendments or waivers thereto applicable to our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions; and any other corporate governance materials contemplated by SEC regulations. These documents are also available in print to any stockholder requesting a copy in writing from our Secretary at our executive offices set forth in this Report.

Board Meetings and Committees; Annual Meeting Attendance

We held seven meetings of the Board of Directors during the year ended December 31, 2015 and conducted other business through unanimous written actions.

Indemnification

Section 145 of the Nevada Corporation Law provides in relevant parts as follows:

(1) A corporation shall have power to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending, or completed action, suit, or proceeding, whether civil, criminal, administrative, or investigative (other than an action by or in the right of the corporation) by reason of the fact that he is or was a director, officer, employee, or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee, or agent of another corporation, partnership, joint venture, trust, or other enterprise, against expenses (including attorneys' fees), judgments, fines, and amounts paid in settlement actually and reasonably incurred by him in connection with such action, suit, or proceeding if he acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding by judgment, order, settlement, conviction, or on a plea of nolo contendere or its equivalent, shall not, of itself, create a presumption that the person did not act in good faith and in a manner which he reasonably believed to be in or not opposed to the best interests of the corporation, and with respect to any criminal action or proceeding by judgment, order, settlement, conviction, or on a plea of nolo contendere or its equivalent, shall not, of itself, create a presumption that the person did not act in good faith and in a manner which he reasonably believed to be in or not opposed to the best interests of the corporation, and with respect to any criminal action or proceeding, had reasonable cause to believe that his conduct was unlawful.

(2) A corporation shall have power to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending, or completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that he is or was a director, officer, employee, or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee, or agent of another corporation, partnership, joint venture, trust, or other enterprise against expenses (including attorneys' fees) actually and reasonably incurred by him in connection with the defense or settlement of such action or suit if he acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the corporation and except that no indemnification shall be made in respect of any claim, issue, or matter as to which such person shall have been adjudged to be liable for negligence or misconduct in the performance of his duty to the corporation that, despite the adjudication of liability but in view of all circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which such court shall deem proper.

(3) To the extent that a director, officer, employee, or agent of a corporation has been successful on the merits or otherwise in defense of any action, suit, or proceeding referred to in (1) or (2) of this subsection, or in defense of any claim, issue or matter therein, he shall be indemnified against expenses (including attorneys' fees) actually and reasonably incurred by him in connection therewith.

(4) The indemnification provided by this section shall not be deemed exclusive of any other rights to which those seeking indemnification may be entitled under any bylaws, agreement, vote of stockholders or disinterested directors or otherwise, both as to action in his official capacity and as to action in another capacity while holding such office, and shall continue as to a person who has ceased to be a director, officer, employee, or agent and shall inure to the benefit of the heirs, executors, and administrators of such a person.

The foregoing discussion of indemnification merely summarizes certain aspects of indemnification provisions and is limited by reference to the above discussed sections of the Nevada Corporation Law.

Our Articles of Incorporation and Bylaws provide that we may indemnify to the full extent of its power to do so, all directors, officers, employees, and/or agents. Insofar as indemnification by us for liabilities arising under the Securities Act that may be permitted to our officers and directors pursuant to the foregoing provisions or otherwise, we are aware that in the opinion of the Commission, such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.

ITEM 11. EXECUTIVE COMPENSATION.

Summary Compensation Table

The table below shows certain compensation information for services rendered in all capacities for the last two fiscal years ended December 31, 2015 and 2014. The information includes the dollar value of base salaries, bonus awards, the number of non-qualified stock options ("Options") granted and certain other compensation, if any, whether paid or deferred.

Name and Principal Position	Salar Year (\$)	•	Bonus (\$)	Stock Awards (\$)	Opti Awa (\$) ⁽¹	ards	Non-Equity Incentive Plan Compensation (\$)	Nonqualified Deferred Compensation Earnings (\$)	All Other Comp (\$)		Total (\$)	
Steven G. Johnson ⁽²⁾	2015\$ 2014\$	250,3853 250,000-		0				_	\$ \$,	\$ \$	305,434 269,862
(President, CEO, Sec., Treas.)												
Sandra K McRee ⁽³⁾	2015\$ 2014\$	210,142- 210,000-			\$	338,000)	_	\$	4,842	\$ \$	552,984 210,000
(COO)												
L. Allen Wheeler ⁽⁴⁾ (Principal Financial Officer)	2015— 2014—		_		\$ 	50,700)				\$	50,700

The valuation methodology used to determine the fair value of the options granted during the year was the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions including volatility of

⁽¹⁾ the stock price, the weighted average risk-free interest rate, and the weighted average expected life of the options. For more detail, see *NOTE 4* in the accompanying consolidated financial statements.

For 2015: All Other Compensation includes \$9,000 for car allowance and \$11,049 for health insurance premiums ⁽²⁾paid on Mr. Johnson's behalf. All Other Compensation includes \$9,000 for car allowance and \$10,862 for health insurance premiums paid on Mr. Johnson's behalf.

⁽³⁾For 2015: Option Awards includes Options to purchase 1,000,000 shares of our Common Stock. All Other Compensation is for health insurance premiums paid on Ms. McRee's behalf.

Mr. Wheeler was named Principal Financial Officer and Chief Accounting Officer effective September 6, 2013 ⁽⁴⁾ upon the resignation of our former CFO. Option Awards include Options to purchase 150,000 shares of our ⁽⁴⁾ Common Stock. This Option was awarded for services as Chairman of the Board of Directors; however, it is not included in the Director Compensation table below.

Outstanding Equity Awards at Fiscal Year End

The table below shows outstanding equity awards for our executive officers as of the fiscal year ended December 31, 2015, which equity awards consists solely of ten-year, non-qualified stock options (the "Options"). No executive officers have exercised any of their Options.

	Option Awa	rds					Stock A	wards		
Name and Office	Number of Securities Underlying Unexercised Options(#) Exercisable	Number of Securities Underlying Unexercised Options (#) Unexercisable	Equity Incentive Plan Awards: Number of Securities Underlying Unexercised Unearned Options (#)	Optio Exer Price (\$)	cise	Option Expiry Date	Number of Shares or Units of Stock That Have Not Vested (#)	Value o Shares or Units of	Number of	Payout Value of Unearned Shares, Units or Other
Steve G. Johnson		_	_	\$	0.52	201/05/20)—	_		
(Pres., CEO, Sec., Treas.)		_	_	\$	0.5	203/25/20)	_	_	_
Sandra K	1,333,333 ⁽³⁾	666,667 ⁽³⁾		\$		111/01/23			_	
McRee (COO)	_	1,000,000 ⁽⁴⁾		\$	0.5	302/25/25	5—		_	
L. Allen Wheeler	75,000 ⁽¹⁾ 75,000 ⁽²⁾	_	_	\$ \$		201/05/20 203/25/20		_		
(Principal Financial Officer)	_	150,000 ⁽⁵⁾	_	\$	0.5	302/25/25	5—		_	

(1) All underlying shares vested on January 6, 2010.

(2) All underlying shares vested on December 31, 2010.

⁽³⁾An aggregate of 666,666 underlying shares vested on November 1, 2014, 666,667 vested on November 1, 2015 and 666,667 underlying shares vest on November 1 2016.

⁽⁴⁾ An aggregate of 333,333 underlying shares vest on each of February 25, 2016 and 2017 and 333,334 underlying shares vest on February 25, 2018.

An aggregate of 50,000 underlying shares vest on each of February 25, 2016, 2017 and 2018. This Option was ⁽⁵⁾awarded for services as Chairman of the Board; however, it is not included in the Director Compensation table below.

Employment Agreements with Executive Officers

We have no employment agreements with our executive officers.

Director Compensation

We do not pay cash fees to directors who attend regularly scheduled and special board meetings; however, we may reimburse out-of-state directors for costs associated with travel and lodging to attend such meetings. Our directors may also be granted non-qualified stock options from time to time.

We paid no compensation to our directors for services rendered for the year ended December 31, 2015. The table below shows outstanding equity awards for our directors who are not executive officers, which equity awards consists solely of ten-year, non-qualified stock options. No options have been exercised.

Name	Fees Earned or Paid in Cash		Opti Awa (\$) ⁽¹⁾	rds	Non-Equity Incentive Plan Compensation (\$)	Nonqual- ified Deferred Compen- sation Earnings (\$)	All Other Com- pensation (\$)	Tota	al
Jason T.			¢	20.000	0			¢	20.000
Thompson ⁽²⁾			\$	39,000)—		_	\$	39,000
David R. White ⁽³⁾)	_	\$	130,000	—0		_	\$	130,000
Dr. James R. Higgins ⁽⁴⁾ `	—	_	\$	66,450	0—		_	\$	66,450
Stavan D. Enstain			\$	221,500(5))		_	\$	221,500
Steven B. Epstein			\$	16,900(6))	—		\$	16,900
Jeffery C. Lightcap		_	—		_	—	—		

The valuation methodology used to determine the fair value of the options granted during the year was the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions including volatility of the stock price, the weighted average risk-free interest rate, and the weighted average expected life of the options. For more detail, see *NOTE 4* in the accompanying consolidated financial statements.

An aggregate of 50,000 Options vested on January 2, 2015 and 50,000 Options vest on each of January 2, 2016 and 2017.

An aggregate of 166,666 Options vested on January 2 2015 and 166,667 Options vest on each of January 1, 2016 and 2017. Although not related to Mr. White's position as a member of the Board of Directors, he has been under contract with the Company since January 1, 2015 to assist us in sales and marketing activities. His compensation for this serves is \$5,000 per month.

⁽⁴⁾ An aggregate of 50,000 Options vested on each of March 31, 2015 and 50,000 Options vest on each of March 31, 2016 and 2017.

⁽⁵⁾ An aggregate of 166,666 Options vested on March 31, 2015 and 166,667 Options vest on each of March 31, 2016 and 2017.

An aggregate of 16,666 Options vest on each of February 25, 2016 and 16,667 Options vest on each of February 25, 2017 and 2018.

ITEMSECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND12.RELATED STOCKHOLDER MATTERS.

Beneficial Security Ownership Table

As of the date of this filing, the following table sets forth certain information with respect to the beneficial ownership of our Common Stock by (i) each shareholder known by us to be the beneficial owner of more than five percent (5%) of our Common Stock, (ii) by each of our current directors and executive officers as identified herein, and (iii) all of our directors and executive officers as a group. Each person has sole voting and investment power with respect to the shares of Common Stock, except as otherwise indicated. Beneficial ownership is determined in accordance with the rules of the SEC and generally includes voting or investment power with respect to securities. Shares of Common Stock and Options, common stock purchase warrants ("Warrants"), and convertible securities that are currently exercisable or convertible into shares of our Common Stock within sixty (60) days of the date of this document, are deemed to be outstanding and to be beneficially owned by the person holding the Options, Warrants, or convertible securities for the purpose of computing the percentage ownership of the person. Unless otherwise noted, the address for all officers and directors listed below is 405 State Highway 121, Suite B-240, Lewisville, Texas 75067.

Title of		Amount and Nature of	Percent
Class	Name and Address of Officer and Directors	Beneficial Ownership ⁽¹⁾	of Class
Common Stock	Steve G. Johnson (Chief Executive Officer, President, Secretary, Treasurer, Director)	15,384,954 ⁽²⁾	10.89%
Common Stock	L. Allen Wheeler (Chairman of the Board, Principal Financial Officer, Chief Accounting Officer)	16,361,427 ⁽³⁾	11.60%
Common Stock	Sandra K. McRee (Chief Operating Officer)	2,231,083 ⁽⁴⁾	1.58%
Common Stock	Jeffrey C. Lightcap (Director)	74,325,240 ⁽⁵⁾	34.78%
Common Stock	David R. White (Director)	333,334 ⁽⁶⁾	0.24%
Common Stock	Jason T. Thompson (Director)	241,105 ⁽⁷⁾	0.17%
Common Stock	Steven B. Epstein (Director)	1,055,524 ⁽⁸⁾	0.75%
Common Stock	Dr. James R. Higgins (Director)	4,561,080 ⁽⁹⁾	3.24%
Common Stock	All Officers & Directors as a Group (8 persons)	114,493,747	51.43%
	Name and Address of Shareholders		
	Robert J. Smith		
Common Stock	13650 Fiddlesticks Blvd., Suite 202-324,	13,868,815 ⁽¹¹⁾	9.66%
	Ft. Myers, FL 33912 Fidelity Puritan Fund, Inc.		
Common Stock	82 Devonshire St.	10,425,300 ⁽¹²⁾	7.48%
	Boston, MA 02109 Wellington Management Company, LLP		
Common Stock	280 Congress Street	19,513,303(13)	14.00%
	Boston, MA 02210 Harford Capital Appreciations HLS Fund, Inc.		
Common Stock	500 Bielenberg Drive	10,082,792 ⁽¹⁴⁾	7.23%
Common	Woodbury, MN 55125-1400 HealthCor Management, LP et al	70,462,142 ⁽¹⁵⁾	33.58%
Stock	Carnegie Hall Tower, 152 West 57th Street		

New York, NY 10019

Unless otherwise noted, we believe that all shares are beneficially owned and that all persons named in the table have sole voting and investment power with respect to all shares of Common Stock owned by them. Applicable percentage of ownership is based on 139,380,748 shares of Common Stock currently outstanding, as adjusted for each shareholder.

This amount includes (i) 208,977 shares directly owned by Johnson, (ii) 100,000 shares due to Johnson upon exercise of vested Options, (iii) 400,001 shares due to Johnson upon exercise of vested warrants, (iv) 1,434,360 shares that may be acquired upon conversion of convertible debt dated February 17, 2015 (including interest paid in kind through May 29, 2016), and (v) 13,241,616 shares beneficially owned by SJ Capital, LLC, a company controlled by Johnson. The percentage of class for Johnson is based on 141,315,109 shares which would be outstanding if all of Johnson's vested Options and Warrants were exercised and convertible debt was converted.

This amount includes (i) 516,345 shares directly owned by Wheeler, (ii) 200,000 shares due to Wheeler upon exercise of Options, (iii) 307,692 shares due to Wheeler upon exercise of vested warrants (iv) 1,103,354 shares that may be acquired upon conversion of convertible debt dated February 17, 2015 (including interest paid in kind ⁽³⁾ through May 29,2016), (v) 14,201,820 shares beneficially owned by Dozer Man, LLC, an entity controlled by Wheeler, and (vi) 32,216 shares beneficially owned by Global FG, LLC, an entity of which Wheeler owns 50%. The percentage of class for Wheeler is based on 140,991,794 shares which would be outstanding if all of Wheeler's vested Options and Warrants were exercised and convertible debt was converted.

This amount includes (i) 1,666,666 shares due to McRee upon exercise of vested Options, (ii) 123,076 shares due to McRee upon exercise of vested warrants, (iii) 441,341 shares that may be acquired upon conversion of convertible ⁽⁴⁾debt dated February 17, 2015 (including interest paid in kind through May 29, 2016). The percentage of class for McRee is based on 141,611,831 shares which would be outstanding if all of McRee's vested Options and Warrants were exercised and convertible debt was converted.

HealthCor Management, LP, HealthCor Associates, LLC, HealthCor Hybrid Offshore Master Fund, LP, HealthCor Hybrid Offshore GP, LLC, HealthCor Group, LLC, HealthCor Partners Management, L.P., HealthCor Partners Management GP, LLC, HealthCor Partners Fund, LP, HealthCor Partners, LP HealthCor Partners GP, LLC, Jeffrey C. Lightcap, Joseph Healey and Arthur Cohen (collectively, the Reporting Persons), beneficially own an aggregate
(5) of 74,325,240 shares, representing (i) 3,971,239 shares that may be acquired upon conversion of convertible debt dated February 17, 2015 (including interest paid in kind through May 29, 2016) (ii) 16,101,665 shares that may be acquired upon conversion of the 2014 Notes (iii) 6,730,054 shares that may be acquired upon conversion of the 2012 Notes, (iv) 29,623,013 shares that may be acquired upon conversion of the 2011 Notes, and (v) 17,899,269 shares that may be acquired upon exercise of Warrants.

The amounts detailed above include (i) 430,769 shares due to Lightcap upon exercise of vested Warrants, (ii) 70,257 vested Warrants held in trust for Lightcap's minor children, (iii) 1,544,695 shares that may be acquired upon conversion of convertible debt dated February 17, 2015 (including interest paid in kind through May 29, 2016), and (iv) 251,934 shares that may be acquired upon conversion of convertible debt dated February 17, 2015 (including interest paid in kind through May 29, 2016) held in trust for Lightcap's minor children.

The percentage of class for Reporting Persons and Lightcap as an individual is based on 213,705,988 shares which would be outstanding if the Reporting Persons notes and convertible debt held Lightcap and his minor children were converted and all Warrants held by the Reporting Persons and Lightcap and his minor children were exercised.

⁽⁶⁾This amount includes (i) 333,334 shares due to White upon exercise of vested Options. The percentage of class for White is based on 139,714,082 shares which would be outstanding if all of White's vested Options were exercised.

This amount includes (i) 100,000 shares due to Thompson upon exercise of vested Options, (ii) 30,769 shares due to Thompson upon exercise of vested warrants, (iii) 110,336 shares that may be acquired upon conversion of (7) convertible debt dated February 17, 2015 (including interest paid in kind through May 29, 2016). The percentage of class for Thompson is based on 139,621,853 shares which would be outstanding if all of Thompson's vested Options and Warrants were exercised and convertible debt was converted.

This amount includes (i) 350,001 shares due to Epstein upon exercise of vested Options, (ii) 153,846 shares due to Epstein upon exercise of vested warrants, (iii) 551,677 shares that may be acquired upon conversion of convertible ⁽⁸⁾ debt dated February 17, 2015 (including interest paid in kind through May 29, 2016). The percentage of class for Epstein is based on 140,436,272 shares which would be outstanding if all of Epstein's vested Options and Warrants were exercised and convertible debt was converted.

This amount includes (i) 3,050,034 shares directly owned by Higgins (ii) 100,000 shares due to Higgins upon exercise of vested Options, (iii) 307,692 shares due to Higgins upon exercise of vested warrants, and (iv) 1,103,354 (9) shares that may be acquired upon conversion of convertible debt dated February 17, 2015 (including interest paid in kind through May 29, 2016). The percentage of class for Higgins is based on 140,891,794 shares which would be outstanding if all of Higgin's vested Options and Warrants were exercised and convertible debt was converted.

This amount includes all shares directly and beneficially owned by all officers and directors and all shares to be issued directly and beneficially upon exercise of vested shares under Options and Warrants and upon conversion of ⁽¹⁰⁾ convertible securities. The percentage of class for all officers and directors is based on 222,623,487 shares which would be outstanding if all the aforementioned Options, Warrants and convertible securities were exercised or converted.

This amount includes: (i) 275,000 shares directly owned by Smith, (ii) 75,000 shares held in trust for Smith's minor children, (iii) 6,210,723 shares and 253,309 Warrants beneficially owned by Plato & Associates, LLC, a company controlled by Smith, (iv) 3,054,783 shares beneficially owned by Energy Capital, LLC, a company controlled by Smith and (v) 4,000,000 shares due to Smith upon the exercise of Warrants. The percentage of class for Smith is based on 143,634,057 shares which would be outstanding if all Warrants owned by Plato & Associates, LLC were exercised.

These shares are beneficially owned by Fidelity Puritan Fund, Inc., an investment company registered under the (12) Investment Company Act of 1940, and an investment company of FMR, LLC. Various persons have the right to vote the shares, receive, or the power to direct the receipt of dividends from, or the proceeds from the sale of these shares.

Wellington Management, in its capacity as investment advisor, may be deemed to beneficially own 19,513,303 shares which are held of record by its clients. Those clients have the right to receive, or the power to direct the ⁽¹³⁾receipt of, dividends from, or the proceeds from the sale of, such shares. Of those clients, only Hartford Capital Appreciation HLS Fund, Inc. is known to have such right or power with respect to more than five percent of the shares.

Hartford Series Fund, Inc., in its capacity as an investment company registered under Section 8 of the Investment ⁽¹⁴⁾Company Act of 1940, may be deemed to beneficially own 10,082,792 shares on behalf of Hartford Capital Appreciate HLS Fund, Inc. and has shared power to vote and direct the sale of the shares.

HealthCor Management, LP, HealthCor Associates, LLC, HealthCor Hybrid Offshore Master Fund, LP, HealthCor Hybrid Offshore GP, LLC, HealthCor Group, LLC, HealthCor Partners Management, L.P., HealthCor Partners Management GP, LLC, HealthCor Partners Fund, LP, HealthCor Partners, LP HealthCor Partners GP, LLC, Jeffrey C. Lightcap, Joseph Healey and Arthur Cohen (collectively, the Reporting Persons), beneficially own an aggregate of 72,027,585 shares, representing (i) 2,174,610 shares that may be acquired upon conversion of ⁽¹⁵⁾ convertible debt dated February 17, 2015 (including interest paid in kind through May 29, 2016) (ii) 16,101,665 shares that may be acquired upon conversion of the 2012 Notes, (iv) 29,623,013 shares that may be acquired upon conversion of the 2011 Notes, and (v) 17,398,243 shares that may be acquired upon exercise of Warrants. The percentage of class for Reporting Persons and is based on 209,842,890 shares which would be outstanding if the Reporting Persons notes were converted and all Warrants held by the Reporting Persons were exercised.

Under Rule 144 promulgated under the Securities Act, our officers, directors and beneficial shareholders may sell up to one percent (1%) of the total outstanding shares (or an amount of shares equal to the average weekly reported volume of trading during the four calendar weeks preceding the sale) every three months provided that (1) current public information is available about our Company, (2) the shares have been fully paid for at least one year, (3) the shares are sold in a broker's transaction or through a market-maker, and (4) the seller files a Form 144 with the SEC if seller is an affiliate.

Section 16(a) Beneficial Ownership Reporting Compliance

During the year ended December 31, 2014, we acknowledge that none of our officers or directors failed to file on a timely basis certain ownership forms required by Section 16(a) of the Exchange Act.

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE.

Exclusive of the Fifth Amendment discussed above in *Item 7*, none of our directors, officers or principal shareholders, nor any associate or affiliate of the foregoing, has any interest, direct or indirect, in any transaction or in any proposed transaction, which materially affected us during the year ended December 31, 2015.

Related Party Transactions Policy

As indicated hereinabove, our Board of Directors adopted a Related Party Transactions Policy and all related party transactions will be disclosed in our applicable filings as required by the Securities Act of 1933 and the Securities Exchange Act of 1934 and related rules and regulations.

Director Independence

Although our Board of Directors believes that our directors will exercise their judgment independently, no director is totally free of relationships that, in the opinion of the Board of Directors, might interfere with their exercise of independent judgment as a director.

Promoters and Certain Control Persons

None.

ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES.

Audit Fees. The aggregate amount expected to be billed for professional services rendered by BDO USA, LLP ("BDO") for the 2015 quarterly reviews and the annual integrated audit for the year ended December 31, 2015 is \$257,000 BDO billed us \$266,579 for professional services rendered for the annual audit fee for the year ended December 31, 2014 and for quarterly review of our financial statements for 2014, and other services that are normally provided by an accountant in connection with statutory and regulatory filings or engagements for the fiscal year.

Tax Fees. The aggregate amount expected to be billed for tax return preparation for the year ended December 31, 2015 rendered by BDO is \$35,300. BDO billed us \$38,953 for tax return preparation for the year ended December 31, 2014.

All Other Fees. We incurred no other fees for the 2015 and 2014 fiscal years.

The Audit Committee of our Board of Directors adopted a policy requiring that it pre-approve all fees paid to our independent registered public accounting firm, regardless of the type of service. All non-audit services were reviewed with the Audit Committee, which concluded that the provision of such services by BDO USA, LLP was compatible with the maintenance of that firm's independence in the conduct of its auditing functions.

ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES.

Exhibi No.	tDate of Document	Name of Document
3.8	11/06/07	Notice of Conversion filed in State of Nevada (to convert CareView Communications, Inc. from a California corporation to a Nevada corporation) ⁽¹⁾
3.9	11/06/07	Articles of Incorporation for CareView Communications, Inc. filed in State of Nevada ⁽¹⁾
3.12	n/a	Bylaws of CareView Communications, Inc., a Nevada corporation ⁽¹⁾
10.00	02/28/05	Subscription and Investor Rights Agreement ⁽¹⁾
10.01	n/a	Products and Services Agreement (a/k/a Hospital Agreement), form of ⁽¹⁾
10.09	12/03/07	CareView Communications, Inc. 2007 Stock Incentive Plan ⁽¹⁾
10.10	12/03/07	Non-Qualified Stock Option, form of ⁽¹⁾
10.11	12/13/07	Audit Committee Charter ⁽¹⁾
10.12	12/13/07	Compensation Committee Charter ⁽¹⁾
10.14	02/13/08	Advisory Board Charter ⁽¹⁾
10.42	09/11/09	CareView Communications, Inc. 2009 Stock Incentive Plan ⁽¹⁾
10.43	10/01/09	Commercial Lease Agreement (for Lewisville location) ⁽¹⁾
10.44	11/16/09	Rockwell JV – Master Investment Agreement ¹⁾
10.45	11/16/09	Rockwell JV – Project Hospital Contract Assignment, form of [₽])
10.46	11/16/09	Rockwell JV – Project Escrow Deposit Agreement, form of €)
10.47	11/16/09	Rockwell JV – Limited License of Intellectual Property Rights, form of €)
10.48	11/16/09	Rockwell JV – Project Note, form $of^{1)}$
10.49	11/16/09	Rockwell JV – Amended and Restated Project Note, form of (f)
10.50	11/16/09	Rockwell JV – Project LLC Operating Agreement, form of
10.51	11/16/09	Rockwell JV – Project Security Agreement, form d^{f}
10.52	11/16/09	Rockwell JV – Project Services Subcontract Agreement, form df)
10.53	11/16/09	Rockwell JV – Project Warrant, form (f)
10.62	06/29/10	First Amendment to Commercial Lease Agreement ⁽¹⁾
10.72	04/21/11	Note and Warrant Purchase Agreement between the Company and HealthCor Partners Fund, LP and HealthCor Hybrid Offshore Master Fund, LP ⁽⁴⁾
10.73	04/21/11	Senior Secured Convertible Note of the Company payable to HealthCor Partners Fund, LP ⁽⁴⁾
10.74	04/21/11	Senior Secured Convertible Note of the Company payable to HealthCor Hybrid Offshore Master Fund, LP ⁽⁴⁾
10.75	04/21/11	Warrant to Purchase 5,488,456 shares of the Company issued to HealthCor Partners Fund, LP ⁽⁴⁾
10.76	04/21/11	Warrant to Purchase 6,293,403 shares of the Company issued to HealthCor Hybrid Offshore Master Fund, LP ⁽⁴⁾
10.77	04/21/11	Registration Rights Agreements between the Company and HealthCor Partners Fund, LP and HealthCor Hybrid Offshore Master Fund, LP ⁽⁴⁾
10.78	04/21/11	Pledge and Security Agreement between the Company and HealthCor Partners Fund, LP and HealthCor Hybrid Offshore Master Fund, LP ⁽⁴⁾
10.79	04/21/11	Intellectual Property Security Agreement between the Company and HealthCor Partners Fund, LP and HealthCor Hybrid Offshore Master Fund, LP ⁽⁴⁾
10.02	00/01/11	Loan and Security Agreement between Comerica Bank and Bridge Bank and CareView
10.83	08/31/11	Communications, Inc., a Nevada corporation, CareView Communications, Inc., a Texas corporation, and CareView Operations, LLC, a Texas limited liability company ⁽⁶⁾
10.84	08/31/11	

Prime Referenced Rated Addendum between the Company and Comerica Bank as Collateral Agent for the ${\rm Banks}^{(6)}$

10.85 08/31/11 Subordination Agreement between Comerica Bank and HealthCor Partners Fund, L.P. and HealthCor Hybrid Offshore Master Fund, L.P. ⁽⁶⁾

10.86 08/31/11 Intellectual Property Security Agreement, form of⁽⁶⁾ 10.87 08/31/11 Warrant issued to Comerica Bank to purchase 714,286 shares of the Company's Common Stock⁶ 10.88 08/31/11 Warrant issued to Bridge Bank to purchase 714,286 shares of Company's Common Stock⁶) 10.90 12/31/11 Note and Warrant Amendment Agreement with HealthCor⁽⁸⁾ 10.91 01/09/12 Binding Term Sheet with HealthCor⁽⁹⁾ 10.92 12/31/11 Note and Warrant Amendment Agreement⁽²⁾ 10.94 01/31/12 Second Amendment to Note and Warrant Purchase Agreement⁽¹⁰⁾ 10.95 01/31/12 Senior Secured Convertible Note of the Company payable to HealthCor Partners Fund, LP⁽¹⁰⁾ 10.96 01/31/12 Senior Secured Convertible Note of the Company payable to HealthCor Hybrid Offshore Master Fund, LP⁽¹⁰⁾ 10.97 01/31/12 First Amendment to Loan and Security Agreement among the Company, certain of its subsidiaries, Comerica Bank and Bridge Bank, National Association⁽¹⁰⁾ 10.98 01/31/12 Amendment to and Affirmation of Subordination Agreement⁽¹⁰⁾ Insider Trading Policy, form of⁽¹¹⁾ 10.100 n/a Whistleblower Policy⁽¹¹⁾ 10.101 n/a Related Party Transactions Policy⁽¹¹⁾ 10.102 n/a 10.10603/20/11 Master Agreement with Health Management Associates, Inc. (15) 10.10803/27/13 Securities Purchase Agreement, form of⁽¹⁶⁾ 10.109 n/a Common Stock Purchase Warrant, form of⁽¹⁶⁾ 10.11101/15/13 Second Amendment to Loan and Security Agreement among the Company, certain of its subsidiaries, Comerica Bank and Bridge Bank, National Association⁽¹⁷⁾ 10.11201/15/13 Amendment to and Affirmation of Subordination Agreement⁽¹⁷⁾ 10.11305/24/13 Extension of Maturity Date for Promissory Note and Investment Interest (related to Hillcrest)⁽¹⁸⁾ 10.11407/19/13 Extension of Maturity Date for Promissory Note and Investment Interest (related to Saline) (18) 10.11508/20/13 Third Amendment to Note and Warrant Purchase Agreement between the Company and HealthCor⁽¹⁹⁾ 10.11608/20/13 Third Amendment to Loan and Security Agreement among the Company, certain of its subsidiaries, Comerica Bank and Bridge Bank, National Association⁽¹⁹⁾ 10.11708/20/13 Affirmation of Subordination Agreement⁽¹⁹⁾ 10.11912/31/13 Separation Agreement and General Release between the Company and Samuel A. Greco⁽²¹⁾ 10.12012/31/13 Consulting Agreement between the Company and Samuel A. Greco (attached as Exhibit "A" to Separation Agreement and General Release (Exhibit 10.119 herein))⁽²¹⁾ 10.12112/31/13 Resignation of Samuel A. Greco (attached as Exhibit "A" to Separation Agreement and General Release (Exhibit 10.119 herein))⁽²¹⁾ 10.12212/31/13 Warrant, form of (attached as Exhibit "C" to Separation Agreement and General Release (Exhibit 10.119 herein))⁽²¹⁾ 10.12306/21/10 Indemnification Agreement between the Company and Samuel A. Greco (attached as Exhibit "D" to Separation Agreement and General Release (Exhibit 10.119 herein))⁽²¹⁾ 10.12412/31/13 Resignation of Tommy G. Thompson⁽²¹⁾ 10.12601/16/14 Fourth Amendment to Note and Warrant Purchase Agreement between the Company and HealthCor⁽²²⁾ 10.12701/16/14 Fourth Amendment to Loan and Security Agreement among the Company, certain of its subsidiaries, Comerica Bank and Bridge Bank, National Association⁽²²⁾ 10.12801/16/142014 Supplemental Closing Note of the Company payable to HealthCor Partners Fund, LP⁽²²⁾ 10.12901/16/14 2014 Supplemental Closing Note of the Company payable to HealthCor Hybrid Offshore Master Fund, LP⁽²²⁾

10.130	01/16/14 ²⁰¹⁴ Supplemental Warrant issued to HealthCor Partners Fund, LP to purchase 1,863,200 shares of the Company's Common Stock ²²)
10.131	2014 Supplemental Warrant issued to HealthCor Hybrid Offshore Master Fund, LP to purchase
	2,136,800 shares of the Company's Common Stock ²²⁾
10.132	01/16/14 Amendment to and Affirmation of Subordination Agreement ⁽²²⁾
10.133	01/16/14 Replacement 2011 Senior Secured Convertible Note of the Company payable to HealthCor Partners Fund, LP ⁽²²⁾
10.134	01/16/14 Replacement 2011 Senior Secured Convertible Note of the Company payable to HealthCor Hybrid Offshore Master Fund, LP ⁽²²⁾
10.135	01/16/14 Replacement 2012 Senior Secured Convertible Note of the Company payable to HealthCor Partners Fund, LP ⁽²²⁾
10.136	01/16/14 Replacement 2012 Senior Secured Convertible Note of the Company payable to HealthCor Hybrid Offshore Master Fund, LP ⁽²²⁾
10.137	Fifth Amendment to Note and Warrant Purchase Agreement between the Company and HealthCor ⁽²³⁾
10.138	12/04/14 Form of Fifth Amendment Supplemental Closing Note ⁽²³⁾
10.139	12/04/14 Form of Fifth Amendment Supplemental Warrant ⁽²³⁾
10.140	Amended Pledge and Security Agreement between the Company and HealthCor Partners Fund, LP and HealthCor Hybrid Offshore Master Fund, LP ⁽²⁵⁾
10.141	Amended Intellectual Property Security Agreement between the Company and HealthCor Partners Fund, LP and HealthCor Hybrid Offshore Master Fund, LP ⁽²⁵⁾
10.142	02/19/15 Extension of Maturity Date for Promissory Note and Investment Interest (related to Hillcrest) ⁽²⁵⁾
10.143	02/19/15 Extension of Maturity Date for Promissory Note and Investment Interest (related to Saline) ⁽²⁵⁾
10.144	02/25/15 CareView Communications, Inc. 2015 Stock Option Plan ⁽²⁴⁾
10.145	03/31/15 Sixth Amendment to Note and Warrant Purchase Agreement between the Company and HealthCor Funds ⁽²⁵⁾
10.146	03/31/15 Sixth Amendment Supplemental Warrant, form of ⁽²⁵⁾
10.147	06/26/15 Credit Agreement between the Company and PDL BioPharma, Inc. ⁽²⁶⁾
10.148	06/26/15 Subordination and Intercreditor Agreement between the Company, PDL BioPharma, Inc., the HealthCor Funds and the Second Lien Claimholders ⁽²⁶⁾
10.149	06/26/15 Guarantee and Collateral Agreement between the Company and PDL BioPharma, Inc. (26)
10.150	06/26/15 Registration Rights Agreement between the Company and PDL BioPharma, Inc. (26)
10.151	Warrant to purchase 4,444,445 shares of the Company's common stock issued to PDL BioPharma, $06/26/15_{\text{Inc.}}^{(26)}$
10.152	06/26/15 Seventh Amendment to Note and Warrant Purchase Agreement between the Company and the HealthCor Funds and the Investors named therein ⁽²⁶⁾
10.153	06/26/15 Amendment to Registration Rights Agreement the Company and the HealthCor Fund ⁽²⁶⁾
10.154	10/07/15 First Amendment to Credit Agreement between the Company and PDL BioPharma, Inc. (27)
10.155	10/07/15 Tranche One Term Note in the Principal amount of \$20 million issued to PDL BioPharma, Inc. ⁽²⁷⁾
10.156	Amended and Restated Warrant to purchase 4,444,445 shares of the Company's common stock 10/17/15 issued to PDL BioPharma, Inc. ⁽²⁷⁾
14.00	n/a 2011 Code of Business Conduct and Ethics, form of ⁽¹⁾
14.01	n/a 2011 Code of Business Ethics for Financial Executives, form of ⁽¹⁾
21.00	03/30/16 Subsidiaries of the Registrant*
31.1	03/30/16 Certification of Chief Executive Officer of Periodic Report pursuant to Rule 13a-14a and Rule 14d-14(a).*
21.2	Certification of Chief Financial Officer of Periodic Report pursuant to Rule 13a-14a and Rule


31.2 $03/30/16 \frac{\text{Certification of Chief Financial Officer of Periodic Report pursuant to Rule 13a-14a and Rule}{15d-14(a).*}$

- 32.1 03/30/16 Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350.*
- 32.2 03/30/16 Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350.*
- 101.INS n/a XBRL Instance Document*
- 101.SCH n/a XBRL Taxonomy Extension Schema Document*
- 101.CALn/a XBRL Taxonomy Extension Calculation Linkbase Document*

101.DEF n/aXBRL Taxonomy Extension Definition Linkbase Document* 101.LAB n/aXBRL Taxonomy Extension Label Linkbase Document* 101.PRE n/aXBRL Taxonomy Extension Presentation Linkbase Document*

	(1) Filed as an exhibit to our Form 10 filed with the SEC on August 23, 2010.
(2)	Filed as an exhibit to our quarterly report on Form 10-Q filed with the SEC on November 7, 2010.
(3)	Filed as an exhibit to our annual report on Form 10-K filed with the SEC on April 15, 2011.
(4)	Filed as an exhibit to our Current Report on Form 8-K filed with the SEC on April 27, 2011.
(5)	Filed as an exhibit to our quarterly report on Form 10-Q filed with the SEC on August 22, 2011.
(6)	Filed as an exhibit to our Current Report on Form 8-K filed with the SEC on September 7, 2011.
(7)	Filed as an exhibit to our Current Report on Form 8-K filed with the SEC on November 10, 2011.
(8)	Filed as an exhibit to our Current Report on Form 8-K filed with the SEC on January 5, 2012.
(9)	Filed as an exhibit to our Current Report on Form 8-K filed with the SEC on January 9, 2012.
(10)	Filed as an exhibit to our Current Report on Form 8-K filed with the SEC on February 2, 2012.
(11)	Filed as an exhibit to our annual report on Form 10-K filed with the SEC on March 15, 2012.
(12)	Filed as an exhibit to our quarterly report on Form 10-Q filed with the SEC on May 9, 2012.
(13)	Filed as an exhibit to our quarterly report on Form 10-Q filed with the SEC on August 8, 2012.
(14)	Filed as an exhibit to our quarterly report on Form 10-Q filed with the SEC on November 8, 2012.
Filed a	s an exhibit to our quarterly report on Form 10.0 . Amendment No. 1, filed with the SEC on February

Filed as an exhibit to our quarterly report on Form 10-Q, Amendment No. 1, filed with the SEC on February 1,
(15)2013. Certain information in this exhibit has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.



(21)	Filed as an exhibit to our Current Report on Form, 8-K filed with the SEC on January 3, 2014.
(22)	Filed as an exhibit to our Current Report on Form 8-K filed with the SEC on January 22, 2014.
(23)	Filed as an exhibit to our Current Report on Form 8-K filed with the SEC on December 10, 2014.
(24)	Filed as an exhibit to our Current Report on Form 8-K filed with the SEC on March 19, 2015.
(25)	Filed as an exhibit to our annual report on Form 10-K filed with the SEC on March 31, 2015
(26)	Filed as an exhibit to our Current Report on Form 8-K filed with the SEC on June 29, 2015.
(27)	Filed as an exhibit to our Current Report on Form 8-K filed with the SEC on October 13, 2015.
*Filed here	ewith.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Company has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

DATE: March 30, 2016

CAREVIEW COMMUNICATIONS, INC.

By:/s/ Steven G. Johnson Steven G. Johnson Chief Executive Officer Principal Executive Officer

By:/s/ L. Allen Wheeler L. Allen Wheeler Principal Financial Officer Chief Accounting Officer

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Steven G. Johnson and L. Allen Wheeler and each of them, his attorney-in-fact with power of substitution for him in any and all capacities, to sign any amendments, supplements or other documents relating to this Annual Report on Form 10-K he deems necessary or appropriate, and to file the same, with exhibits thereto, and other documents in connection therewith, with the SEC, hereby ratifying and confirming all that such attorney-in-fact or their substitute may do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this Report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.

Signature	Title	Date
/s/ Steven G. Johnson Steven G. Johnson	Chief Executive Officer, President, Secretary, Treasurer, Director	March 30, 2016
/s/ L. Allen Wheeler L. Allen Wheeler	Chairman of the Board, Principal Financial Officer, Chief Accounting Officer	March 30, 2016
/s/ Sandra K. McRee Sandra K. McRee	Chief Operating Officer	March 30, 2016
/s/ Jeffrey C. Lightcap Jeffrey C. Lightcap	Director	March 30, 2016
/s/ David R. White David R. White	Director	March 30, 2016
/s/ Jason T. Thompson Jason T. Thompson	Director	March 30, 2016
/s/ Steven B. Epstein Steven B. Epstein	Director	March 30, 2016
/s/ Dr. James R. Higgins Dr. James R. Higgins	^S Director	March 30, 2016

INDEX TO FINANCIAL STATEMENTS

	Page
Report of Independent Registered Public Accounting Firm	F-1
Consolidated Balance Sheets as of December 31, 2015 and 2014	F-2
Consolidated Statements of Operations for the years ended December 31, 2015 and 2014	F-3
Consolidated Statements of Stockholders' Equity for the years ended December 31, 2015 and 2014	F-4
Consolidated Statements of Cash Flows for the years ended December 31, 2015 and 2014	F-5
Notes to Consolidated Financial Statements	F-6

Report of Independent Registered Public Accounting Firm

Board of Directors and Stockholders

CareView Communications, Inc.

Lewisville, TX

We have audited the accompanying consolidated balance sheets of CareView Communications, Inc. as of December 31, 2015 and 2014 and the related consolidated statements of operations, stockholders' deficit, and cash flows for each of the two years in the period ended December 31, 2015. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of CareView Communications, Inc. at December 31, 2015 and 2014, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2015, in conformity with accounting principles generally accepted in the United States of America.

/s/ BDO USA, LLP

Dallas, TX

March 30, 2016

CAREVIEW COMMUNICATIONS, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

	December 31, 2015	2014
ASSETS		
Current Assets:		
Cash and cash equivalents	\$17,678,969	\$2,546,262
Accounts receivable, net	1,176,404	680,143
Other current assets	471,075	276,910
Total current assets	19,326,448	3,503,315
Property and equipment, net	4,483,440	5,344,792
Other Assets:		
Restricted cash	3,250,000	
Intangible assets, net	380,765	261,283
Other assets	2,689,758	832,930
	6,320,523	1,094,213
Total assets	\$30,130,411	\$9,942,320
LIABILITIES AND STOCKHOLDERS' DEFICIT		
Current Liabilities:		
Accounts payable	\$332,402	\$244,782
Notes payable	441,498	
Mandatorily redeemable equity in joint venture	441,498	
Accrued interest	261,450	191,596
Other current liabilities	479,226	791,284
Total current liabilities	1,956,074	1,227,662
Long-term Liabilities:		
Senior secured convertible notes, net of debt discount and debt costs of \$23,041,363 and \$21,457,970, respectively	33,729,093	22,834,641
Loan payable	20,000,000	
Notes payable		441,594
Mandatory redeemable equity in joint venture		441,594
Fair value of warrant liability	168,805	301,864
Total long-term liabilities	53,897,898	24,019,693
Total liabilities	55,853,972	25,247,355

Commitments and Contingencies

Stockholders' Deficit:

Preferred stock - par value \$0.001; 20,000,000 shares authorized; no shares issued and outstanding Common stock - par value \$0.001; 300,000,000 shares authorized; 139,380,748 139,381 139,381 issued and outstanding Additional paid in capital 76,502,913 82,434,461 Accumulated deficit (107,795,712) (91,510,720) Total CareView Communications Inc. stockholders' deficit (25,221,870) (14,868,426)Noncontrolling interest (501,691 (436,609)) Total stockholders' deficit (25,723,561) (15,305,035)Total liabilities and stockholders' deficit \$30,130,411 \$9,942,320

The accompanying footnotes are an integral part of these consolidated financial statements.

CAREVIEW COMMUNICATIONS INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

	Year Ended D 2015	ecember 31, 2014
Revenues, net	\$5,139,450	\$3,061,298
Operating expenses:		
Network operations	4,597,887	3,386,645
General and administration	3,744,095	3,282,816
Sales and marketing	845,322	676,394
Research and development	1,085,760	843,416
Depreciation and amortization	1,727,440	1,651,310
Total operating expense	12,000,504	9,840,581
Operating loss	(6,861,054) (6,779,283)
Other income and (expense)		
Interest expense	(9,651,869) (7,819,340)
Change in fair value of warrant liability	133,059	69,001
Interest income	8,642	3,644
Other income	21,148	15,913
Total other income (expense)	(9,489,020) (7,730,782)
Loss before taxes	(16,350,074) (14,510,065)
Provision for income taxes	_	_
Net loss	(16,350,074) (14,510,065)
Net loss attributable to noncontrolling interest	(65,082) (58,340)
Net loss attributable to CareView Communications, Inc.	\$(16,284,992) \$(14,451,725)
Net loss per share attributable to CareView Communications, Inc., basic and diluted	\$(0.12) \$(0.10)
Weighted average number of common shares outstanding, basic and diluted	139,380,748	139,120,996

The accompanying footnotes are an integral part of these consolidated financial statements.

CAREVIEW COMMUNICATIONS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT

FOR THE YEARS ENDED DECEMBER 31, 2015 AND 2014

	Common Stock Shares Amount		Additional Paid in Capital	Accumulated Deficit	Noncontrolling Interest Tota		Fotal
Balance, December 31, 2013	138,753,397	138,753	71,202,451	(77,058,995)	(378,269)	(6,096,060)
Shares issued for cashless exercise of warrants	627,351	628	(628)				
Options granted as compensation	_	_	714,123				714,123
Warrants issued in connection with senior secured convertible notes	_	_	1,146,732	_	_		1,146,732
Beneficial conversion features for senior secured convertible notes	_	_	3,440,235	_	_		3,440,235
Net loss	_	_		(14,451,725)	(58,340)	(14,510,065)
Balance, December 31, 2014	139,380,748	139,381	76,502,913	(91,510,720)	(436,609)	(15,305,035)
Options granted as compensation	_	_	774,322	_	_		774,322
Warrants issued in connection with senior secured convertible notes	_	_	1,471,105	_	_		1,471,105
Warrants issued in connection with loan payable	_	_	1,257,778	_	_		1,257,778
Warrants issued for services	_	_	9,655	_	_		9,655
Adjustment to fair value of warrants for extension of	_	—	102,457	_	—		102,457

exercise period						
Beneficial conversion features for senior secured convertible notes	_	_	2,316,231	_	_	2,316,231
Net loss	—	—		(16,284,992)	(65,082) (16,350,074)
Balance, December 31, 2015	139,380,748	\$139,381	\$82,434,461	\$(107,795,712) \$	\$ (501,691) \$(25,723,561)

The accompanying footnotes are an integral part of these consolidated financial statements.

CAREVIEW COMMUNICATIONS, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS

	Year Ended D 2015	December, 31, 2014
CASH FLOWS FROM OPERATING ACTIVITIES Net loss Adjustments to reconcile net loss to net cash flows used in operating activities:	\$(16,350,074) \$(14,510,065)
Depreciation	1,693,128	1,623,723
Amortization of debt discount and debt costs	2,311,167	2,152,055
Amortization of deferred installation costs	355,335	306,111
Amortization of deferred debt issuance and debt financing costs	165,911	284,692
Amortization of intangible assets	34,312	27,587
Interest incurred and paid in kind	6,477,845	
Stock based compensation related to options granted	774,322	714,123
Stock based costs related to warrants issued	112,112	
(Gain) loss on disposal of assets	47,137	4,050
Change in fair value of warrant liability) (69,001)
Changes in operating assets and liabilities:		, , , ,
Accounts receivable	(496,261) (375,110)
Other current assets) (111,379)
Other assets	16,393	170,624
Accounts payable	87,620	(170,106)
Accrued expenses and other current liabilities) 317,411
Lease liability		(8,607)
Net cash flows used in operating activities	(5,340,481) (4,541,173)
CASH FLOWS FROM INVESTING ACTIVITIES		
Change in restricted cash	(3,250,000) —
Purchase of property and equipment	(878,913) (602,107)
Payment for deferred installation costs	(330,771) (369,803)
Patent and trademark costs	(148,995) (24,726)
Purchase of computer software and website costs	(4,799) (17,004)
Net cash flows used in investing activities	(4,613,478) (1,013,640)
CASH FLOWS FROM FINANCING ACTIVITIES		
Proceeds from notes and loan payable	26,000,000	5,000,000
Financing costs	(913,142) (40,000)
Repayment of notes payable	(192) (1,850)
Repayment of revolving line of credit		(982,255)
Net cash flows provided by financing activities	25,086,666	3,975,895
Increase (decrease) in cash	15,132,707	(1,578,918)
Cash and cash equivalent, beginning of period	2,546,262	4,125,180
Cash and cash equivalents, end of period	\$17,678,969	\$2,546,262

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:Cash paid for interest\$640,970Cash paid for income taxes\$----SUPPLEMENTAL SCHEDULE OF NON-CASH FINANCING ACTIVITIES:Beneficial conversion features for senior secured convertible notes\$2,316,231\$3,440,235

Beneficial conversion features for senior secured convertible notes	\$2,316,231	\$3,440,235
Warrants issued in connection with senior secured convertible notes	\$1,471,105	\$1,146,732
Warrants issued in connection with the loan payable	\$1,257,778	\$—

The accompanying footnotes are an integral part of these consolidated financial statements.

CAREVIEW COMMUNICATION, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 – DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION

Description of Business

CareView Communications, Inc., a Nevada corporation ("CareView-NV" or the "Company"), was originally formed in California on July 8, 1997 under the name Purpose, Inc., changing our name to Ecogate, Inc. in April 1999, and CareView Communications, Inc. in October 2007. We began our current operation in 2003 as a healthcare information technology company with a patented patient monitoring and entertainment system. CareView developed a suite of products and hardware to help connect patients, families and health care providers through one easy-to-install and simple-to-use data and patient monitoring system (the "CareView System"). The CareView System runs on each hospital's coaxial cable television network that provides television signals to patient room; consequently, CareView's network does not need to run on or through the hospital. The Company's proprietary, high-speed data network system may be deployed throughout a healthcare facility and will provide the facility with recurring revenue and infrastructure for future applications. Real-time bedside and point-of-care video monitoring and recording improve efficiency while limiting liability, and entertainment packages and patient education enhance the patient's quality of stay.

Throughout these Notes to the Consolidated Financial Statements, the terms "we," "us," "our," "CareView," or the "Company' refers to CareView-NV, and unless otherwise specified, includes our wholly owned subsidiaries, CareView Communications, Inc., a Texas corporation ("CareView-TX") and CareView Operations, LLC, a Nevada limited liability company ("CareView Operations"). Also included are CareView-Hillcrest, LLC ("CareView-Hillcrest") and CareView-Saline, LLC ("CareView-Saline"), collectively, (the "Project LLCs"). We own 50% of CareView-Hillcrest and CareView-Saline, with each determined to be variable interest entities ("VIEs") in which we exercise control and are deemed the Primary Beneficiary (See *NOTE 14* for further details). Our business consists of a single segment of products and services all of which are sold and provided within the United States.

Principles of Consolidation

The accompanying consolidated financial statements include the accounts of the Company, our wholly owned subsidiaries and our Project LLCs for which we control the operating activities. All material inter-company balances

and transactions have been eliminated in consolidation.

We report noncontrolling interests in our VIEs as a component of stockholders' deficit in the Consolidated Balance Sheets and the loss attributable to noncontrolling interests as an adjustment to net loss to arrive at net loss attributable to the Company in the Consolidated Statements of Operations.

CAREVIEW COMMUNICATION, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Variable Interest Entities

We use a qualitative analysis to determine if we are the primary beneficiary of a VIE. We consider whether the enterprise's variable interest or interests give it a controlling financial interest in a VIE. This analysis identifies the primary beneficiary of a VIE as the enterprise that has both of the following characteristics, among others: (a) the power to direct the activities of a VIE that most significantly impacts the entity's economic performance, and (b) the obligation to absorb losses or the right to receive benefits from the entity, that could potentially be significant to the VIE.

Cash and Cash Equivalents

We consider all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. We maintain cash at financial institutions that at times may exceed federally insured limits. We have never experienced any losses related to these funds. The Company periodically deposits cash with financial institutions in excess of the maximum federal insurance limits (FDIC) of \$250,000 per bank.

Restricted Cash

At December 31, 2015, we recorded \$3,250,000 of restricted cash in other assets on the consolidated balance sheet. The restricted cash is associated with our minimum cash requirement as stipulated in our credit agreement with PDL BioPharma, Inc. See further discussion in *Note 13*.

Trade Accounts Receivable

Trade accounts receivable are customer obligations due under normal trade terms. We provide an allowance for doubtful accounts, which is based upon a review of outstanding receivables, historical collection information and existing economic conditions. Trade accounts receivable past due more than 90 days are considered delinquent. Delinquent receivables are written off based on individual credit evaluations, results of collection efforts, and specific circumstances of the customer. Recoveries of accounts previously written off are recorded as reductions of bad debt expense when received.

Property and Equipment

Property and equipment is stated at cost, net of accumulated depreciation. Maintenance costs, which do not significantly extend the useful lives of the respective assets, and repair costs are charged to operating expense as incurred. We include Network Equipment in fixed assets upon receipt, and begin depreciating the Network Equipment when such equipment passes our incoming inspection and is available for use. We attribute no salvage value to the Network Equipment and depreciation is computed using the straight-line method based on the estimated useful life of seven years. Also using the straight-line method, depreciation of office and test equipment, warehouse equipment and furniture is based on the estimated useful lives of the assets, generally three years for office and test equipment, and five years for warehouse equipment and furniture.

Allowance for System Removal

We would remove the CareView System from customer premises due to a number of factors; including, but not limited to, collection/revenue performance issues and contract expiration/non-renewal. We regularly evaluate the installed CareView Systems for such factors and an allowance is set up based on the estimated cost of removal. As of December 31, 2015 and 2014, an allowance of \$54,771 and \$277,000, respectively, was recorded.

CAREVIEW COMMUNICATION, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Impairment of Long-Lived Assets

Carrying values of property and equipment and finite-lived intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that their carrying values may not be recoverable. Such events or circumstances include, but are not limited to:

> Significant declines in an asset's market price; Significant deterioration in an asset's physical condition; Significant changes in the nature or extent of an asset's use or operation;

Significant adverse changes in the business climate that could impact an asset's value, including adverse actions or assessments by regulators;

Accumulation of costs significantly in excess of original expectations related to the acquisition or construction of an asset;

Current-period operating or cash flow losses combined with a history of such losses or a forecast that demonstrates continuing losses associated with an asset's use; and

Expectations that it is more likely than not that an asset will be sold or otherwise disposed of significantly before the end of our previously estimated useful life.

If impairment indicators are present, we determine whether an impairment loss should be recognized by testing the applicable asset or asset groups' carrying value for recoverability. This test requires long-lived assets to be grouped at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities, the determination of which requires judgment. We estimate the undiscounted future cash flows expected to be generated from the use and eventual disposal of the assets and compare that estimate to the respective carrying values in order to determine if such carrying values are recoverable. This assessment requires the exercise of judgment in assessing the future use of and projected value to be derived from the eventual disposal of the assets to be held and used. Assessments also consider changes in asset utilization, including the temporary idling of capacity and the expected timing for placing this capacity back into production. If the carrying value of the assets is not recoverable, then a loss is recorded for the difference between the assets' fair value and respective carrying value. The fair value of the assets is determined using an "income approach" based upon a forecast of all the expected discounted future net cash flows associated with the subject assets. Some of the more significant estimates and assumptions include: market size and growth, market share, projected selling prices, manufacturing cost and discount rate. Our estimates are based upon our historical experience, our commercial relationships, market conditions and available external information about

future trends. We believe our current assumptions and estimates are reasonable and appropriate; however, unanticipated events and changes in market conditions could affect such estimates resulting in the need for an impairment charge in future periods. During the years ended December 31, 2015 and 2014, no impairment was recognized.

Research and Development

Research and development costs are expensed as incurred. Costs regarding the development of software to be sold, leased or otherwise marketed are subject to capitalization beginning when a product's technological feasibility has been established and ending when a product is available for general release to customers. We did not capitalize any such costs during 2015 or 2014.

CAREVIEW COMMUNICATION, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Intellectual Property

We capitalize certain costs of developing software upon the establishment of technological feasibility and prior to the availability of the product for general release to customers for our CareView System in accordance with accounting principles generally accepted in the United States of America ("GAAP"). Capitalized costs are reported at the lower of unamortized cost or net realizable value and are amortized over the estimated useful life of the CareView System not to exceed five years. Additionally, we test our intangible assets for impairment whenever circumstances indicate that their carrying value may not be recoverable. No impairment was recorded for the years ended December 31, 2015 and 2014.

Intellectual property is comprised of purchased and internally developed software costs totaling approximately \$2,800,000, all of which was capitalized prior to 2008 and was fully amortized at December 31, 2012. During the years ended December 31, 2015 and 2014, we capitalized no additional intellectual property costs.

Patents and Trademarks

We have capitalized certain costs related to registering trademarks and patent pending technology. In accordance with GAAP, we amortize our intangible assets with a finite life on a straight-line basis, over 10 years for trademarks and 20 years for patents. We begin amortization of these costs on the date patents or trademarks are awarded.

Derivative Financial Instruments

Derivatives are recorded on the balance sheet at fair value and changes in fair value are recorded in earnings at each reporting date in accordance with GAAP. See *Fair Value of Financial Instruments* and *NOTE 4* for further details regarding derivative activity during the years ended December 31, 2015 and 2014.

Fair Value of Financial Instruments

Our financial instruments consist primarily of receivables, accounts payable, accrued expenses and short and long-term debt. The carrying amount of receivables, accounts payable and accrued expenses approximates our fair value because of the short-term maturity of such instruments and they are considered Level 1 assets under the fair value hierarchy. We have elected not to carry our debt instruments at fair value. The carrying amount of our debt approximates fair value. Interest rates that are currently available to us for issuance of short and long-term debt with similar terms and remaining maturities are used to estimate the fair value of the our short and long-term debt and would be considered Level 3 inputs under the fair value hierarchy.

We have categorized our assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy in accordance with GAAP. Accounting Standards Codification ("ASC") 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3).

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Fair Value of Financial Instruments (continued)

Assets and liabilities recorded in the consolidated balance sheets at fair value are categorized based on a hierarchy of inputs, as follows:

Level 1 -- Unadjusted quoted prices in active markets for identical assets or liabilities.

Level 2 -- Quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument.

Level 3 -- Unobservable inputs for the asset or liability.

Description

The Company's financial assets and liabilities recorded at fair value on a recurring basis include the fair value of warrant liability discussed in *NOTE 4*. The fair value of this warrant liability is included in long-term liabilities on the accompanying consolidated financial statements.

The following table provides the financial assets and liabilities reported at fair value and measured on a recurring basis at December, 31:

Assets/ (Liabilities) Measured at Fair Value	Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Other Unobservable Inputs (Level 3)
---	---	---	---

Fair value of warrant liability				
2015	\$(168,805) \$	—\$	— \$ (168,805)
2014	\$(301,864) \$	—\$	— \$ (301,864)

The following table provides a summary of changes in fair value associated with the Level 3 liabilities for the year ended December 31:

	Fair Value	
	Measurements Using	
	Significant	
	Unobservable Inputs	
	(Level 3)	
	2015	2014
Balance, beginning of period	\$(301,864)	\$(370,865)
Issuances of derivative liabilities		
Change in fair value of warrant liability	133,059	69,001
Transfers in and/out of Level 3		
Balance, end of period	\$(168,805)	\$(301,864)

CAREVIEW COMMUNICATION, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Fair Value of Financial Instruments (continued)

The above table of Level 3 liabilities begins with the prior period balance and adjusts the balance for changes that occurred during the current period. The ending balance of the Level 3 financial instrument presented above represent our best estimates and may not be substantiated by comparisons to independent markets and, in many cases, could not be realized in immediate settlement of the instruments.

Income Taxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which the related temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized when the rate change is enacted. Valuation allowances are recorded to reduce deferred tax assets to the amount that will more likely than not be realized. In accordance with GAAP, we recognize the effect of uncertain income tax positions only if the positions are more likely than not of being sustained in an audit, based on the technical merits of the position. Recognized uncertain income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which those changes in judgment occur. We recognize both interest and penalties related to uncertain tax positions as part of the income tax provision.

Revenue Recognition

Revenue is recognized when persuasive evidence of a sales arrangement exists, when the selling price is fixed or determinable, when installation and official acceptance by the facility occurs, and when collection is probable. Because we consolidate our financial statements, 100% of the revenue generated by the Project LLCs is included in our results with all intra-company accounts and transactions eliminated in consolidation.

We offer CareView's services through a subscription-based contract with each facility for a standard term of three to five years. We begin to bill monthly subscription fees to the facility upon official acceptance of the CareView System by the facility. The contract requires the facility to pay us the subscription fee monthly. During the term of the contract, we provide continuous monitoring of the CareView System and are required to maintain and service all CareView System equipment. If the customer requires additional products or services, the contract is amended accordingly.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Earnings Per Share

We calculate earnings per share ("EPS") in accordance with GAAP, which requires the computation and disclosure of two EPS amounts, basic and diluted. Basic EPS is computed based on the weighted average number of common shares outstanding during the period. Diluted EPS is computed based on the weighted average number of common shares outstanding plus all potentially dilutive common shares outstanding during the period under the treasury stock method. Such potential dilutive common shares consist of stock options, warrants to purchase our Common Stock (the "Warrants") and convertible debt. Potential common shares totaling approximately 108,000,000 and 94,000,000 at December 31, 2015 and 2014, respectively, have been excluded from the diluted earnings per share calculation as they are anti-dilutive due to our reported net loss.

Stock Based Compensation

We recognize compensation expense for all share-based payments granted and amended based on the grant date fair value estimated in accordance with GAAP. Compensation expense is generally recognized on a straight-line basis over the employee's requisite service period based on the award's estimated lives for fixed awards with ratable vesting provisions.

Debt Discount Costs

Costs incurred with parties who are providing long-term financing, with Warrants issued with the underlying debt, are reflected as a debt discount based on the relative fair value of the debt and Warrants. These discounts are generally amortized over the life of the related debt, using the effective interest rate method or other methods approximating the effective interest method. Additionally, convertible debt issued with a beneficial conversion feature is recorded at a discount based on the difference in the effective conversion price and the fair value of the Company's stock on the date of issuance, if any. Outstanding debt is presented net of any such discounts on the accompanying consolidated financial statements.

Deferred Debt Issuance and Financing Costs

Costs incurred through the issuance of Warrants to parties who are providing long-term financing availability, which includes revolving credit lines, are reflected as deferred debt issuance based on the fair value of the Warrants issued. Costs incurred with third parties related to issuance of debt are recorded as deferred financing costs. These costs are generally amortized over the life of the financing instrument using the effective interest rate method or other methods approximating the effective interest method. Amounts associated with our senior secured convertible notes are netted with the outstanding debt on the accompanying consolidated financial statements while amount associated with credit facilities are presented in other assets on the accompanying consolidated financial statements.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Installation Costs

We defer all costs associated with the installation of the CareView System into a particular hospital until the CareView System is fully operational and accepted by the hospital. Upon acceptance, the associated costs are expensed ratably over the life of the hospital contract. These costs are included in network operations on the accompanying consolidated statements of operations.

Shipping and Handling Costs

We expense all shipping and handling costs as incurred. These costs are included in network operations on the accompanying consolidated financial statements.

Advertising Costs

We consider advertising costs as costs associated with the promotion of our products through the various media outlets and trade shows. We expense all advertising costs as incurred. Our advertising expense for the years ended December 31, 2015 and 2014 totaled approximately \$222,000 and \$0, respectively.

Concentration of Credit Risks and Customer Data

We derive all of our revenues from hospitals. For the year ended December 31, 2015, 96 hospitals accounted for all of our revenue. During 2015 IASIS Healthcare Corporation ("IASIS"), Community Health Systems, Inc. ("CHS") (CHS acquired Health Management Associates, Inc. ("HMA") in January, 2014) and Tenet Healthsystems Medical, Inc., accounted for 33%, 20% and 15% of our net revenues, respectively. For the year ended December 31, 2014, 91

hospitals accounted for all of our revenue. During 2014 IASIS Healthcare Corporation ("IASIS"), Community Health Systems, Inc. ("CHS") (CHS acquired Health Management Associates, Inc. ("HMA") in January, 2014) and Tenet Healthsystems Medical, Inc., accounted for 49%, 21% and 12% of our net revenues, respectively.

Use of Estimates

Our financial statements have been prepared in accordance with GAAP. The preparation of these financial statements requires us to make significant estimates and judgments that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosure of contingent assets and liabilities. We evaluate our estimates, including those related to contingencies, on an ongoing basis. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Recently Issued Accounting Pronouncements

In February 2016, the FASB issued ASU 2016-02, *Leases* ("ASU 2016-02"). The new standard establishes a right-of-use ("ROU") model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. We are evaluating the impact that ASU 2016-03 will have on our consolidated financial statements and related disclosures.

In April 2015, the Financial Accounting Standards Board ("FASB"), issued Accounting Standards Update ("ASU") No. 2015-03, Interest-Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs. ASU 2015-03 requires that debt issuance costs be reported in the balance sheet as a direct deduction from the face amount of the related liability, consistent with the presentation of debt discounts and further requires the amortization of debt issuance cost to be reported as interest expense. Similarly, debt issuance costs and any discount or premium are considered in the aggregate when determining the effective interest rate of the debt. ASU 2015-03 is effective for fiscal years beginning after December 15, 2015 and interim periods within those fiscal years. Early adoption is permitted for annual or interim reporting periods for which the financial statements have not previously been issued. Management has opted for early adoption of ASU 2015-03 and there was no material effect on the 2015 consolidated financial statements upon adoption.

In February 2015, the FASB issued ASU 2015-02, *Amendments to the Consolidation Analysis* ("ASU 2015-02"). The ASU amends the consolidation guidance for VIEs and general partners' investments in limited partnerships and modifies the evaluation of whether limited partnerships and similar legal entities are VIEs or voting interest entities. The ASU is effective for interim and annual reporting periods beginning after December 15, 2015, with early adoption permitted. We are evaluating the effect that ASU 2015-02 will have on our consolidated financial statements and related disclosures.

In August 2014, the FASB issued ASU 2014-15, *Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern* ("ASU 2014-15"), to provide guidance on management's responsibility to perform interim and annual assessments of an entity's ability to continue as a going concern. ASU 2014-15 also requires certain disclosures if conditions or events raise substantial doubt about the entity's ability to continue as a going concern. ASU 2014-15 also requires certain disclosures if applies to all entities and is effective for annual periods ending after December 15, 2016, and interim periods thereafter, with early adoption permitted. We do not expect the adoption of this standard will have an impact on our financial position, results of operations or cash flows.

In May 2014, the FASB issued ASU 2014-09, *Revenue from Contracts with Customers* ("ASU 2014-09"). ASU 2014-09 is a comprehensive new revenue recognition model, which requires a company to recognize revenue to depict the transfer of promised goods or services to a customer in an amount that reflects the consideration the company expects to receive in exchange for those goods or services. The update will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. In August 2015, the FASB issued ASU 2015-14, *Revenue From Contracts With Customers (Topic 606):*

CAREVIEW COMMUNICATION, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Recently Issued Accounting Pronouncements (continued)

Deferral of the Effective Date, which defers the effective date to fiscal periods beginning after December 15, 2017. Early adoption is permitted for fiscal periods beginning after December 15, 2016. The standard permits the use of either the retrospective or cumulative effect transition method. We are evaluating the effect that ASU 2014-09 will have on our consolidated financial statements and related disclosures. We have not yet selected a transition method.

NOTE 3 – LIQUIDITY AND MANAGMENTS PLAN

Our cash position at December 31, 2015 was approximately \$17,679,000. We also have \$3,250,000 recorded as restricted cash related to a debt covenant in our credit agreement with PDL BioPharma, Inc. as discussed below.

Pursuant to the terms of a Note and Warrant Purchase Agreement dated April 21, 2011 (as subsequently amended) with HealthCor Partners Fund, LP and HealthCor Hybrid Offshore Master Fund, LP ("HealthCor") we are required to maintain a minimum cash balance \$2,000,000 (see *NOTE 11* for further details), and we are in compliance with the minimum cash balance as of the date of this filing.

Our continued successful operation is dependent upon us achieving positive cash flow through operations while maintaining adequate liquidity. We expect that the cash on hand, as well as our existing and projected cash flow from billable contracts, will enable us to continue to operate for the next twelve month period. We believe that our sales and marketing plan to attract new business and our ongoing deployment and installation of units under existing hospital agreements, will meet our near-term cash needs and will help us achieve future operating profitability.

At present, we have sufficient inventory to install and service a select number of large customers, but eventually we will need to address additional capital requirements. To that end, on June 26, 2015, we entered into a Credit

Agreement with PDL Biopharma, Inc., as administrative agent and lender ("the Lender"), (the "PDL Credit Agreement") pursuant to which the Lender made available to us up to \$40 million in two tranches of \$20 million each, with each tranche contingent upon us meeting certain milestones. On October 7, 2015, pursuant to the First Amendment to the PDL Credit Agreement (the "First Amendment") the Lender made the first tranche of \$20 million available and funded us \$19,533,992, net of fees. As of December 31, 2015, we are including \$20 million in long-term liabilities on the accompanying consolidated financial. Pursuant to the terms of the PDL Credit Agreement, we are required to maintain a minimum cash balance \$3,250,000, and we are in compliance with the minimum cash balance as of the date of this filing (see *NOTE13* for further details). No funds under the second tranche of the PDL Credit Agreement were available to us as of December 31, 2015.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 4 – STOCKHOLDERS' EQUITY

Preferred Stock

At December 31, 2015 and 2014, we had 20,000,000 shares of Preferred Stock, par value \$0.001 authorized and none outstanding, which can be designated by our Board of Directors.

Common Stock

At December 31, 2015 and 2014, we had 300,000,000 shares of Common Stock, \$0.001 par value authorized, and 139,380,748 shares of Common Stock issued and outstanding.

Common Stock Issuances During 2015

No shares of Common Stock were issued during 2015.

Common Stock Issuances During 2014

Cashless Warrant Exercise

During 2014, certain individuals and entities exercised Warrants to purchase an aggregate of 3,554,750 shares of our Common Stock. In order to exercise the Warrants pursuant to the cashless provisions contained therein, they surrendered their right to receive 2,927,399 shares, resulting in an issuance of 627,351 shares of Common Stock.

Warrants to Purchase Common Stock of the Company

We use the Black-Scholes-Merton option pricing model ("Black-Scholes Model") to determine the fair value of Warrants (except certain Warrants issued to HealthCor in 2011 as discussed in *Note 11* and the warrants issued in connection with a private placement completed in April 2013 "Private Placement Warrants". The Private Placement Warrants contain provisions that protect the holders from a decline in the issue price of our common stock or "down round" provisions. In accordance with the accounting standards, we determined that these instruments qualify as derivative liabilities and should be recorded at their fair value on the date of issuance and re-measured at fair value each reporting period with the change reported in earnings). The Black-Scholes Model is an acceptable model in accordance with the GAAP. The Black-Scholes Model requires the use of a number of assumptions including volatility of the stock price, the weighted average risk-free interest rate, and the weighted average term of the Warrant. The fair value of the Warrants issued to HealthCor and the Private Placement Warrants was computed using the Binomial Lattice model, incorporating transaction details such as the price of our Common Stock, contractual terms, maturity and risk free rates, as well as assumptions about future financings, volatility, and holder behavior. Due to the down round provisions associated with the exercise price of these Warrants, we determined that the Binomial Lattice model for valuing these instruments. As discussed in *Note 11*, the warrants issued to HealthCor in 2011 were subsequently amended and no longer contain down round provisions.

The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the term of the Warrants and is calculated by using the average daily historical stock prices through the day preceding the grant date.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 4 - STOCKHOLDERS' EQUITY (Continued)

Warrants to Purchase Common Stock of the Company (continued)

Estimated volatility is a measure of the amount by which our stock price is expected to fluctuate each year during the expected life of the award. Our estimated volatility is an average of the historical volatility of our stock prices (and that of peer entities whose stock prices were publicly available). Our calculation of estimated volatility is based on historical stock prices over a period equal to the expected life of the awards. Where appropriate we used the historical volatility of peer entities due to the lack of sufficient historical data of our stock price during 2007-2009.

The assumptions used in the Black-Scholes Model during the years ended December 31, 2015 and 2014 are set forth in the table below.

	2015	2014
Risk-free interest rate	1.37-2.49%	2.86%
Volatility	60.02-77.14%	78.88%
Expected life	5-10	10
Dividend yield	0.00%	0.00%

A summary of our Warrants activity and related information follows:

	Number of Shares Under Warrant	Range of Warrant Price Per Share	Weighted Average Exercise Price	Weighted Average Remaining Contractual Life
Balance at December 31, 2013	34,465,822	\$0.52-\$1.65	\$ 0.96	4.0
Granted	4,000,000	\$0.40	\$ 0.40	9.0
Exercised	(3,554,750)			
Expired	(312,500)			
Balance at December 31, 2014	34,598,572	\$0.40-\$1.65	\$ 0.93	4.2

Granted	9,191,752	\$0.33-\$0.52	\$ 0.46	9.3
Exercised				
Expired	(8,592,626)			
Balance at December 31, 2015	35,197,698	\$0.33-\$1.65	\$ 0.82	5.6
Vested and Exercisable at December 31, 2015	35,197,698	\$0.33-\$1.65	\$ 0.82	5.6

As of December 31, 2015 and 2014, we had no unamortized costs associated with capitalized Warrants, excluding the HealthCor Warrants and Private Placement Warrants.

Warrant Activity During 2015

At December 31, 2015, the Private Placement Warrants, discussed above in this *NOTE*, were re-valued with a fair value determination of \$168,805 and the difference of \$133,059 was included as change in fair value of warrant liability in the accompanying consolidated financial statements.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 4 - STOCKHOLDERS' EQUITY (Continued)

Warrants to Purchase Common Stock of the Company (continued)

Warrant Activity During 2015 (continued)

On October 1, 2015, we issued a five-year Warrant to purchase 50,000 shares of our Common Stock (with a fair value of \$8,800) at an exercise price of \$0.34 per share to an individual.

On August 12, 2015, we issued a five-year Warrant to purchase 5,000 shares of our Common Stock (with a fair value of \$855) at an exercise price of \$0.33 per share to an individual.

On June 26, 2015, in conjunction with the PDL Credit Agreement, we issued a warrant to purchase 4,444,445 shares of our Common Stock, subject to adjustment as described therein (the "PDL Warrant"). The PDL Warrant has an exercise price of \$0.40, a fair value of \$1,257,778, and expires on June 26, 2025 (see *NOTE 12* for further details).

On March 31, 2015, we issued HealthCor a Warrant for up to an aggregate of 1,000,000 shares of our Common Stock in consideration for certain prior waivers of the minimum cash balance requirement in the Purchase Agreement. This Warrant has an exercise price of \$0.53 per share, expires on March 31, 2025 and has a fair value of \$378,000 (see *NOTE 11* for further details).

On February 17, 2015, with the closing of the Fifth Amendment to the Note and Warrant Purchase Agreement with HealthCor and certain other investors and agreed to sell and issue (i) additional notes in the initial aggregate principal amount of \$6,000,000, with a conversion price per share equal to \$0.52 (subject to adjustment for standard anti-dilution provisions) and (ii) additional Warrants for an aggregate of up to 3,692,307 shares of our Common Stock at an exercise price per share equal to \$0.52 (subject to adjustment for standard anti-dilution provisions) (the "Fifth Amendment Warrants"). The fair value of the convertible debt and the Fifth Amendment Warrants was determined to be \$7,336,615, resulting in a relative fair value of \$1,093,105 for the Fifth Amendment Warrants on the date of grant

(see NOTE 11 for further details)

Warrant Activity During 2014

During 2014, certain Warrant holders exercised their rights to purchase 627,351 shares of our Common Stock using the cashless provision provided by their Warrant agreements, resulting in the surrender of their rights to purchase an aggregate of 2,927,399 shares of our Common Stock. Also during this period, Warrants to purchase an aggregate of 312,500 shares of our Common Stock expired.

On January 16, 2014, we entered into a Fourth Amendment to the Note and Warrant Purchase Agreement dated April 21, 20111 with HealthCor and agreed to sell and issue (i) additional notes in the initial aggregate principal amount of \$5,000,000, with a conversion price per share equal to \$0.40 (subject to adjustment for standard anti-dilution provisions) and (ii) additional Warrants to purchase an aggregate of up to 4,000,000 shares of our Common Stock at an exercise price per share equal to \$0.40 (subject to adjustment for standard anti-dilution provisions). The fair value of the convertible debt was determined to be \$5,000,000. Using the Black-Sholes Model, this resulted in a relative fair value of \$1,146,732 for the Warrants on the date of grant. See *NOTE 11* for further details.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 4 - STOCKHOLDERS' EQUITY (Continued)

Warrants to Purchase Common Stock of the Company (continued)

Warrant Activity During 2014 (continued)

At December 31, 2014, the Private Placement Warrants, discussed above in this *NOTE*, were re-valued with a fair value determination of \$301,864 and the difference of \$69,001 was included as change in fair value of warrant liability in the accompanying consolidated financial statements.

For year ended December 31, 2014, we also amortized \$284,692 of previously capitalized Warrant costs as interest expense in the accompanying consolidated financial statements.

Stock Options

Effective December 3, 2007, we established the CareView Communications, Inc. 2007 Stock Incentive Plan ("2007 Plan") pursuant to which 8,000,000 shares of Common Stock were reserved for issuance upon the exercise of options ("2007 Plan Option(s)"). The 2007 Plan was designed to serve as an incentive for retaining our qualified and competent key employees, officers and directors, and certain consultants and advisors. The 2007 Plan Options vest over three years and have an exercise period of ten years from the date of issuance. At December 31, 2015, 2007 Plan Options to purchase 8,000,000 shares of our Common Stock have been issued with 318,684 remaining outstanding.

Effective September 30, 2009, we established the CareView Communications, Inc. 2009 Stock Incentive Plan (the "2009 Plan") pursuant to which 10,000,000 shares of Common Stock was reserved for issuance upon the exercise of options ("2009 Plan Option(s)"). The 2009 Plan was designed to serve as an incentive for retaining our qualified and competent key employees, officers and directors. The 2009 Plan Options vest over three years and have an exercise period of ten years from the date of issuance. As of December 31, 2015, 2009 Plan Options to purchase 10,000,000 shares of our Common Stock have been issued with 6,774,927 remaining outstanding.

On February 25, 2015, we established the CareView Communications, Inc. 2015 Stock Option Plan (the "2015 Plan") pursuant to which 5,000,000 shares of Common Stock was reserved for issuance upon the exercise of options ("2015 Plan Option(s)"). The 2015 Plan was designed to serve as an incentive for retaining our qualified and competent key employees, officers and directors. The 2015 Plan Options vest over three years and have an exercise period of ten years from the date of issuance. As of December 31, 2015, 2015 Plan Options to purchase 2,337,056 shares of our Common Stock have been issued with 2,257,056 remaining outstanding.

The valuation methodology used to determine the fair value of the 2007 Plan Options, 2009 Plan Options and 2015 Plan Options, collectively, (the "Option(s)") issued during the year was the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions including volatility of the stock price, the weighted average risk-free interest rate, and the weighted average expected term of the options.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 4 – STOCKHOLDERS' EQUITY (Continued)

Stock Options (continued)

The assumptions used in the Black-Scholes Model during the years ended December 31, 2015 and 2014 are set forth in the table below.

	2015	2014
Risk-free interest rate	1.41-1.74%	1.59-1.83%
Volatility	61.00-71.86%	72.82-75.42%
Expected life	6	6
Dividend yield	0.00%	0.00%

The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the expected term of the stock option and is calculated by using the average daily historical stock prices through the day preceding the grant date.

Estimated volatility is a measure of the amount by which our stock price is expected to fluctuate each year during the expected life of the award. Our estimated volatility is an average of the historical volatility of peer entities whose stock prices were publicly available. Our calculation of estimated volatility is based on historical stock prices of these peer entities over a period equal to the expected life of the awards. Where appropriate we used the historical volatility of peer entities due to the lack of sufficient historical data of our stock price during 2007-2009.

A summary of our Option activity and related information follows:

Number of	Weighted	Weighted	Aggregate
Shares	Average	Average	Intrinsic
Under	Exercise	Remaining	Value
Option	Price	Contractual	

		Life	
Balance at December 31, 2013	12,747,476 \$ 0.59	6.9	\$ —
Granted	1,688,000 \$ 0.42		
Exercised	_		
Expired	(44,999))		
Forfeited	(116,667)		
Balance at December 31, 2014	14,273,810 \$ 0.54	6.3	\$ —
Granted	2,393,500 \$ 0.47		
Exercised	—		
Expired	(6,795,471)		
Forfeited	(521,172)		
Balance at December 31, 2015	9,350,667 \$ 0.58	7.6	\$ 15,705
Vested and Exercisable at December 31, 2015	4,817,823 \$ 0.66	6.7	\$—

The weighted-average grant date fair value of Options granted during the years ended December 31, 2015 and 2014 was \$0.29 and \$0.35 per share, respectively.

CAREVIEW COMMUNICATION, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 4 - STOCKHOLDERS' EQUITY (Continued)

Stock Options (continued)

Share-based compensation expense for Options charged to our operating results for the years ended December 31, 2015 and 2014 (\$774, 322 and \$714,123, respectively) is based on awards vested. The estimate of forfeitures are to be estimated at the time of grant and revised in subsequent periods if actual forfeitures differ from the estimates. We have not included an estimate for forfeitures due to our limited history and we revise based on actual forfeitures each period.

At December 31, 2015, total unrecognized estimated compensation expense related to non-vested Options granted prior to that date was approximately \$1,039,000, which is expected to be recognized over a weighted-average period of 1.6 years. No tax benefit was realized due to a continued pattern of operating losses.

Option Activity During 2015

In February 2015, we granted 2009 Plan Options to purchase 56,444 shares with an exercise price of \$0.53 per share to an employee

In February 2015, we granted 2015 Plan Options to a director (150,000), an executive officer (1,000,000) and certain employees (558,556) to purchase shares with an exercise price of \$0.53 per share,

In March 2015, we granted 2015 Plan Options to purchase 50,000 shares with an exercise price of \$0.50 per share to a director,

In August 2015, we granted 2015 Plan Options to purchase 5,000 shares with an exercise price of \$0.38 per share to an employee,

In November 2015, we granted 2015 Plan Options to purchase 50,000 shares with an exercise price of \$0.31 per share to an employee, and

In December 2015, we granted 2015 Plan Options to purchase 523,500 shares with an exercise price of \$0.26 per share to certain employees.

Option Activity During 2014

In January 2014, we granted 2009 Plan Options to two directors (500,000) and (150,000) to purchase shares with an exercise price of \$0.40 per share,

In April 2014, we granted 2009 Plan Options to two directors (500,000) and (150,000) to purchase shares with an exercise price of \$0.68 per share,

In July 2014, we granted 2009 Plan Options to purchase 20,000 shares with an exercise price of \$0.68 per share to employees,

In August 2014, we granted 2009 Plan Options to purchase 20,000 shares with an exercise price of \$0.56 per share to an employee, and

In December 2014, we granted 2009 Plan Options to purchase 348,000 shares with an exercise price of \$0.480 per share to employees.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 5 - INCOME TAXES

At December 31, 2015, we had approximately \$61 million of federal net operating tax loss carry-forward which begins to expire in 2029 and approximately \$13 million of state net operating losses which begins to expire in 2027.

The differences between the actual income tax benefit and the amount computed by applying the statutory federal tax rate (35%) to the loss before taxes are as follows:

	Years Ended December 31,	
	2015	2014
Expected income tax benefit at statutory rate	\$(5,699,747)	\$(5,078,523)
Debt discount amortization	700,029	700,000
Permanently disallowed interest	914,129	734,499
Other permanent differences	41,515	42,696
State income tax benefit, net of tax effect at state statutory rate		1,438
Deferred pool true-ups/corrections related to:		
Amortization		2,857,686
Net operating losses	232,567	(14,579)
Other	104,765	86,041
Change in valuation account	3,706,742	670,742
Income tax expense (benefit)	\$—	\$—

The components of the deferred tax assets and liabilities are as follows:

	December 31, 2015	2014
Deferred Tax Assets:		
Tax benefit of net operating loss carry-forward	\$21,321,688	\$19,138,526
Accrued interest	4,199,730	2,837,284
Stock based compensation	1,556,344	1,281,952
Amortization of intangible assets	441,399	496,012

Depreciation of fixed assets	(57,012)	36,318
Accrued expenses	96,284	151,783
Research and development credit carry-forward	29,084	29,084
Donations	11,241	10,541
Total deferred tax assets	27,598,758	23,981,500
Deferred tax liability-beneficial conversion feature	(2,589,615)	(2,679,098)
Valuation allowance for deferred tax assets	(25,009,143)	(21,302,402)
Deferred tax assets, net of valuation allowance	\$—	\$—

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 5 - INCOME TAXES (Continued)

As a result of certain income tax accounting realization requirements with respect to accounting for share based compensation, the table of deferred tax assets shown above does not include certain deferred tax assets at December 31, 2015 that arose directly from tax deductions related to equity compensation that is greater than the compensation recognized for financial reporting. If such deferred tax assets are subsequently realized, they will be recorded to contributed capital in the amount of approximately \$490,000.

In 2015 and 2014, the deferred tax valuation allowance increased by \$3,706,742 and \$670,742 respectively. The realization of the tax benefits is subject to the sufficiency of taxable income in future years. The combined deferred tax assets represent the amounts expected to be realized before expiration.

We periodically assess the likelihood that we will be able to recover our deferred tax assets. We consider all available evidence, both positive and negative, including historical levels of income, expectations and risks associated with estimates of future taxable income and ongoing prudent and feasible profits.

As of December 31, 2015 and 2014, we established valuation allowances equal to the full amount of the net deferred tax assets due to the uncertainty of the utilization of the operating losses in future periods.

For the years ended December 31, 2015 and 2014, no amounts have been recognized for uncertain tax positions and no amounts have been assessed or recognized related to interest or penalties related to uncertain tax positions. We have determined that it is not reasonably likely for the amounts of unrecognized tax benefits to significantly increase or decrease within the next twelve months. We are currently subject to the general three year statute of limitation for federal tax. Under this general rule, the earliest period subject to potential audit is 2012. For years in which the company may utilize its net operating losses, the IRS the ability to examine the tax year that generated those losses and propose adjustments up to the amount of losses utilized.

NOTE 6 - OTHER CURRENT ASSETS

Other current assets consist of the following:

	December 31,		
	2015 2014		
Prepaid expenses	\$467,137	\$254,998	
Other current assets	3,938	21,912	
TOTAL OTHER CURRENT ASSETS	\$471,075	\$276,910	

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 7 - PROPERTY AND EQUIPMENT

Property and equipment consist of the following:

	December 31,		
	2015	2014	
Network equipment	\$11,310,494	\$10,753,542	
Office equipment	200,683	160,890	
Vehicles	158,803	132,797	
Test equipment	115,712	87,059	
Furniture	81,838	75,673	
Warehouse equipment	9,524	6,867	
Leasehold improvements	5,121	5,121	
	11,882,175	11,221,949	
Less: accumulated depreciation	(7,398,736)	(5,877,157)	
TOTAL PROPERTY AND EQUIPMENT	\$4,483,440	\$5,344,792	

Depreciation expense for the years ended December 31, 2015 and 2014 was \$1,693,128 and \$1,623,723, respectively.

NOTE 8 - OTHER ASSETS

Intangible assets consist of the following:

December 31, 2015

		Accumulated	
	Cost	Amortization	Net
Patents and trademarks	\$420,137	\$53,706	\$366,431
Other intangible assets	56,263	41,929	14,334
TOTAL INTANGIBLE ASSETS	\$476,400	\$95,635	\$380,765

December 31,2014

	Cost	Accumulated Amortization	Net
Patents and trademarks	\$ 271,142	\$ 26,157	\$ 244,985
Other intangible assets	51,464	35,166	16,298
TOTAL INTANGIBLE ASSETS	\$ 322,606	\$ 61,323	\$ 261,283

Other assets consist of the following:

December 31, 2015

		Accumulated Amortization	
	Cost		Net
Deferred debt issuance costs	\$1,257,778	\$91,840	\$1,165,938
Deferred financing costs	805,917	74,070	731,847
Deferred installation costs	1,787,869	1,220,982	566,887
Prepaid license fee	249,999	71,038	178,962
Security deposit	46,124	_	46,124
TOTAL OTHER ASSETS	\$4,147,687	\$1,457,930	\$2,689,758

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 8 – OTHER ASSETS (Continued)

December 31, 2014

		Accumulated Amortization	
	Cost		Net
Deferred installation costs	\$1,457,098	\$865,647	\$591,451
Deferred debt issuance costs	1,600,000	1,600,000	—
Prepaid license fee	249,999	54,644	195,355
Deferred closing costs	583,967	583,967	—
Security deposit	46,124	—	46,124
TOTAL OTHER ASSETS	\$3,937,188	\$3,104,258	\$832,930

NOTE 9 - OTHER CURRENT LIABILITIES

Other current liabilities consist of the following:

	December 31,	
	2015 2014	
Allowance for system removal	\$54,771	\$277,000
Accrued professional services	67,500	204,675
Accrued taxes	235,162	145,183
Accrued paid time off	108,526	87,319
Other accrued liabilities	13,267	77,107
TOTAL OTHER CURRENT LIABILITIES	\$479,226	\$791,284

NOTE 10- COMMITMENTS AND CONTINGENCIES

Operating Lease

On September 8, 2009, we entered into a Commercial Lease Agreement (the "Lease") for 10,578 square feet of office and warehouse space expiring on June 30, 2015. On December 8, 2014, we entered into a Lease Extension Agreement (the "Lease Extension"), wherein we extended the Lease through June 30, 2020. The Lease Extension contains a renewal provision under which we may renew the Lease for an additional five year period under the same terms and conditions. Rent expense for the years ended December 31, 2015 and 2014 was \$214,147 and \$232,927, respectively.

A summary of the monthly base rent per the Lease and the Lease Extension follows:

Years Ending	
June 30,	
2016	\$14,188
2017	\$16,613
2018	\$15,052
2019	\$15,503
2020	\$15,968

CAREVIEW COMMUNICATION, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 10- COMMITMENTS AND CONTINGENCIES (Continued)

Operating Lease (continued)

As of December 31, 2015, future minimum rental payments are as follows:

Years Ending	
December 31,	
2016	\$184,806
2017	189,990
2018	183,330
2019	188,830
Through June 30, 2020	95,810
Total	\$842,766

Debt Maturity

As of December 31, 2015, future debt payments due are as follows:

Years Ending December 31,	Total	Loan Payable	Senior Secured Convertible Notes ⁽¹⁾	Notes Payable	Mandatorily Redeemable Equity in Joint Venture
2016	\$882,996	\$—	\$—	\$441,498	\$ 441,498
2017				_	
2018	6,666,667	6,666,667			
2019	6,666,667	6,666,667			
2020	6,666,666	6,666,666			
Thereafter	56,770,456		56,770,456		

Total \$77,653,452 \$20,000,000 \$56,770,456 \$441,498 \$441,498

⁽¹⁾Senior Secured Convertible Notes are included on the accompanying consolidated financial statements as \$34,072,409, which represents this amount less debt discount of \$22,698,047.

NOTE 11 – AGREEMENT WITH HEALTHCOR

On April 21, 2011, we entered into a Note and Warrant Purchase Agreement (as subsequently amended) (the "HealthCor Purchase Agreement") with HealthCor. Pursuant to the HealthCor Purchase Agreement, we sold Senior Secured Convertible Notes to HealthCor in the principal amount of \$9,316,000 and \$10,684,000, respectively (collectively the "2011 HealthCor Notes"). The 2011 HealthCor Notes have a maturity date of April 20, 2021. We also issued Warrants to HealthCor for the purchase of an aggregate of up to 5,488,456 and 6,294,403 shares, respectively, of our Common Stock at an exercise price of \$1.40 per share (collectively the "2011 HealthCor Warrants").

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 11 – AGREEMENT WITH HEALTHCOR (Continued)

So long as no event of default has occurred, the outstanding principal balances of the 2011 HealthCor Notes accrue interest from April 21, 2011 through April 20, 2016 (the "First Five Year Note Period") at the rate of 12.5% per annum, compounding quarterly and shall be added to the outstanding principal balances of the 2011 HealthCor Notes on the last day of each calendar quarter. Interest accruing from April 21, 2016 through April 20, 2021 (the "Second Five Year Note Period") at a rate of 10% per annum, compounding quarterly, may be paid quarterly in arrears in cash or, at our option, such interest may be added to the outstanding principal balances of the 2011 HealthCor Notes on the last day of each calendar.

From the date any event of default occurs, the interest rate, then applicable, shall be increased by five percent (5%) per annum. HealthCor has the right, upon an event of default, to declare due and payable any unpaid principal amount of the 2011 HealthCor Notes then outstanding, plus previously accrued but unpaid interest and charges, together with the interest then scheduled to accrue (calculated at the default rate described in the immediately preceding sentence) through the end of the First Five Year Note Period or the Second Five Year Note Period, as applicable.

At any time after April 21, 2011, HealthCor is entitled to convert any portion of the outstanding and unpaid accrued interest on and principal balances of the 2011 HealthCor Notes into fully paid and non-assessable shares of our Common Stock at a conversion rate of \$1.25 per share, subject to adjustment in accordance with anti-dilution provisions set forth in the 2011 HealthCor Notes. As of December 31, 2015, the underlying shares of our Common Stock related to the 2011 HealthCor Notes totaled approximately 29,000,000.

On January 31, 2012, we entered into the Second Amendment to the HealthCor Purchase Agreement with HealthCor (the "Second Amendment") amending the HealthCor Purchase Agreement, and sold Senior Secured Convertible Notes to HealthCor in the principal amounts of \$2,329,000 and \$2,671,000, respectively (collectively the "2012 HealthCor Notes"). As provided by the Second Amendment, the 2012 HealthCor Notes are in substantially the same form as the 2011 HealthCor Notes, with changes to the "Issuance Date," "Maturity Date," "First Five Year Note Period" and other terms to take into account the timing of the issuance of the 2012 HealthCor Notes. The 2012 HealthCor Notes have a maturity date of January 30, 2022. In addition, the provisions regarding interest payments, interest acceleration, optional conversion, negative covenants, and events of default, preemptive rights and registration rights are the same as those of the 2011 HealthCor Notes. At any time after January 30, 2012, HealthCor is entitled to convert any portion of the outstanding and unpaid accrued interest on and principal balances of the 2012 HealthCor Notes into fully paid and non-assessable shares of our Common Stock at a conversion rate of \$1.25 per share, subject to adjustment in accordance with anti-dilution provisions set forth in the 2012 HealthCor Notes. As of December 31, 2015, the

underlying shares of our Common Stock related to the 2012 HealthCor Notes totaled approximately 6,000,000.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 11 – AGREEMENT WITH HEALTHCOR (Continued)

On August 20, 2013, we entered into a Third Amendment to the HealthCor Purchase Agreement with HealthCor (the "Third Amendment") to redefine our minimum cash balance requirements. Previously we were required to maintain a minimum cash balance of \$5,000,000 and should we drop below that balance, it triggered a default. The Third Amendment allowed for a reduced minimum cash period, as defined in the HealthCor Purchase Agreement, which allowed us to drop below \$5,000,000, but not below \$4,000,000. All other terms and conditions of the HealthCor Purchase Agreement, including all amendments thereto, remain the same. Upon entering the reduced minimum cash period (which occurred on October 7, 2013), we had 120 days to return our minimum cash balance to the original \$5,000,000. On January 16, 2014, we increased our cash balance to in excess of the original \$5,000,000 minimum allowable balance.

On January 16, 2014, we entered into a Fourth Amendment to the HealthCor Purchase Agreement with HealthCor (the "Fourth Amendment") and sold Senior Secured Convertible Notes to HealthCor in the principal amounts of \$2,329,000 and \$2,671,000 (collectively the "2014 HealthCor Notes"). As provided by the Fourth Amendment, the 2014 HealthCor Notes are in substantially the same form as the 2011 HealthCor Notes, with changes to the "Issuance Date," "Maturity Date," "First Five Year Note Period" and other terms to take into account the timing of the issuance of the 2014 HealthCor Notes. The 2014 HealthCor Notes have a maturity date of January 15, 2024. In addition, the provisions regarding interest payments, interest acceleration, optional conversion, negative covenants, and events of default, preemptive rights and registration rights are the same as those of the 2011 HealthCor Notes. At any time after January 16, 2014, HealthCor Notes into fully paid and non-assessable shares of our Common Stock at a conversion rate of \$0.40 per share, subject to adjustment in accordance with anti-dilution provisions set forth in the 2014 HealthCor Notes. Additionally we issued Warrants to HealthCor for the purchase of an aggregate of up to 4,000,000 shares of our Common Stock at an exercise price of \$0.40 per share (collectively the "2014 HealthCor Warrants"). As of December 31, 2015, the underlying shares of our Common Stock related to the 2014 HealthCor Notes totaled approximately 16.000.000.

On December 4, 2014, we entered into a Fifth Amendment to the HealthCor Purchase Agreement (the "Fifth Amendment") with HealthCor and certain additional investors (such additional investors, the "New Investors" and, collectively with HealthCor Partners Fund, LP, the "Investors") and agreed to sell and issue (i) additional notes in the initial aggregate principal amount of \$6,000,000,with a conversion price per share of \$0.52 (subject to adjustment as described therein) (the "Fifth Amendment Notes") and (ii) additional Warrants for an aggregate of up to 3,692,308 shares of our Common Stock at an exercise price per share of \$0.52 (subject to adjustment as described therein) (the "Fifth Amendment Warrants"). As provided by the Fifth Amendment, the Fifth Amendment Notes are in substantially the same form as the 2011 HealthCor Notes, with changes to the "Issuance Date," "Maturity Date," "First Five Year Note

Period" and other terms to take into account the timing of the issuance of the Fifth Amendment Notes. The Fifth Amendment Notes have a maturity date of February 16, 2025. In addition, the provisions regarding interest payments, interest acceleration, optional conversion, negative covenants, and events of default, preemptive rights and registration rights are the same as those of the 2011 HealthCor Notes. The New Investors are composed of all but one of our current directors and one of our officers. On February 17, 2015, the Company and the Investors closed on the transactions contemplated by the Fifth Amendment. In connection with this closing, the Company and the Investors entered into an Amended and Restated Pledge and Security Agreement (the "Amended Security Agreement"), amending and restating that certain Pledge and Security Agreement dated as of April 20, 2011, and an Amended and Restated Intellectual Property Security Agreement (the "Amended IP Security Agreement"), amending and restating that certain functional the "Amended IP Security Agreement"), amending and restating that certain functional to the Fifth Amendment Notes totaled approximately 2,000,000 to HealthCor and 11,000,000 to the New Investors.

CAREVIEW COMMUNICATION, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 11 – AGREEMENT WITH HEALTHCOR (Continued)

On March 31, 2015, we entered into the Sixth Amendment to the HealthCor Purchase Agreement (the "Sixth Amendment") pursuant to which, among other things, (i) the requirement to maintain a minimum cash balance of \$5,000,000 was reduced to a minimum cash balance of \$2,000,000 and (ii) the amendment provision was revised to permit the HealthCor Purchase Agreement to be amended by the Company and the holders of the majority of the Common Stock underlying the outstanding notes and warrants to purchase shares of our Common Stock sold pursuant to the HealthCor Purchase Agreement. On March 31, 2015, we also issued a warrant to HealthCor to purchase up to an aggregate of 1,000,000 shares of our Common Stock in consideration for certain prior waivers of the minimum cash balance requirement in the HealthCor Purchase Agreement (the "Sixth Amendment Warrant"). The Sixth Amendment Warrant has an exercise price per share of \$0.53 (subject to adjustment as described therein) and an expiration date of March 31, 2025.

On June 26, 2015, we (i) entered into a Seventh Amendment to the HealthCor Purchase Agreement (the "Seventh Amendment") pursuant to which the HealthCor Purchase Agreement was amended to permit the Company to enter into and perform its obligations under the Credit Agreement entered into with PDL BioPharma, Inc., as administrative agent and lender (the "Lender") (the "PDL Credit Agreement"); (ii) executed an Amendment to the Registration Rights Agreement between the Company and HealthCor dated April 21, 2011 (the "RR Agreement") pursuant to which the RR Agreement was amended to make its priority of registration consistent with the Registration Rights Agreement executed by the Company and Lender (as detailed in *NOTE 12*); (iii) amended the 2011 HealthCor Notes to extend the maturity date, in the event that Tranche Two of the PDL Credit Agreement is funded, for such notes to 90 days after the earlier of the Tranche Two maturity date or repayment date, but not later than December 31, 2022, (iv) amended the 2012 HealthCor Notes, to set the maturity date to 90 days after the earlier of the Tranche Two of the PDL Credit Agreement is funded, in the event that Tranche Two maturity date to 90 days after the earlier of the Tranche Two of the PDL Credit Agreement is funded, in the event that Tranche Two maturity date to 90 days after the earlier of the Tranche Two maturity date at January 30, 2022 and, in the event that Tranche Two of the PDL Credit Agreement is funded, to extend such maturity date to 90 days after the earlier of the Tranche Two maturity date or repayment date, but later than December 31, 2022; and (v) amended each of the Senior Secured Convertible Notes issued under the HealthCor Purchase Agreement (the "HealthCor Notes") to, among other things, subordinate the HealthCor Notes to the loans under the PDL Credit Agreement (as detailed in *NOTE 12*) and to increase certain event of default acceleration and payment thresholds.

Accounting Treatment

When issuing debt or equity securities convertible into common stock at a discount to the fair value of the common stock at the date the debt or equity financing is committed, a company is required to record a beneficial conversion

feature ("BCF") charge. We had three separate issuances of equity securities convertible into common stock that qualify under this accounting treatment, (i) the 2011 HealthCor Notes, (ii) the 2012 HealthCor Notes and (iii) the 2014 HealthCor Notes. Because the conversion option and the 2011 HealthCor Warrants on the 2011 HealthCor Notes were originally classified as a liability when issued due to the down round provision and the removal of the provision requiring liability treatment, and subsequently reclassified to equity on December 31, 2011 when the 2011 HealthCor Notes were amended, only the accrued interest capitalized as payment in kind ("PIK") since reclassification qualifies under this accounting treatment. The face amount of the 2012 and 2014 HealthCor Notes and all accrued PIK interest also qualify for this accounting treatment. During years ended December 31, 2015 and 2014, we recorded a BCF of \$2,316,231 and \$3,440,235 respectively. The BCF was recorded as a charge to debt discount and a credit to additional paid in capital, with the debt discount, using the effective interest method, amortized to interest expense over the term of the notes. As Warrants were issued with the Fifth Amendment Notes, the proceeds were allocated to the instruments based on relative fair value as the warrants did not contain any features requiring liability treatment and therefore were classified as equity. The warrants issued with the Sixth Amendment also did not contain features requiring liability accounting and were recorded at fair value on the date of issuance with the offsetting credit recorded in equity. The value allocated to the Fifth Amendment Warrants was \$1,093,105, which was recorded as debt discount with the credit to additional paid in capital. The value allocated to the Sixth Amendment Warrant was \$378,000, which was recorded as debt costs with the credit to additional paid in capital. The discount associated with the Fifth Amendment Notes (\$98,555) and the expense related to the Sixth Amendment (\$8,669) are amortized to interest expense using the effective interest method.

CAREVIEW COMMUNICATION, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 11 – AGREEMENT WITH HEALTHCOR (Continued)

Accounting Treatment (continued)

We recorded an aggregate of \$2,267,814 and \$2,152,055 in interest expense for the years ended December 31, 2015 and 2014, respectively, related to these transactions. The carrying value of the debt with HealthCor and the New Investors at December 31, 2015 approximates fair value as the interest rates used are those currently available to us and would be considered level 3 inputs under the fair value hierarchy.

NOTE 12 - LOAN AND SECURITY AGREEMENT WITH COMERICA BANK AND BRIDGE BANK

On August 31, 2011, we entered into and closed a Loan and Security Agreement (the "Revolving Line") with Comerica Bank ("Comerica") and Bridge Bank, National Association ("Bridge Bank") (collectively the "Banks") providing for a \$20,000,000 revolving line of credit. On June 30, 2014, the Revolving Line, previously due on that date was extended to July 31, 2014. On July 31, 2014, we allowed the Revolving Line to terminate pursuant to its terms, at which time the outstanding balance of \$982,255 was repaid.

Pursuant to the terms of the Revolving Line, as amended, we issued Warrants to the Banks to purchase an aggregate of 1,428,572 shares of our Common Stock. The Warrants have an exercise price of \$1.10 per share and expire on January 15, 2020. The fair value of the Warrants at issuance was \$1,535,714, with an additional \$64,286 added pursuant to an amendment, all of which has been recorded as deferred financing costs. The deferred financing costs were amortized to interest expense over the term of the Revolving Line and were fully amortized as of June 30, 2014. The Warrants have not been exercised as of December 31, 2015. During the years ended December 31, 2015 and 2014, \$0 and \$284,692, respectively, was amortized to interest expense in the accompanying consolidated financial statements.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 13 - AGREEMENT WITH PDL BIOPHARMA, INC.

On June 26, 2015, we entered into a Credit Agreement with PDL BioPharma, Inc., as administrative agent and lender ("the Lender") (the "PDL Credit Agreement"). Under the PDL Credit Agreement the Lender made available to us up to \$40 million in two tranches of \$20 million each.

Certain covenants of the PDL Credit Agreement include (a) in the event that a milestone relating to the placement of 9,000 billable units occurs on or before October 31, 2015, the Lender will fund us \$20 million (the "Tranche One Loan") and (b) in the event that additional milestones relating to (i) the placement of 27,750 billable units and (ii) the Company recording earnings before interest, tax, depreciation, and amortization (EBITDA) of not less than \$7,000,000 on an annualized basis for the three calendar month period prior to the funding (on or before June 30, 2017), the Lender will fund us an additional \$20 million (the "Tranche Two Loan" and, together with the Tranche One Loan, the "Loans"). Outstanding borrowings under the Tranche One Loan bear interest at the rate of 13.5% per annum, payable quarterly in arrears. From the date any event of default occurs, the interest rate shall be increased five percent (5%) per annum. The PDL Credit Agreement includes a minimum cash balance requirement of \$3,250,000 and should we drop below \$3,250,000 it will trigger a default.

On October 7, 2015, the Company entered into a First Amendment (the "First Amendment") to the PDL Credit Agreement. The First Amendment modified the conditions precedent to the funding of each tranche, such that, among other things, we no longer need to attain a specified milestone relating to the placement of our products in order for the Lender to fund us the Tranche One Loan. Contemporaneously with the execution of the First Amendment we borrowed the Tranche One Loan and issued to the Lender a term note in the principal amount of \$20 million (the "Tranche One Term Note"), payable in accordance with the terms of the Credit Agreement, as amended. The First Amendment also included a revision to the Tranche Two Milestone, which changed from a minimum of 27,750 billable units (defined as one unit for each room control platform and two units for each nurse station monitor) to 31,500 Bed Equivalent Units (defined as a billable unit plus 14 units for each head-end server operating as the communication center and fractional units for mobile assets as applicable).

Once funded, the PDL Credit Agreement requires interest only payments for the first eight interest payment dates and principal plus interest payments will commence on the ninth interest payment date. We may elect to pay a portion of the interest due in the form of additional loans (interest paid in kind) during the first eight interest payment dates. The first principal payment on the Tranche One Term Note is due on January 8, 2018 in the amount of \$1,666,667, with similar amounts due quarterly thereafter with the final payment due on October 8, 2020. Each tranche will mature on

the fifth anniversary of the date borrowed. We may elect to prepay the Loans at any time without any premium or penalty, subject to certain conditions.

The obligations under the PDL Credit Agreement are secured by a pledge of substantially all of the assets of the Company and certain of its domestic subsidiaries. We executed a Subordination and Intercreditor Agreement (the "Subordination and Intercreditor Agreement"), with the Lender, HealthCor and the New Investors (as defined in *NOTE 11*) pursuant to which we granted first-priority liens on our pledged assets to the Lender and second-priority liens on such pledged assets to HealthCor and the New Investors.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 13 - AGREEMENT WITH PDL BIOPHARMA, INC. (Continued)

The PDL Credit Agreement contains customary affirmative covenants for transactions of this type and other affirmative covenants agreed to by the Company and the Lender, including, among others, the provision of annual and quarterly reports, maintenance of property, insurance, compliance with laws and contractual obligations and payment of taxes. The PDL Credit Agreement contains customary negative covenants for transactions of this type and other negative covenants agreed to by the Company and the Lender, including, among others, restrictions on the incurrence of indebtedness, the granting of liens, making restricted payments and investments, entering into affiliate transactions and transferring assets. The PDL Credit Agreement also provides for a number of customary events of default, including payment, bankruptcy, covenant, representation and warranty and judgment defaults.

Contemporaneously with the execution of the PDL Credit Agreement, we issued to the Lender a warrant to purchase 4,444,445 shares of our Common Stock at an exercise price of \$0.45 per share, subject to adjustment as described therein (the "PDL Warrant"). The PDL Warrant expires on June 26, 2025. Pursuant to the terms of the First Amendment we amended and restated the PDL Warrant, reducing the exercise price per share from \$0.45 to \$0.40 (the "Amended Warrant"). All other provisions of the Amended Warrant remained unchanged.

In addition, contemporaneously with the execution of the PDL Credit Agreement the Company and the Lender executed (i) a Registration Rights Agreement pursuant to which the Company agreed to provide the Lender with certain registration rights with respect to the shares of Common Stock issuable upon exercise of the PDL Warrant (the "PDL RRA"), (ii) a Guarantee and Collateral Agreement (the "Guarantee and Collateral Agreement") pursuant to which certain of our subsidiaries guaranteed the performance of our obligations under the PDL Credit Agreement and granted the Lender a security interest in such subsidiaries' tangible and intangible assets securing our performance of the same, and (iii) a Patent Security Agreement and a Trademark Security Agreement pursuant to which we granted the Lender a security interest in a certain subsidiary's tangible and intangible assets securing the performance of our obligations under the PDL Credit Agreement.

Accounting Treatment

In connection with the Credit Agreement, we issued the PDL Warrant to the Lender. The fair value of the PDL Warrant at issuance was \$1,257,778, which has been recorded as deferred issuance costs in the accompanying consolidated financial statements. The deferred debt issuance costs associated with the PDL Credit Agreement are

recorded as assets in accordance with the accounting standards as the PDL Credit Agreement is considered to be a credit facility and the warrants were payment for the facility and not the drawdowns. These costs are amortized to interest expense using the straight line method over the term of the Credit Agreement. Upon amendment of the PDL Warrant, we evaluated whether there was an increase in fair value which would require recognition of additional costs. No such increase in fair value was noted and no adjustment to the PDL Warrant valuation was necessary. Through December 31, 2015, \$91,840 was amortized to interest expense. The PDL Warrant has not been exercised. We also incurred certain financing costs totaling \$805,917 in the accompanying consolidated financial statements. These costs have been recorded as deferred financing costs and are being amortized to interest expense over the term of the Credit Agreement. Through December 31, 2015, \$74,071 has been amortized.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 14 – JOINT VENTURE AGREEMENT

On November 16, 2009, we entered into a Master Investment Agreement (the "Rockwell Agreement") with Rockwell Holdings I, LLC, a Wisconsin limited liability ("Rockwell"). Under the terms of the Rockwell Agreement, we used funds from Rockwell to fully implement the CareView System[™] in Hillcrest Medical Center in Tulsa, Oklahoma ("Hillcrest") and Saline Memorial Hospital in Benton, Arkansas ("Saline") (the "Project Hospital(s)"). CareView-Hillcrest, LLC and CareView-Saline, LLC were created as the operating entities for the Project Hospitals under the Rockwell Agreement (the "Project LLC(s) ").

Rockwell and the Company own 50% of each Project LLC. We contributed our intellectual property rights and hospital contract with each Project Hospital and Rockwell contributed cash to be used for the purchase of equipment for the Project LLCs. Rockwell provided \$1,151,205 as the initial funding, \$575,603 was provided under promissory notes (the "Project Notes") and \$575,602 was provided under an investment interest ("Rockwell's Preferential Return"). We classified Rockwell's Preferential Return as a liability since it represents an unconditional obligation by us and is recorded in mandatorily redeemable equity in joint venture on the accompanying consolidated financial statements. The Project Notes and Rockwell's Preferential Returns both earn interest at the rate of ten percent (10%) and are secured by a security interest in all of the equipment in the Project Hospitals, intellectual property rights, and the Project Hospital Contract.

In accordance with GAAP, we determined the Project LLCs are VIEs based on the fact that the total equity investment at risk was not sufficient to finance the entities activities without additional financial support. We consolidate the Project LLCs as we have the power to direct the activities and an obligation to absorb losses of the VIEs. We have no contractual liability to Rockwell with respect to the repayment obligations of the Project LLCs.

As additional consideration to Rockwell for providing the funding, we granted Rockwell Warrants to purchase 1,151,206 shares of our Common Stock on the date of the Rockwell Agreement, and using the Black-Scholes Model valued the Warrants at \$1,124,728 (the "Project Warrant"). The Project Warrant is classified as equity and is included in additional paid-in-capital on the accompanying consolidated financial statements. We allocated the proceeds to the Project Warrant, the Project Notes and Preferential Returns based on the relative fair value. The originally recorded debt discount of \$636,752 was amortized over the expected life of the debt and was fully amortized at December 31, 2015.

Hillcrest notified us of its desire to terminate its hospital agreement effective January 27, 2012. This termination resulted in the loss of monthly revenue totaling approximately \$20,000, which revenue was used to make payments on our indebtedness to Rockwell. To date, we have incurred system removal costs of approximately \$3,000 for removing our equipment from the hospital premises. We currently have approximately 100 units remaining on site at Hillcrest. Included in other current liabilities in the accompanying consolidated financial statements is an allowance for system removal totaling \$10,250 to reserve for the removal of the remaining units.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 14 – JOINT VENTURE AGREEMENT (Continued)

As of December 31, 2015 and 2014, the Project LLCs' indebtedness to Rockwell, including principal and interest totaled approximately \$1,139,000 and \$1,075,000, respectively. On March 18, 2014, the Project Notes and Rockwell's Preferential Returns, previously due on June 30, 2014 (the "June 2014 extensions"), were extended to June 30, 2015. On February 19, 2015, the Project Notes and Rockwell's Preferential Returns were extended to June 30, 2016. In conjunction with an August 2013 extension of the due dates of the Project Notes and Rockwell's Preferential Returns to December 31, 2013, the expiration date of the Project Warrant was also extended from November 16, 2014 to November 16, 2015. In October 2015, the expiration date of the Project Warrant was further extended from November 16, 2015 to November 16, 2017. In both cases, all other provisions of the Project Warrant remained unchanged. The Project Warrant were revalued in August 2013 resulting in a \$25,327 increase in fair value, which has been recorded as non-cash costs included in general and administration expense in the accompanying consolidated financial statements. The Project Warrant were also revalued in October 2015 resulting in a \$102,457 increase in fair value, which has been recorded as non-cash costs included in general and administration expense in the accompanying consolidated financial statements. CareView, as 50% owner of the LLCs, is currently negotiating with Rockwell to settle the debt of the LLCs through the issuance of shares of CareView's Common Stock. Although CareView anticipates that this settlement will be forthcoming in the near future, CareView and the LLCs can give no assurances that a settlement will be negotiated, or if negotiated and settled, that it will be through the issuance of CareView's Common Stock.

NOTE 15 – VARIABLE INTEREST ENTITIES

The Company consolidates VIEs of which it is the primary beneficiary. The liabilities recognized as a result of consolidating these VIEs do not necessarily represent additional claims on our general assets; rather, they represent claims against the specific assets of the consolidated VIEs. Conversely, assets recognized as a result of consolidating these VIEs do not represent additional assets that could be used to satisfy claims against our general assets.

The total consolidated VIE assets and liabilities reflected on our consolidated balance sheets at December 31, 2015 and 2014 are as follows:

Assets		
Cash	\$2,146	\$2,770
Receivables	4,731	2,365
Total current assets	6,877	5,135
Property, net	50,382	46,762
Total assets	\$57,259	\$51,897
Liabilities		
Accounts payable	\$132,170	\$122,558
Notes payable	441,498	441,594
Mandatorily redeemable interest	441,498	441,594
Accrued interest	261,450	191,596
Other current liabilities	26,936	24,889
Total liabilities	\$1,303,552	\$1,222,231

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 15 - VARIABLE INTEREST ENTITIES (Continued)

The financial performance of the consolidated VIEs reflected on our consolidated statements of operations for the years ended December 31, 2015 and 2014 is as follows:

	Year Ended December 31, 2015	Year Ended December 31, 2014
Revenue, net	\$28,388	\$28,452
Network operations expense	16,655	16,665
General and administrative expense	3,177	(12,089)
Depreciation	49,091	50,771
Total operating costs	68,923	55,347
Operating income (loss)	(40,535) (26,895)
Other income (expense)	(89,629) (89,785)
Loss before taxes	(130,164)) (116,680)
Provision for taxes		
Net loss	(130,164)) (116,680)
Net loss attributable to noncontrolling interest	(65,082)) (58,340)
Net loss attributable to CareView Communications, Inc.	\$(65,082)	\$(58,340)